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1. Preamble
Guidelines summarize and evaluate all available evidence on a par-
ticular issue at the time of the writing process, with the aim of as-
sisting health professionals in selecting the best management
strategies for an individual patient with a given condition, taking
into account the impact on outcome, as well as the risk–benefit
ratio of particular diagnostic or therapeutic means. Guidelines
and recommendations should help health professionals to make
decisions in their daily practice. However, the final decisions con-
cerning an individual patient must be made by the responsible
health professional(s) in consultation with the patient and care-
giver as appropriate.
A great number of Guidelines have been issued in recent years by
the European Society of Cardiology (ESC) and by the European
Respiratory Society (ERS), as well as by other societies and organi-
sations. Because of the impact on clinical practice, quality criteria for
the development of guidelines have been established in order to
make all decisions transparent to the user. The recommendations
for formulating and issuing ESC Guidelines can be found on the
ESC website (http://www.escardio.org/Guidelines-&-Education/
Clinical-Practice-Guidelines/Guidelines-development/Writing-
ESC-Guidelines). ESC Guidelines represent the official position of
the ESC on a given topic and are regularly updated.
Members of this Task Force were selected by the ESC and ERS
to represent professionals involved with the medical care
of patients with this pathology. Selected experts in the field
undertook a comprehensive review of the published evidence
for management (including diagnosis, treatment, prevention and
rehabilitation) of a given condition according to ESC Committee
for Practice Guidelines (CPG) policy and approved by the ERS.
A critical evaluation of diagnostic and therapeutic procedures
was performed, including assessment of the risk–benefit ratio.
Estimates of expected health outcomes for larger populations
were included, where data exist. The level of evidence and
the strength of the recommendation of particular management
options were weighed and graded according to predefined scales,
as outlined in Tables 1 and 2.
The experts of the writing and reviewing panels provided declar-
ation of interest forms for all relationships that might be perceived as
real or potential sources of conflicts of interest. These forms were
compiled into one file and can be found on the ESC website (http://
www.escardio.org/guidelines). Any changes in declarations of inter-
est that arise during the writing period must be notified to the ESC
and ERS and updated. The Task Force received its entire financial
support from the ESC and ERS without any involvement from the
healthcare industry.
The ESC CPG supervises and coordinates the preparation of new
Guidelines produced by task forces, expert groups or consensus pa-
nels. The Committee is also responsible for the endorsement pro-
cess of these Guidelines. The ESC Guidelines undergo extensive
review by the CPG and external experts, and in this case by
ERS-appointed experts. After appropriate revisions the Guidelines
are approved by all the experts involved in the Task Force. The fina-
lized document is approved by the CPG and by ERS for publication
in the European Heart Journal and in the European Respiratory Jour-
nal. The Guidelines were developed after careful consideration of
the scientific and medical knowledge and the evidence available at
the time of their dating.
The task of developing ESC/ERS Guidelines covers not only
integration of the most recent research, but also the creation of
educational tools and implementation programmes for the recom-
mendations. To implement the guidelines, condensed pocket guide-
line versions, summary slides, booklets with essential messages,
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summary cards for non-specialists and an electronic version for
digital applications (smartphones, etc.) are produced. These ver-
sions are abridged and thus, if needed, one should always refer to
the full text version, which is freely available on the ESC website.
The National Societies of the ESC are encouraged to endorse,
translate and implement all ESC Guidelines. Implementation pro-
grammes are needed because it has been shown that the outcome
of disease may be favourably influenced by the thorough application
of clinical recommendations.
Surveys and registries are needed to verify that real-life daily prac-
tice is in keeping with what is recommended in the guidelines, thus
completing the loop between clinical research, writing of guidelines,
disseminating them and implementing them into clinical practice.
Health professionals are encouraged to take the ESC/ERS Guide-
lines fully into account when exercising their clinical judgment, as
well as in the determination and the implementation of preventive,
diagnostic or therapeutic medical strategies. However, the ESC/ERS
Guidelines do not override in any way whatsoever the individual re-
sponsibility of health professionals to make appropriate and accur-
ate decisions in consideration of each patient’s health condition and
in consultation with that patient and the patient’s caregiver where
appropriate and/or necessary. It is also the health professional’s re-
sponsibility to verify the rules and regulations applicable to drugs
and devices at the time of prescription.
2. Introduction
Pulmonary hypertension (PH) is a pathophysiological disorder that
may involve multiple clinical conditions and can complicate the major-
ity of cardiovascular and respiratory diseases. The composition of the
guidelines task force reflects the multidisciplinary nature of PH, includ-
ing members of different medical societies, associations and working
groups. The current document follows the two previous ESC and ERS
Guidelines, published in 2004 and 2009, focusing on clinical manage-
ment of PH. A systematic literature review was performed from
MEDLINEw to identify new studies published since 2009 concerning
the topic of PH. Task force members selected studies based on rele-
vance and appropriateness. The main changes and adaptations as
compared with the 2009 ESC and ERS PH guidelines are as follows:
† The table of contents structure has been simplified, with three
initial general chapters including classifications, basic aspects
and differential diagnosis, two chapters for pulmonary arterial
hypertension (PAH) and one chapter each for PH due to left
heart disease (LHD), lung disease and/or hypoxia, chronic
thromboembolic pulmonary hypertension (CTEPH) and unclear
and/or multifactorial mechanisms.
† New wordings and parameters for the haemodynamic definition
of post-capillary PH subgroups have been adopted. Pulmonary
vascular resistance (PVR) has been included in the haemodynamic
definition of PAH.
† An updated common clinical classification for adult and paediatric
patients is reported.
† New advances in pathology, pathobiology, genetics, epidemi-
ology and risk factors are reported.
Table 1 Classes of recommendations
Classes of 
recommendations
Suggested wording to use
Class I Evidence and/or general 
agreement that a given treatment 
or procedure is beneficial, useful,
effective.
Is recommended/is 
indicated
Class II 
divergence of opinion about the 
Conflicting evidence and/or a
usefulness/efficacy of the given
favour of usefulness/efficacy.
Usefulness/efficacy is less well
treatment or procedure. 
Class IIa Weight of evidence/opinion is in Should be considered
Class IIb
established by evidence/opinion. 
May be considered
Class III Evidence or general agreement 
that the given treatment or 
procedure is not useful/effective,  
and in some cases may be harmful. 
Is not recommended
Table 2 Level of evidence
Level of 
evidence A 
Data derived from multiple randomized 
clinical trials or meta-analyses. 
Level of 
evidence B 
Data derived from a single randomized 
clinical trial or large non-randomized 
studies. 
Level of 
evidence C 
Consensus of opinion of the experts and/
or small studies, retrospective studies, 
registries.
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† An updated diagnostic algorithm has been provided in an inde-
pendent chapter and novel screening strategies are proposed in
the web addenda.
† The importance of expert referral centres in the management of
PH patients has been highlighted in both the diagnostic and treat-
ment algorithms.
† New developments on PAH severity evaluation and on treat-
ments and treatment goals are reported, including combination
therapy and two new recently approved drugs. The treatment al-
gorithm has been updated accordingly.
† The chapters on PH due to LHD and lung diseases have been up-
dated. The term ‘out of proportion PH’ has been abandoned in
both conditions.
† New diagnostic and treatment algorithms are reported in the
CTEPH chapter, including general criteria for operability and bal-
loon pulmonary angioplasty (BPA) and a newly approved drug.
† A short chapter on PH due to unclear and/or multifactorial
mechanisms has been added.
3. Definitions and classifications
3.1 Definitions
PH is defined as an increase in mean pulmonary arterial pressure
(PAPm) ≥25 mmHg at rest as assessed by right heart catheteriza-
tion (RHC).1 Available data have shown that the normal PAPm at
rest is 14+3 mmHg with an upper limit of normal of approximately
20 mmHg.1,2 The clinical significance of a PAPm between 21 and 24
mmHg is unclear. Patients presenting with a pulmonary artery
pressure (PAP) in this range should be carefully followed when
they are at risk for developing PAH [e.g. patients with connective
tissue disease (CTD) or family members of patients with heritable
PAH (HPAH)].1
Due to the lack of reliable data that define which levels of
exercise-induced changes in PAPm or PVR have prognostic implica-
tions, a disease entity ‘PH on exercise’ cannot be defined and should
not be used.1 A recent retrospective study has proposed a definition
of PH on exercise with the combination of PAPm and total PVR
data, but no outcome prospective validation has been provided.3
The term PAH describes a group of PH patients characterized
haemodynamically by the presence of pre-capillary PH, defined by
a pulmonary artery wedge pressure (PAWP) ≤15 mmHg and a
PVR .3 Wood units (WU) in the absence of other causes of pre-
capillary PH such as PH due to lung diseases, CTEPH or other rare
diseases.1
According to various combinations of PAP, PAWP, cardiac output
(CO), diastolic pressure gradient (DPG) and PVR, assessed in stable
clinical conditions, different haemodynamic definitions of PH are
shown in Table 3 together with their corresponding clinical
classification (Table 4).1,4 The reasons for the updated definitions
of post-capillary PH are reported in the specific section (8.0).
3.2 Classifications
The clinical classification of PH is intended to categorize multiple
clinical conditions into five groups according to their similar clinical
presentation, pathological findings, haemodynamic characteristics
and treatment strategy.5 The clinical classification may be updated
when new data are available on the above features or when add-
itional clinical entities are considered. A comprehensive version of
the clinical classification is presented in Table 4.6 A condensed ver-
sion is provided in a web addenda (Web Table I).
The new findings are as follows:
† New conditions that are frequently found in children have been in-
cluded in different clinical groups in order to provide a comprehen-
sive classification appropriate to both adult and paediatric patients.
† Recently identified gene mutations have been included in the
HPAH subgroup of clinical group 1 (PAH). The new mutations
are more rare as compared with the traditional bone morpho-
genetic protein receptor 2 (BMPR2) mutations (Table 4).
† Pre-capillary PH associated with chronic haemolytic anaemia
appears to be significantly different from other forms of PAH in
Table 3 Haemodynamic definitions of pulmonary hypertensiona
Characteristicsa Clinical group(s)b
PH PAPm ≥25 mmHg All
Pre-capillary PH PAPm ≥25 mmHg
PAWP ≤15 mmHg
1. Pulmonary arterial hypertension 
3. PH due to lung diseases
4. Chronic thromboembolic PH
5. PH with unclear and/or multifactorial mechanisms
Post-capillary PH
 
Isolated post-capillary PH
Combined post-capillary and pre-capillary PH 
(Cpc-PH)
PAPm ≥25 mmHg
PAWP >15 mmHg
DPG <7 mmHg and/or
PVR ≤3 WUc 
DPG ≥7 mmHg and/or
PVR >3 WUc
2. PH due to left heart disease
5. PH with unclear and/or multifactorial mechanisms
(Ipc-PH)
CO¼ cardiac output; DPG ¼ diastolic pressure gradient (diastolic PAP – mean PAWP); mPAP ¼ mean pulmonary arterial pressure; PAWP ¼ pulmonary arterial wedge pressure;
PH ¼ pulmonary hypertension; PVR ¼ pulmonary vascular resistance; WU ¼ Wood units.
aAll values measured at rest; see also section 8.0.
bAccording to Table 4.
cWood Units are preferred to dynes.s.cm25.
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regard to pathological findings (absence of plexiform lesions),
haemodynamic characteristics (low PVR and high CO) and re-
sponse to PAH-specific therapies (no demonstration of efficacy).
Therefore these clinical conditions have been moved from group
1 (PAH) to group 5 (unclear and/or multifactorial mechanisms).
† Group 1’ [pulmonary veno-occlusive disease (PVOD) and/or
pulmonary capillary haemangiomatosis (PCH)] has been
expanded and includes idiopathic, heritable, drug-, toxin- and
radiation-induced and associated forms.
Table 4 Comprehensive clinical classification of
pulmonary hypertension (updated from Simonneau et al.5)
1. Pulmonary arterial hypertension  
1.1 Idiopathic 
1.2 Heritable
1.2.1 BMPR2 mutation
1.2.2 Other mutations
1.3 Drugs and toxins induced
1.4 Associated with:
1.4.1 Connective tissue disease
1.4.3 Portal hypertension
1.4.4 Congenital heart disease (Table 6)
1.4.5 Schistosomiasis
1’. Pulmonary veno-occlusive disease and/or pulmonary 
capillary haemangiomatosis
1’.1 Idiopathic 
1’.2 Heritable
1’.2.1 EIF2AK4 mutation
1’.2.2 Other mutations
1’.3 Drugs, toxins and radiation induced
1’.4 Associated with:
1’.4.1 Connective tissue disease
1’.4.2 HIV infection
1”. Persistent pulmonary hypertension of the newborn
2. Pulmonary hypertension due to left heart disease
2.1 Left ventricular systolic dysfunction
2.2 Left ventricular diastolic dysfunction
2.3 Valvular disease
obstruction and congenital cardiomyopathies
2.5 Congenital /acquired pulmonary veins stenosis
3. Pulmonary hypertension due to lung diseases and/or
hypoxia
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other pulmonary diseases with mixed restrictive and   
 obstructive pattern
3.4 Sleep-disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Developmental lung diseases (Web Table III)
4. Chronic thromboembolic pulmonary hypertension 
and other pulmonary artery obstructions
4.1 Chronic thromboembolic pulmonary hypertension 
4.2 Other pulmonary artery obstructions
4.2.1 Angiosarcoma
4.2.2 Other intravascular tumors
4.2.3 Arteritis
4.2.4 Congenital pulmonary arteries stenoses
4.2.5 Parasites (hydatidosis)
5. Pulmonary hypertension with unclear and/or 
multifactorial mechanisms
5.1 Haematological disorders: chronic haemolytic anaemia, 
 myeloproliferative disorders, splenectomy
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, 
     lymphangioleiomyomatosis, neurofibromatosis
5.3 Metabolic disorders: glycogen storage disease, Gaucher 
 disease, thyroid disorders 
5.4 Others: pulmonary tumoral thrombothic microangiopathy, 
 osing mediastinitis, chronic renal failure (with/without 
 dialysis), segmental pulmonary hypertension
BMPR2 ¼ bone morphogenetic protein receptor, type 2; EIF2AK4 ¼ eukaryotic.
translation initiation factor 2 alpha kinase 4; HIV ¼ human immunodeficiency virus.
Table 5 Important pathophysiological and clinical
definitions
1. Pulmonary hypertension (PH) is a haemodynamic and 
pulmonary arterial pressure ≥25 mmHg at rest as assessed by right 
heart catheterization (Table 3). PH can be found in multiple clinical 
conditions (Table 4).
2. Pulmonary arterial hypertension (PAH, group 1) is a clinical 
condition characterized by the presence of pre-capillary PH (Table 3)
and pulmonary vascular resistance >3 Wood units, in the absence 
of other causes of pre-capillary PH such as PH due to lung diseases, 
chronic thromboembolic PH, or other rare diseases (Table 4). PAH 
includes different forms that share a similar clinical picture and 
virtually identical pathological changes of the lung microcirculation 
(Table 4).
exercise’.
3.
Table 6 Clinical classification of pulmonary arterial
hypertension associated with congenital heart disease
(updated from Simonneau et al.5)
1. Eisenmenger’s syndrome 
Includes all large intra- and extra-cardiac defects which begin as 
systemic-to-pulmonary shunts and progress with time to severe 
elevation of PVR and to reversal (pulmonary-to-systemic) or 
bidirectional shunting; cyanosis, secondary erythrocytosis, and 
multiple organ involvement are usually present.
2. PAH associated with prevalent systemic-to-pulmonary shunts 
• Correctablea
• Non-correctable
Includes moderate to large defects; PVR is mildly to moderately 
increased, systemic-to-pulmonary shunting is still prevalent, whereas 
cyanosis at rest is not a feature.
3. PAH with small/coincidental defects b
Marked elevation in PVR in the presence of small cardiac defects 
(usually ventricular septal defects <1 cm and atrial septal defects <2 cm 
of effective diameter assessed by echo), which themselves do not 
account for the development of elevated PVR; the clinical picture is 
very similar to idiopathic PAH. Closing the defects is contra-indicated.
4. PAH after defect correction
Congenital heart disease is repaired, but PAH either persists 
immediately after correction or recurs/develops months or years
haemodynamic lesions.
PAH ¼ pulmonary arterial hypertension; PVR ¼ pulmonary vascular resistance.
aWith surgery or intravascular percutaneous procedure.
bThe size applies to adult patients. However, also in adults the simple diameter may
be not sufficient for defining the haemodynamic relevance of the defect and also
the pressure gradient, the shunt size and direction, and the pulmonary to systemic
flows ratio should be considered (Web Table II).
ESC/ERS Guidelines 73
Downloaded from https://academic.oup.com/eurheartj/article-abstract/37/1/67/2887599
by Olivier Borsus user
on 26 January 2018
† Persistent PH of the newborn (PPHN) includes a heterogeneous
group of conditions that may differ from classical PAH. As a con-
sequence, PPHN has been subcategorised as group I′′.7– 9
† Paediatric heart diseases such as congenital or acquired left heart
inflow or outflow tract obstruction and congenital cardiomyop-
athies have been included in group 2 (PH due to LHD).
† No changes are proposed for group 3 (PH due to lung diseases
and/or hypoxia).
† Group 4 has been renamed as ‘CTEPH and other pulmonary
artery (PA) obstructions’, which includes CTEPH, pulmonary
angiosarcoma, other intravascular tumours, arteritis, congenital
pulmonary arteries stenoses and parasites (Table 4).
† Segmental PH is observed in discrete lung areas perfused by aorto-
pulmonary collaterals in congenital heart diseases such as pulmon-
ary or tricuspid atresia. This very unusual haemodynamic condition
has been included in group 5 (unclear and/or multifactorial
mechanisms).
† Some pathological and pathophysiological information on the
clinical groups are reported in the web addenda.
Important pathophysiological and clinical definitions are reported in
Table 5. A clinical classification of PAH associated with congenital
heart disease (CHD) is reported in Table 6.
An anatomical–pathophysiological classification of congenital
systemic-to-pulmonary shunts associated with PAH is presented
in Web Table II. A list of developmental lung diseases associated
with PH is presented in Web Table III.
4. Epidemiology and genetics
of pulmonary hypertension
4.1 Epidemiology and risk factors
Reporting in the literature of PH incidence data at the global level is
poor. In the UK, a prevalence of 97 cases per million with a female:-
male ratio of 1.8 has been reported. The age-standardized death rate
in the USA ranges between 4.5 and 12.3 per 100,000 population.
Comparative epidemiological data on the prevalence of the different
groups of PH are not widely available, but it is clear that LHD (group
2) is believed to be the most common cause of PH, although severe
PH is relatively uncommon in this setting. Although patients belonging
to groups 2 and 3 represent an important part of the clinical practice,
there is disproportionately little information about the demographics
and clinical course of this segment of the PH population, suggesting
that registry database methodology may be useful for these groups.
Globally, schistosomiasis-associated PAH and high altitude–related
PH represent an important burden to mankind.
† Group 1 (PAH): Several registries have described the epidemiology
of PAH.10–12 The lowest estimate of the prevalence of PAH and
idiopathic PAH (IPAH) are 15 cases and 5.9 cases per million adult
population, respectively. The lowest estimate of PAH incidence is
2.4 cases per million adult population per year. In Europe, PAH
prevalence and incidence are in the range of 15–60 subjects per mil-
lion population and 5–10 cases per million per year, respectively.11
In registries, around half of PAH patients have idiopathic, heritable or
drug-induced PAH. In the subgroup of associated PAH conditions
(APAH), the leading cause is CTD, mainly systemic sclerosis (SSc).10
PAH may occur in different settings depending on associated
clinical conditions.13 IPAH corresponds to sporadic disease, without
any familial history of PAH or known triggering factor. While the
mean age of patients with IPAH in the first US National Institutes
of Health registry created in 1981 was 36 years, PAH is now
more frequently diagnosed in elderly patients, resulting in a mean
age at diagnosis between 50 and 65 years in current registries.
Furthermore, the female predominance is quite variable among
registries and may not be present in elderly patients, and survival ap-
pears to have improved over time.
A number of risk factors for the development of PAH has been
identified and are defined as any factor or condition that is suspected
to play a predisposing or facilitating role in disease development. Risk
factors were classified as definite, likely or possible, based on the
strength of their association with PH and their probable causal
role.13 A definite association is acknowledged in the case of either an
epidemic, such as occurred with appetite suppressants, or if large,
multicentre epidemiological studies demonstrate an association
between the clinical condition or drug and PAH. A likely association
is acknowledged if a single-centre case–control study or multiple
case series demonstrate an association or if clinical and haemo-
dynamic recovery occurs after stopping exposure, such as oc-
curred in dasatinib-induced PAH. A possible association can be
suspected, for example, for drugs with similar mechanisms of action
as those in the definite or likely category but which have not yet
been studied, such as drugs used to treat attention deficit disorder.
Definite clinical associations are listed among APAH in Table 4 and
the risk level of different drugs and toxins are listed inTable 7.6,14–16
† Group 2 (PH due to LHD): The prevalence of PH in patients with
chronic heart failure increases with the progression of functional
class (FC) impairment. Up to 60% of patients with severe left ven-
tricular (LV) systolic dysfunction and up to 70% of patients with heart
failure with preserved ejection fraction may present with PH. In left-
sided valvular diseases, the prevalence of PH increases with the se-
verity of the defect and of the symptoms. PH can be found in virtually
all patients with severe symptomatic mitral valve disease and in up to
65% of those with symptomatic aortic stenosis.17–19
† Group 3 (PH due to lung diseases and/or hypoxaemia): Mild PH is
common in both severe interstitial lung disease and severe chronic
Table 7 Updated risk level of drugs and toxins known
to induce pulmonary arterial hypertension
Likely Possible
• Aminorex
• F
• Dexf
• Toxic rapeseed oil
• ex
• Selective serotonin 
 reuptake inhibitorsa 
• Amphetamines
• Dasatinib 
• L-tryptophan
• Methamphetamines
• Cocaine
• Phenylpropanolamine
• St John’s Wort
• Amphetamine-like 
 drugs 
• Interferon α and β 
• Some 
 chemotherapeutic 
 agents such as 
 alkylating agents 
 (mytomycine C, 
 cyclophosphamide)b
aIncreased risk of persistent pulmonary hypertension in the newborns of mothers
with intake of selective serotonin reuptake inhibitors.
bAlkylating agents are possible causes of pulmonary veno-occlusive disease.
ESC/ERS Guidelines74
Downloaded from https://academic.oup.com/eurheartj/article-abstract/37/1/67/2887599
by Olivier Borsus user
on 26 January 2018
obstructive pulmonary disease (COPD),20 while severe PH is un-
common.21 Severe PH can be seen in the combined emphysema/
fibrosis syndrome, where the prevalence of PH is high.22
† Group 4 [CTEPH and other PA obstructions]: In the Spanish PH
Registry, CTEPH prevalence and incidence were 3.2 cases per
million and 0.9 cases per million per year, respectively.23 Even
though a prevalence of CTEPH of 3.8% has been reported in sur-
vivors of acute pulmonary embolism (PE), the true incidence of
CTEPH after acute PE is lower, in the range of 0.5–2%.24 A his-
tory of acute PE was reported for 74.8% of patients from the
International CTEPH Registry.25 Associated conditions included
thrombophilic disorders (lupus anticoagulant/antiphospholipid
antibodies, protein S and C deficiency, activated protein C resist-
ance including factor V Leiden mutation, prothrombin gene mu-
tation, antithrombin III deficiency and elevated factor VIII) in
31.9% of patients and splenectomy in 3.4%.
4.2 Genetics
† Group 1 (PAH): Heterozygous BMPR2 mutations account for
approximately 75% of familial PAH and up to 25% of apparently
sporadic PAH cases.26 BMPR2 encodes a type 2 receptor for
bone morphogenetic proteins involved in the control of vascular
cell proliferation. Mutations of genes coding for activin receptor-like
kinase 1 and endoglin have been identified in PAH patients with a
personal or family history of hereditary haemorrhagic telangiectasia,
as well as in BMPR1B and SMAD9, supporting a prominent role for
transforming growth factor b (TGF-b) family members in PAH.26
Whole exome sequencing has identified rare heterozygous muta-
tions in genes coding for proteins such as caveolin 1 (CAV1) and the
potassium channel subfamily K member 3 (KCNK3).26,27
† Group 1: Heritable PVOD/PCH has been recognized in consan-
guineous families, suggesting recessive transmission. Whole gen-
ome sequencing demonstrated that bi-allelic mutations in
eukaryotic translation initiation factor 2 alpha kinase 4 (EIF2AK4)
were present in all familial PVOD/PCH and in 25% of histologically
confirmed sporadic PVOD/PCH.28 EIF2AK4 encodes a serine-
threonine kinase present in all eukaryotes that can induce changes
in gene expression in response to amino acid deprivation.
† Group 2 (PH due to LHD): No specific genetic linkage has been
identified.18
† Group 3 (PH due to lung diseases and/or hypoxaemia): Gene
polymorphism might contribute towards determining the sever-
ity of PH in hypoxaemic patients with COPD.29
† Group 4 (CTEPH and other PA obstructions): No specific genet-
ic mutations have been linked to the development of CTEPH.
† Group 5 (PH with unclear and/or multifactorial mechanisms):
The heterogeneity of this group prevents an appropriate descrip-
tion of genetics, epidemiology and risk factors in these guidelines.
5. Pulmonary hypertension
diagnosis
5.1 Diagnosis
The diagnosis of PH requires a clinical suspicion based on symptoms
and physical examination and review of a comprehensive set of
investigations to confirm that haemodynamic criteria are met and
to describe the aetiology and the functional and haemodynamic
severity of the condition. The interpretation of these investigations
requires, at the very least, expertise in cardiology, imaging and
respiratory medicine and may best be discussed at a multidisciplin-
ary team meeting. This is particularly important for identifying
patients who may have more than one cause of PH. The main
cause of PH should be identified according to the clinical classifica-
tion in Table 4. An algorithm for reaching a diagnosis is shown in
Figure 1.
5.1.1 Clinical presentation
The symptoms of PH are non-specific and mainly related to progres-
sive right ventricular (RV) dysfunction. Initial symptoms are typically
induced by exertion. They include shortness of breath, fatigue,
weakness, angina and syncope. Less commonly patients may also de-
scribe dry cough and exercise-induced nausea and vomiting. Symp-
toms at rest occur only in advanced cases. Abdominal distension and
ankle oedema will develop with progressing RV failure. The presen-
tation of PH may be modified by diseases that cause or are asso-
ciated with PH as well as other concurrent diseases.
In some patients the clinical presentation may be related to mech-
anical complications of PH and the abnormal distribution of blood
flow in the pulmonary vascular bed. These include haemoptysis re-
lated to rupture of hypertrophied bronchial arteries, as well as
symptoms attributable to pulmonary arterial dilatation such as
hoarseness caused by compression of the left recurrent laryngeal
nerve, wheeze caused by large airway compression and angina
due to myocardial ischaemia caused by compression of the left
main coronary artery. Significant dilation of the PA may result in
its rupture or dissection, leading to signs and symptoms of cardiac
tamponade.
The physical signs of PH include left parasternal lift, an accentu-
ated pulmonary component of the second heart sound, an RV third
heart sound, a pansystolic murmur of tricuspid regurgitation and a
diastolic murmur of pulmonary regurgitation. Elevated jugular ven-
ous pressure, hepatomegaly, ascites, peripheral oedema and cool
extremities characterize patients with advanced disease. Wheeze
and crackles are usually absent.
Clinical examination may suggest an underlying cause of PH.
Telangiectasia, digital ulceration and sclerodactyly are seen in sclero-
derma, inspiratory crackles may point towards interstitial lung dis-
ease and spider naevi, testicular atrophy, and palmar erythema
suggest liver disease. When digital clubbing is encountered,
PVOD, cyanotic CHD, interstitial lung disease or liver disease
should be considered.
5.1.2 Electrocardiogram
An electrocardiogram (ECG) may provide supportive evidence of
PH, but a normal ECG does not exclude the diagnosis. An abnormal
ECG is more likely in severe rather than mild PH. ECG abnormalities
may include P pulmonale, right axis deviation, RV hypertrophy, RV
strain, right bundle branch block, and QTc prolongation. While RV
hypertrophy has insufficient sensitivity (55%) and specificity (70%)
to be a screening tool, RV strain is more sensitive.30 Prolongation
of the QRS complex and QTc suggest severe disease.31,32 The
ECG differential diagnosis includes anterolateral myocardial
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ischaemia. In contrast to PH, ECG changes in ischaemia more com-
monly affect the lateral and inferior leads, and when present in the
anterior chest leads are usually accompanied by a Q wave in V1 to
V3, and rarely cause right axis deviation.
Supraventricular arrhythmias may occur in advanced disease, in
particular atrial flutter, but also atrial fibrillation, with a cumulative
incidence in 25% of patients after 5 years.33 Atrial arrhythmias com-
promise CO and almost invariably lead to further clinical deterior-
ation. Ventricular arrhythmias are rare.
5.1.3 Chest radiograph
In 90% of patients with IPAH the chest radiograph is abnormal at the
time of diagnosis.34 Findings in patients with PAH include central
pulmonary arterial dilatation, which contrasts with ‘pruning’ (loss)
of the peripheral blood vessels. Right atrium (RA) and RV enlarge-
ment may be seen in more advanced cases. A chest radiograph may
assist in differential diagnosis of PH by showing signs suggesting lung
disease (group 3, Table 4) or pulmonary venous congestion due to
LHD (group 2, Table 4). Chest radiography may help in distinguishing
between arterial and venous PH by respectively demonstrating in-
creased and decreased artery:vein ratios.35
Overall, the degree of PH in any given patient does not correlate
with the extent of radiographic abnormalities. As for ECG, a normal
chest radiograph does not exclude PH.
5.1.4 Pulmonary function tests and arterial blood gases
Pulmonary function tests and arterial blood gases identify the con-
tribution of underlying airway or parenchymal lung disease. Patients
with PAH have usually mild to moderate reduction of lung volumes
related to disease severity.36,37 Although diffusion capacity can be
normal in PAH, most patients have decreased lung diffusion capacity
for carbon monoxide (DLCO). An abnormal low DLCO, defined as
,45% of predicted, is associated with a poor outcome.36,37 The
differential diagnosis of a low DLCO in PAH includes PVOD, PAH
associated with scleroderma and parenchymal lung disease.
Although airflow obstruction is unusual, peripheral airway obstruc-
tion can be detected. Due to alveolar hyperventilation at rest, arter-
ial oxygen pressure (PaO2) remains normal or is only slightly lower
than normal and arterial carbon dioxide pressure (PaCO2) is
decreased.38
COPD as a cause of hypoxic PH is diagnosed on the evidence of
irreversible airflow obstruction together with increased residual vo-
lumes and reduced DLCO.39 Arterial blood gases of COPD patients
show a decreased PaO2 with normal or increased PaCO2.
40 A de-
crease in lung volume combined with decreased diffusion capacity
for carbon monoxide may indicate interstitial lung disease.39 The se-
verity of emphysema and of interstitial lung disease can be diagnosed
using high-resolution computed tomography (CT). Combined em-
physema and pulmonary fibrosis may pseudonormalize spirometry,
although the DLCO is almost always reduced, emphasizing the need
to interpret pulmonary function alongside lung imaging.
The prevalence of nocturnal hypoxaemia and central sleep ap-
noeas are high in PAH (70–80%).41,42 Overnight oximetry or poly-
somnography should be performed where obstructive sleep apnoea
syndrome or hypoventilation are considered.
5.1.5 Echocardiography
Transthoracic echocardiography is used to image the effects of PH
on the heart and estimate PAP from continuous wave Doppler mea-
surements. Echocardiography should always be performed when
PH is suspected and may be used to infer a diagnosis of PH in pa-
tients in whom multiple different echocardiographic measurements
are consistent with this diagnosis. When treatment of PH itself is
being considered, echocardiography alone is not sufficient to sup-
port a treatment decision and cardiac catheterization is required.
Detailed guidelines describing the echocardiographic assessment
of the right heart can be found in documents created and/or en-
dorsed by the European Association of Cardiovascular Imaging
Table 8A Echocardiographic probability of
pulmonary hypertension in symptomatic patients with
a suspicion of pulmonary hypertension
Peak tricuspid 
regurgitation 
velocity (m/s)
Presence of 
other echo 
‘PH signs’a
Echocardiographic 
probability of pulmonary 
hypertension
≤2.8 or not 
≤2.8 or not 
measurable
No Low
measurable
Yes
Intermediate
2.9–3.4 No
2.9–3.4 Yes
High
>3.4 Not required
PH ¼ pulmonary hypertension.
aSee Table 8B.
Table 8B Echocardiographic signs suggesting
pulmonary hypertension used to assess the probability
of pulmonary hypertension in addition to tricuspid
regurgitation velocity measurement in Table 8A
A: The ventriclesa B: Pulmonary 
arterya
C: Inferior vena 
cava and right 
atriuma
Right ventricle/
left ventricle basal 
diameter ratio >1.0
Right ventricular 
acceleration time 
<105 msec and/or 
midsystolic notching
Inferior cava diameter 
>21 mm with 
decreased inspiratory 
collapse (<50 % with 
a sniff or <20 % with 
quiet inspiration)
Flattening of the 
interventricular 
septum (left ventricular 
eccentricity index
 >1.1 in systole and/or 
diastole)
Early diastolic 
pulmonary 
regurgitation velocity 
>2.2 m/sec
Right atrial area
(end-systole) >18 cm2 
PA diameter >25 mm.
PA ¼ pulmonary artery.
aEchocardiographic signs from at least two different categories (A/B/C) from the
list should be present to alter the level of echocardiographic probability of
pulmonary hypertension.
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(EACVI), a registered branch of the ESC, and the reader is referred
to these for further instruction.43,44
The estimation of systolic PAP is based on the peak tricuspid re-
gurgitation velocity (TRV) taking into account right atrial pressure
(RAP) as described by the simplified Bernoulli equation. RAP can
be estimated by echocardiography based on the diameter and re-
spiratory variation in diameter of the inferior vena cava (IVC): an
IVC diameter ,2.1 cm that collapses .50% with a sniff suggests
a normal RA pressure of 3 mmHg (range 0–5 mmHg), whereas
an IVC diameter .2.1 cm that collapses ,50% with a sniff
or ,20% on quiet inspiration suggests a high RA pressure of
15 mmHg (range 10–20 mmHg). In scenarios in which the IVC
diameter and collapse do not fit this paradigm, an intermediate value
of 8 mmHg (range 5–10 mmHg) may be used. The EACVI recom-
mends such an approach rather than using a fixed value of 5 or 10
mmHg for PA systolic pressure (PASP) estimations. However, given
the inaccuracies of RAP estimation and the amplification of meas-
urement errors by using derived variables, we recommend using
the continuous wave Doppler measurement of peak TRV (and
not the estimated PASP) as the main variable for assigning the echo-
cardiographic probability of PH.
When peak TRV is technically difficult to measure (trivial or mild
tricuspid regurgitation) some laboratories use contrast echocardi-
ography [e.g. agitated saline administered by intravenous (i.v.) injec-
tion], which may improve the Doppler signal, allowing measurement
of peak TRV velocity. Unfortunately, despite the strong correlation
of TRV with a tricuspid regurgitation pressure gradient, Doppler-
derived pressure estimation may be inaccurate in the individual pa-
tient. In patients with severe tricuspid regurgitation, TRV may be sig-
nificantly underestimated and cannot be used to exclude PH.
Overestimation may also occur.44 PH cannot be reliably defined
by a cut-off value of TRV. Consequently, estimation of PAP based
solely on Doppler transthoracic echocardiography measurements
is not suitable for screening for mild, asymptomatic PH. Other echo-
cardiographic variables that might raise or reinforce suspicion of PH
independent of TRV should always be sought.
Conclusions derived from an echocardiographic examination
should aim to assign a level of probability of PH. This ESC Guideline
suggests grading the probability of PH based on TRV at rest and on
the presence of additional pre-specified echocardiographic variables
suggestive of PH (Table 8A). The probability of PH may then be
judged as high, intermediate or low. When interpreted in a clinical
context, the echocardiographic result is required to decide the need
for cardiac catheterization in individual patients. In order to facilitate
and standardize assignment to the level of probability of PH, several
additional echocardiographic signs are proposed in addition to cri-
teria based on TRV (Table 8B). These signs provide assessment of
the RV size and pressure overload, the pattern of blood flow vel-
ocity out of the RV, the diameter of the PA and an estimate of
RAP.43 – 45 Their measurement has been defined in recommenda-
tions endorsed by the EACVI.43,44
The recommended plan for further patient investigation based on
echocardiographic probability of PH is shown in Table 9 for symp-
tomatic patients. In the Web addendum, a similar table (Web
Table IX) for screening for asymptomatic patients with risk factors
for PAH or with incidental findings suggesting the possibility of PH
on ECG or lung imaging is provided.
Echocardiography can be helpful in detecting the cause of sus-
pected or confirmed PH. Two-dimensional, Doppler and contrast
examinations can be used to identify CHD. High pulmonary blood
flow found on pulsed wave Doppler in the absence of a detectable
shunt or significant dilatation of proximal PA despite only moderate
PH may warrant transoesophageal examination with contrast or
cardiac magnetic resonance (CMR) imaging to exclude sinus
Table 9 Diagnostic management suggested according to echocardiographic probability of pulmonary hypertension in
patients with symptoms compatible with pulmonary hypertension, with or without risk factors for pulmonary arterial
hypertension or chronic thromboembolic pulmonary hypertension
Echocardiographic 
probability of PH
Without risk factors or 
associated condition for PAH 
or CTEPHd
Classa Levelb
With risk factors or 
associated conditions for 
PAH or CTEPHc
Classa Levelb Ref c
Low
Alternative diagnosis should be 
considered
IIa C
Echo follow-up should be 
considered
IIa C
Intermediate
Alternative diagnosis, echo follow-up, 
should be considered
IIa
C
Further assessment of PH including 
RHC should be considerede
IIa B 45, 46
Further investigation of PH may be 
considerede
IIb
High
Further investigation of PH 
(including RHCe) is recommended
I C
Further investigation of PHe 
including RHC is recommended
I C
CTEPH ¼ chronic thromboembolic pulmonary hypertension; Echo ¼ echocardiographic; PAH ¼ pulmonary arterial hypertension; PH ¼ pulmonary hypertension; RHC ¼ right
heart catheterization.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
dThese recommendations do not apply to patients with diffuse parenchymal lung disease or left heart disease.
eDepending on the presence of risk factors for PH group 2, 3 or 5.
Further investigation strategy may differ depending on whether risk factors/associated conditions suggest higher probability of PAH or CTEPH – see diagnostic algorithm.
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venosus atrial septal defect and/or anomalous pulmonary venous re-
turn. In cases of suspicion of LV diastolic dysfunction, Doppler echo-
cardiographic signs should be assessed even if their reliability is
considered low. RHC should be considered when the diagnosis re-
mains uncertain after non-invasive investigations (see section 8.1).
The practical clinical value of exercise Doppler echocardiography
in the identification of cases with PH limited to exercise is
uncertain because of the lack of validated criteria and prospective
confirmatory data.
5.1.6 Ventilation/perfusion lung scan
A ventilation/perfusion (V/Q) lung scan should be performed in pa-
tients with PH to look for CTEPH. The V/Q scan has been the
screening method of choice for CTEPH because of its higher sensi-
tivity compared with CT pulmonary angiogram (CTPA), especially in
inexperienced centres.47 A normal- or low-probability V/Q scan ef-
fectively excludes CTEPH with a sensitivity of 90–100% and a spe-
cificity of 94–100%; however, many V/Q scans are not diagnostic.
While in PAH the V/Q lung scan may be normal, it may also show
small peripheral unmatched and non-segmental defects in perfusion.
A caveat is that unmatched perfusion defects may also be seen in
other pulmonary vascular disease such as PVOD. While a V/Q
scan is still recommended as the screening test of choice, ventilation
scans are often replaced with either a recent chest radiograph or a
recent high-resolution CT of the lungs, but such practices are not
really evidence-based. Also, CT is preferred in many centres since
it is more readily available. A few studies suggest that single photon
emission CT, also a nuclear medicine technique, could be superior
to V/Q planar scan and CTPA, but these results need more exten-
sive evaluation.48 More recently, newer techniques such as three-
dimensional magnetic resonance (MR) perfusion mapping, have
been demonstrated to be as sensitive as traditional perfusion scintig-
raphy in screening for CTEPH; MR can also be used as a radiation-
free modality to assess both ventilation and perfusion in CTEPH.49
5.1.7 High-resolution computed tomography,
contrast-enhanced computed tomography, and
pulmonary angiography
CT imaging is a widely available tool that can provide important in-
formation on vascular, cardiac, parenchymal and mediastinal abnor-
malities. It may suggest the diagnosis of PH (PA or RV enlargement),
identify a cause of PH such as CTEPH or lung disease, provide clues
as to the form of PAH (e.g. oesophageal dilation in SSc or congenital
cardiac defects such as anomalous pulmonary venous drainage) and
also provide prognostic information.50
CT may raise a suspicion of PH in symptomatic patients or those
examined for unrelated indications by showing an increased PA
diameter (≥29 mm) and pulmonary:ascending aorta diameter ratio
(≥1.0). A segmental artery:bronchus ratio .1 : 1 in three or four
lobes has been reported to have high specificity for PH.51,52
High-resolution CT provides detailed views of the lung paren-
chyma and facilitates the diagnosis of interstitial lung disease and em-
physema. High-resolution CT may also be very helpful where there
is a clinical suspicion of PVOD. Characteristic changes of interstitial
oedema with diffuse central ground-glass opacification and thicken-
ing of interlobular septa support the diagnosis of PVOD; additional
findings may include lymphadenopathy, pleural shadows and
effusions.53 Pulmonary capillary haemangiomatosis is suggested by
diffuse bilateral thickening of the interlobular septa and the presence
of small, centrilobular, poorly circumscribed nodular opacities.
However, ground-glass abnormalities are also present in PAH, oc-
curring in more than one-third of patients.50
Contrast CT angiography of the PA is helpful in determining
whether there is evidence of surgically accessible CTEPH. It can de-
lineate the typical angiographic findings in CTEPH, such as complete
obstruction, bands and webs and intimal irregularities, as accurately
and reliably as digital subtraction angiography.54,55 With this tech-
nique, collaterals from bronchial arteries can be identified.
Traditional pulmonary angiography is required in most patients
for the workup of CTEPH to identify those who may benefit from
pulmonary endarterectomy (PEA) or BPA.56,57 Angiography can be
performed safely by experienced staff in patients with severe PH
using modern contrast media and selective injections. Angiography
may also be useful in the evaluation of possible vasculitis or pulmon-
ary arteriovenous malformations, but CT angiography has similar or
even higher accuracy for both diagnoses, and is less invasive.58,59
5.1.8 Cardiac magnetic resonance imaging
CMR imaging is accurate and reproducible in the assessment of RV
size, morphology and function and allows non-invasive assessment
of blood flow, including stroke volume, CO, pulmonary arterial dis-
tensibility and RV mass.
In patients with suspected PH, the presence of late gadolinium en-
hancement, reduced pulmonary arterial distensibility and retrograde
flow have high predictive value for the identification of PH; however,
no single CMR measurement can exclude PH.60 –62 In patients with
PH, CMR may also be useful in cases of suspected CHD if echocar-
diography is not conclusive.
Contrast-enhanced and unenhanced MR angiography have a po-
tential in the study of the pulmonary vasculature in patients with sus-
pected CTEPH, particularly in clinical scenarios such as suspected
chronic embolism in pregnant women, young patients or when
iodine-based contrast media injection is contraindicated.63
CMR provides useful prognostic information in patients with PAH
both at baseline and at follow-up.64–66
5.1.9 Blood tests and immunology
Blood tests are not useful in diagnosing PH, but are required to iden-
tify the aetiology of some forms of PH as well as end organ damage.
Routine biochemistry, haematology and thyroid function tests are
required in all patients, as well as a number of other specific blood
tests. Liver function tests may be abnormal because of high hepatic
venous pressure, liver disease and/or endothelin receptor antagon-
ist (ERA) therapy. Hepatitis serology should be performed if clinical
abnormalities are noted. Thyroid disease is common in PAH and
may develop during the course of the disease. This should always
be considered in cases of abrupt deterioration.
Serological testing is required to detect underlying CTD, hepatitis
and human immunodeficiency virus (HIV). Up to 40% of patients
with IPAH have elevated antinuclear antibodies usually in a low titre
(1:80). It is important to look for evidence of SSc since this disease
has a relatively high prevalence of PAH. Limited scleroderma typic-
ally has antinuclear antibodies, including anti-centromere, dsDNA,
anti-Ro, U3-RNP, B23, Th/To and U1-RNP. Diffuse scleroderma is
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typically associated with a positive U3-RNP. Patients with systemic
lupus erythematosus may have anticardiolipin antibodies.
Patients with CTEPH should undergo thrombophilia screening,
including antiphospholipid antibodies, anticardiolipin antibodies
and lupus anticoagulant. HIV testing is required in PAH. N-terminal
pro-brain natriuretic peptide (NT-proBNP) may be elevated in pa-
tients with PH and is an independent risk predictor in these patients.
5.1.10 Abdominal ultrasound scan
Similar to blood tests, abdominal ultrasound may be useful for
identification of some of the clinical entities associated with PAH.
Abdominal ultrasound may confirm but not formally exclude portal
hypertension. The use of contrast agents and the addition of a
colour Doppler examination may improve the accuracy of the
diagnosis.67 Portal hypertension can be reliably confirmed or
excluded by measurement of the gradient between free and
occluded (wedge) hepatic vein pressure at the time of RHC.68
5.1.11 Right heart catheterization and vasoreactivity
RHC is required to confirm the diagnosis of PAH and CTEPH, to
assess the severity of haemodynamic impairment and to undertake
vasoreactivity testing of the pulmonary circulation in selected pa-
tients (Table 10). When performed at expert centres, these proce-
dures have low morbidity (1.1%) and mortality (0.055%) rates.69
The threshold to perform left heart catheterization in addition to
RHC should be low in patients with clinical risk factors for coronary
artery disease or heart failure with preserved ejection fraction, as
well as in patients with echocardiographic signs of systolic and/or
diastolic LV dysfunction. Specific recommendations for catheteriza-
tion of patients with LHD or lung disease in addition to Table 10 are
described in Tables 31 and 33, respectively. Measurement of LV end-
diastolic pressure is also important to avoid misclassification of
patients with an elevated PAWP when this is unexpected and may
be inaccurate [absence of risk factors for heart failure with pre-
served ejection fraction, normal left atrial (LA) size and absence
of echocardiographic markers of elevated LV filling pressures].
The interpretation of invasive haemodynamics should be made in
the context of the clinical picture and imaging, in particular echocar-
diography. Cardiac catheterization should be performed after the
completion of other investigations so that it can answer specific
questions that may arise from these investigations and avoid an un-
necessary procedure where an alternative diagnosis is revealed.
RHC is a technically demanding procedure that requires meticu-
lous attention to detail to obtain clinically useful information. To ob-
tain high-quality results and to be of low risk to patients, the
procedure should be limited to expert centres. Particular attention
should be paid to the following issues:
† The external pressure transducer should be zeroed at the mid-
thoracic line in a supine patient, halfway between the anterior ster-
num and the bed surface.70 This represents the level of the LA.
† Pressure measurements should be made in the PA, PA wedge
position, RV and RA. Where a balloon catheter is used, it should
be inflated in the RA, from where the catheter should be ad-
vanced until it reaches the PAWP position. Repeated deflations
and inflations of the balloon in the end pulmonary arteries should
be avoided because this has been associated with rupture of the
pulmonary arteries. The PAWP is a surrogate of LA pressure and
should be recorded as the mean of three measurements. Blood
sampling should also be considered with the balloon inflated in
the wedge position to confirm that a true PAWP measurement
has been taken, as this should have the same saturation as system-
ic blood. All pressure measurements should be determined at the
end of normal expiration (breath holding is not required). Alter-
natively, assuming that negative inspiratory and positive expira-
tory intrathoracic pressures cancel each other out, averaging
pulmonary vascular pressures over several respiratory cycles is
also acceptable, except in dynamic hyperinflation states.70 Ideally,
high-fidelity tracings that can be printed on paper should be used
rather than small moving traces on a cardiac monitor. Non-
invasive blood pressure should be recorded at the time of the
procedure if left heart catheterization is not undertaken.
† Blood samples for oximetry should be taken from the high super-
ior vena cava, IVC and PA at a minimum. Systemic arterial blood
oxygen (O2) saturation should also be determined. A stepwise
assessment of O2 saturation should be performed in every pa-
tient with a pulmonary arterial O2 saturation .75% and when-
ever a left-to-right shunt is suspected.
† CO should be measured using thermodilution or the direct Fick
method. Thermodilution measured in triplicate is the preferred
method because it can provide reliable measurements even in pa-
tients with low CO and/or severe tricuspid regurgitation.71 In pa-
tients with intracardiac shunts, thermodilution may be inaccurate
because of early recirculation of the injectate. The direct Fick
method requires direct measurement of O2 uptake, a technique
that is not widely available. The indirect Fick method, which uses
estimated values of O2 uptake, is acceptable but lacks reliability.
† Pulmonary vasoreactivity testing for identification of patients suit-
able for high-dose calcium channel blocker (CCB) treatment is re-
commended only for patients with IPAH, HPAH or drug-induced
PAH. It should be performed at the time of RHC. In all other forms
of PAH and PH the results can be misleading and responders are
rare. Inhaled nitric oxide (NO) at 10–20 parts per million (ppm)
is the standard of care for vasoreactivity testing, but i.v. epoproste-
nol, i.v. adenosine or inhaled iloprost can be used as alternatives
(Web Table IV). A positive acute response is defined as a reduction
of the mean PAP ≥10 mmHg to reach an absolute value of mean
PAP ≤40 mmHg with an increased or unchanged CO. Only about
10% of patients with IPAH will meet these criteria. The use of
CCBs, O2, phosphodiesterase type 5 inhibitors or other vasodila-
tors for acute vasoreactivity testing is discouraged.
† Interpretation of the PAWP at a single point in time needs to be
performed in a clinical context. In many patients with LHD,
PAWP may be reduced to ,15 mmHg with diuretics.72 – 74 For
this reason, the effect of an acute volume challenge on left heart
filling pressures has been considered.75 Limited data suggest that
a fluid bolus of 500 ml appears to be safe and may discriminate
patients with PAH from those with LV diastolic dysfunction.76,77
Further evaluation of administering a fluid challenge is required
before this can be considered for routine clinical practice. Similar-
ly, exercise haemodynamics to identify patients with LV diastolic
dysfunction is likely to be useful,2,78,79 but lacks standardisation
and requires further evaluation.17 Furthermore, PAWP may
underestimate LV end-diastolic pressure.80
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† Derived variables calculated from the RHC measurements
should include transpulmonary pressure gradient (TPG) and
PVR. A PVR .3 WU is required for the diagnosis of PAH.1
PVR is commonly used but has the disadvantage of being a com-
posite variable that is highly sensitive to changes in both flow and
filling pressure and may not reflect changes in the pulmonary cir-
culation at rest.81,82 The DPG between the mean PAWP and dia-
stolic PAP is less affected by flow and filling pressures81 but may
not be of prognostic value.83 DPG may have a role in patients sus-
pected of having PH related to LHD, as discussed in section 8.4
† Coronary angiography may be required in the presence of angina,
risk factors for coronary artery disease and listing for PEA or lung
transplantation. It may identify left main stem coronary artery com-
pression by an enlarged PA as well as coronary artery disease.
Recommendations for right and left heart catheterization and vasor-
eactivity testing are summarised in the Tables 10 and 11.
5.1.12 Genetic testing
The availability of molecular genetic diagnosis has opened up a new field
for patient care, including genetic counselling for PAH (developed in
section 6.3.1.8).26 Genetic testing and counselling follows strict local reg-
ulations that set the conditions for prescribing and conducting reviews
of the genetic characteristics of a patient. The ethical principles are to
inform patients properly to avoid harm, to allow patients to preserve
their autonomy (disclosure about the process, risks and benefits of
the genetic test without external pressures) and to allow equal access
to genetic counselling and testing. Patients with sporadic or familial PAH
or PVOD/PCH should be advised about the availability of genetic testing
and counselling because of the strong possibility that they carry a
disease-causing mutation. Trained professionals should offer counselling
Table 11 Recommendations for vasoreactivity
testing
Recommendations Classa Levelb Ref.c
Vasoreactivity testing is indicated only in
expert centres
I C 69
Vasoreactivity testing is recommended in
patients with IPAH, HPAH and PAH
associated with drugs use to detect
patients who can be treated with high
doses of a CCB
I C 84,85
A positive response to vasoreactivity
testing is defined as a reduction of mean
PAP ≥10 mmHg to reach an absolute
value of mean PAP ≤40 mmHg with an
increased or unchanged cardiac output
I C 85,86
Nitric oxide is recommended for
performing vasoreactivity testing
I C 85,86
Intravenous epoprostenol is
recommended for performing
vasoreactivity testing as an alternative
I C 85,86
Adenosine should be considered for
performing vasoreactivity testing as an
alternative
IIa C 87,88
Inhaled iloprost may be considered for
performing vasoreactivity testing as an
alternative
IIb C 89,90
The use of oral or intravenous CCBs in
acute vasoreactivity testing is not
recommended
III C
Vasoreactivity testing to detect patients
who can be safely treated with high doses
of a CCB is not recommended in patients
with PAH other than IPAH, HPAH and
PAH associated with drugs use and is not
recommended in PH groups 2, 3, 4 and 5
III C
CCB ¼ calcium channel blocker; HPAH ¼ heritable pulmonary arterial
hypertension; IPAH ¼ idiopathic pulmonary arterial hypertension; PAP ¼
pulmonary arterial pressure; PAH ¼ pulmonary arterial hypertension.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
Table 10 Recommendations for right heart
catheterization in pulmonary hypertension
Recommendations Classa Levelb Ref.c
RHC is recommended to confirm the
diagnosis of pulmonary arterial
hypertension (group 1) and to support
treatment decisions
I C
In patients with PH, it is recommended
to perform RHC in expert centres
(see section 12) as it is technically
demanding and may be associated with
serious complications
I B 69
RHC should be considered in pulmonary
arterial hypertension (group 1) to assess
the treatment effect of drugs (Table 16)
IIa C
RHC is recommended in patients with
congenital cardiac shunts to support
decisions on correction (Table 24)
I C
RHC is recommended in patients with
PH due to left heart disease (group 2) or
lung disease (group 3) if organ
transplantation is considered
I C
When measurement of PAWP is
unreliable, left heart catheterization
should be considered to measure LVEDP
IIa C
RHC may be considered in patients with
suspected PH and left heart disease or
lung disease to assist in the differential
diagnosis and support treatment decisions
IIb C
RHC is indicated in patients with CTEPH
(group 4) to confirm the diagnosis and
support treatment decisions
I C
CTEPH ¼ chronic thromboembolic pulmonary hypertension; LVEDP ¼ left
ventricular end-diastolic pressure; PAWP ¼ pulmonary artery wedge pressure;
PH ¼ pulmonary hypertension; RHC ¼ right heart catheterization.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
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and testing to the patient. Genetic counselling and BMPR2 mutation
screening (point mutations and large rearrangements) should be offered
by expert referral centres to patients with IPAH considered to be spor-
adic or induced by anorexigens and to patients with a family history of
PAH. When no BMPR2 mutations are identified in familial PAH patients
or in IPAH patients,40 years old, or when PAH occurs in patients with
a personal or familial history of hereditary haemorrhagic telangiectasia,
screening of the ACVRL1 and ENG genes may be performed. If no muta-
tions in the BMPR2, ACVRL1 and ENG genes are identified, screening of
rare mutations may be considered (KCNK3, CAV1, etc.).
Patients with sporadic or familial PVOD/PCH should be tested
for EIF2AK4 mutations.28 The presence of a bi-allelic EIF2AK4 muta-
tion is sufficient to confirm a diagnosis of PVOD/PCH without per-
forming a hazardous lung biopsy for histological confirmation.
5.2 Diagnostic algorithm
The diagnostic algorithm is shown in Figure 1: the diagnostic process
starts after the suspicion of PH and echocardiography compatible
with PH (according to the different levels of PH probability reported
in Tables 8 and 9) and continues with the identification of the more
Symptoms, signs, history suggestive of PH
Echocardiographic probability of PH (Table 8)
Diagnosis of left heart diseases or
lung diseases confirmed?
V/Q scana
Mismatched perfusion defects?
Consider left heart disease and lung diseases
by symptoms, signs, risk factors, ECG,
PFT+DLCO, chest radiograph and HRCT,
arterial blood gases  (Table 9)
Consider other causes
and/or follow-up (Table 9)
Signs of severe PH/RV 
dysfunction
Refer to PH
expert centre
No signs of severe
PH/RV dysfunction
Treat underlying
disease
Refer to PH
expert centre
PAH likely
Specific diagnostic tests
Consider other
causes
Group 5
CTD
Drugs - Toxin
HIV
Idiopathic
PVOD/PCH
Heritable
PVOD/PCH
Heritable
PAH
Idiopathic
PAH
CHD
Porto-
pulmonary
Schistosomiasis
CTEPH possible:
CT pulmonary angiography,
RHC +/- Pulmonary Angiography
RHC (Table 10)
mPAP 25 mmHg, PAWP
15 mmHg, PVR >3 Wood units 
High or intermediate
Yes
Yes No
No
Yes
No
Yes
Low
CHD = congenital heart diseases; CT = computed tomography; CTD = connective tissue disease; CTEPH = chronic thromboembolic pulmonary hypertension;
pressure; PA = pulmonary angiography; PAH = pulmonary arterial hypertension; PAWP = pulmonary artery wedge pressure; PFT = pulmonary function tests; 
PH = pulmonary hypertension; PVOD/PCH = pulmonary veno-occlusive disease or pulmonary capillary hemangiomathosis; PVR = pulmonary vascular resistance; 
RHC = right heart catheterisation; RV = right ventricular;  V/Q = ventilation/perfusion.
aCT pulmonary angiography alone may miss diagnosis of chronic thromboembolic pulmonary hypertension.
Figure 1 Diagnostic algorithm.
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common clinical groups of PH [group 2 (LHD) and group 3 (lung
diseases)], then distinguishes group 4 (CTEPH) and finally makes
the diagnosis and recognizes the different types in group 1 (PAH)
and the rarer conditions in group 5.
PAH should be considered in the differential diagnosis of exer-
tional dyspnoea, syncope, angina and/or progressive limitation of
exercise capacity, particularly in patients without apparent
risk factors, symptoms or signs of common cardiovascular and
respiratory disorders. Special awareness should be directed
towards patients with associated conditions and/or risk factors
for the development of PAH, such as family history, CTD,
CHD, HIV infection, portal hypertension or a history of drug
or toxin intake known to induce PAH (Table 7). In everyday clin-
ical practice such awareness may be low. More often PH is found
unexpectedly on transthoracic echocardiography requested for
another indication.
If transthoracic echocardiography is compatible with a high or
intermediate probability of PH (Table 9), a clinical history, symp-
toms, signs, ECG, chest radiograph, pulmonary function tests
(PFTs, including DLCO, arterial blood gases analysis and nocturnal
oximetry, if required) and high-resolution CT of the chest are re-
quested to identify the presence of group 2 (LHD) or group 3
(lung diseases) PH. In case of an echocardiographic low probability
of PH (Table 9), no additional investigations are required and other
causes for the symptoms should be considered together with
follow-up. If the diagnosis of left heart or lung diseases is con-
firmed, the appropriate treatment for these conditions should
be considered. In the presence of severe PH and/or RV dysfunc-
tion, the patient should be referred to a PH expert centre where
additional causes of PH can be explored. If the diagnosis of left
heart or lung diseases is not confirmed, a V/Q lung scan should
be performed for the differential diagnosis between CTEPH and
PAH. Concurrently the patient should be referred to a PH expert
centre.
If the V/Q scan shows multiple segmental perfusion defects, a
diagnosis of group 4 (CTEPH) PH should be suspected.91 The final
diagnosis of CTEPH (and the assessment of suitability for PEA) will
require CT pulmonary angiography, RHC and selective pulmonary
angiography. The CT scan may also show signs suggestive of group
1′ (PVOD). If a V/Q scan is normal or shows only subsegmental
‘patchy’ perfusion defects, a diagnosis of group 1 (PAH) or the
rarer conditions of group 5 should be considered. In Table 9,
further management according to the probability of PH is given,
including indications for RHC. Additional specific diagnostic tests,
including haematology, biochemistry, immunology, serology, ultra-
sonography and genetics, will allow the final diagnosis to be
refined.
Open or thoracoscopic lung biopsy entails a substantial risk of
morbidity and mortality.92 Because of the low likelihood of altering
the diagnosis and treatment, biopsy is not recommended in PAH
patients.
The recommendations for a diagnostic strategy are reported in
the Table 12.
The pulmonary arterial hypertension screening programme is
reported in the Web Addenda.
6. Pulmonary arterial
hypertension (group 1)
6.1 Clinical characteristics
The clinical characteristics of PAH are not specific and can be de-
rived from the general description reported in section 5.1.1. More
detailed descriptions of the individual PAH subsets are reported
in the section 7.
6.2 Evaluation of severity
6.2.1 Clinical parameters, imaging and haemodynamics
Clinical assessment remains a key part of the evaluation of patients
with PH, as it provides valuable information for determining disease
severity, improvement, deterioration or stability. Elementary parts
of history taking between follow-up visits include changes in exer-
cise capacity, episodes of chest pain, arrhythmia, haemoptysis or
Table 12 Recommendations for diagnostic strategy
Recommendations Classa Levelb Ref.c
Echocardiography is recommended as a
first-line non-invasive diagnostic
investigation in case of suspicion of PH
I C
Ventilation/perfusion or perfusion lung
scan is recommended in patients with
unexplained PH to exclude CTEPH
I C 47
Contrast CT angiography of the PA is
recommended in the workup of patients
with CTEPH
I C 93
Routine biochemistry, haematology,
immunology, HIV testing and thyroid
function tests are recommended in all
patients with PAH to identify the specific
associated condition
I C
Abdominal ultrasound is recommended
for the screening of portal hypertension
I C 67
Lung function test with DLCO is
recommended in the initial evaluation of
patients with PH
I C 36
High-resolution CT should be
considered in all patients with PH
IIa C 94
Pulmonary angiography should be
considered in the workup of patients with
CTEPH
IIa C
Open or thoracoscopic lung biopsy is not
recommended in patients with PAH
III C
CT ¼ computed tomography; CTEPH ¼ chronic thromboembolic pulmonary
hypertension; DLCO ¼ diffusing capacity of the lung for carbon monoxide;
PAH ¼ pulmonary arterial hypertension; PH ¼ pulmonary hypertension.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
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syncope and changes in medications, as well as adherence to the
prescribed drugs. Physical examination provides information on
the presence or absence of peripheral or central cyanosis, enlarged
jugular veins, oedema, ascites and pleural effusions and on heart
rate, rhythm and blood pressure.
The World Health Organization functional class (WHO-FC)
(Web Table V), despite its interobserver variability,95 remains one
of the most powerful predictors of survival, not only at diagnosis,
but also during follow-up.96–98 A worsening FC is one of the most
alarming indicators of disease progression, which should trigger further
diagnostic studies to identify the causes of clinical deterioration.97,99
As RV function is a key determinant of exercise capacity and out-
come in patients with PH, echocardiography remains an important
follow-up tool. In contrast to common belief, the estimated systolic
PAP (PAPs) at rest is usually not prognostic and not relevant for
therapeutic decision making.96,97,100 An increase in PAPs does not
necessarily reflect disease progression and a decrease in PAPs
does not necessarily signal improvement. A comprehensive echo-
cardiographic assessment includes a description of chamber sizes,
particularly of the RA and RV area, the magnitude of tricuspid regur-
gitation, the LV eccentricity index and RV contractility, which can be
determined by several variables, including RV longitudinal systolic
strain/strain rate and RV fractional area change, Tei index and tricus-
pid annular plane systolic excursion (TAPSE).101 – 108
Three-dimensional echocardiography may achieve a better esti-
mation than standard two-dimensional assessment, but underesti-
mations of volumes and ejection fractions have been reported.109
Speckle tracking improves the quantification of RV function.110
Given the complex geometry of the RV, none of these variables
alone is sufficient to describe RV function, and the overall impres-
sion of an experienced physician is often more important than single
variables. Echocardiography during exercise provides additional in-
formation on RV function. Of note, a marked increase (.30 mmHg)
of PAPs during exercise reflects better RV function and is associated
with a better long-term outcome than a modest or no increase.111
This so-called contractile reserve has recently been shown to be an
independent prognostic marker in patients with severe PH.111
CMR imaging is more accurate for the assessment of RV morph-
ology and function than echocardiography and also allows measure-
ment of stroke volume and CO. A number of CMR prognostic
markers have been identified, including increased RV volume, re-
duced LV volume, reduced RV ejection fraction and reduced stroke
volume. There is some evidence that follow-up CMR studies may
have utility in the long-term management of PAH by identifying
RV failure prior to the development of clinical features.64,66,112,113
Haemodynamics assessed by RHC provide important prognostic
information, both at the time of diagnosis and during follow-up. RA
pressure, cardiac index (CI) and mixed venous oxygen saturation
(SvO2) are the most robust indicators of RV function and prognosis,
whereas PAPm provides little prognostic information (except for
CCB responders).96,97,99,100,114 Non-invasive assessment of CO
by rebreathing techniques71 or bioreactance115 has not yet been
sufficiently validated to allow routine clinical use and therapeutic de-
cision making.
There are still uncertainties around the optimal timing of follow-
up RHC. Strategies vary between centres, from regular invasive
haemodynamic assessments to a predominantly non-invasive
follow-up strategy. There is no evidence that an approach involving
regular RHC is associated with better outcomes than a predomin-
antly non-invasive follow-up strategy. However, there is consensus
among experts that RHC should be performed whenever thera-
peutic decisions can be expected from the results, which may in-
clude changes in medications and/or decisions regarding listing for
transplantation.
6.2.2 Exercise capacity
The 6-minute walking test (6MWT), a submaximal exercise test, re-
mains the most widely used exercise test in PH centres. The test is
easy to perform, inexpensive and familiar to patients and centres. As
with all PH assessments, 6MWT results must always be interpreted
in the clinical context. The 6-minute walking distance (6MWD) is in-
fluenced by several factors, including sex, age, height, weight, co-
morbidities, need for O2, learning curve and motivation. Neverthe-
less, test results are usually given in absolute numbers rather than
percent predicted. Absolute values, but not changes in 6MWD, pro-
vide prognostic information, but there is no single threshold that is
applicable for all patients (see below).96,99,116 – 118 It is recom-
mended to use the Borg score at the end of the 6MWT to deter-
mine the level of effort. In addition, some studies suggest that
adding peripheral O2 measurements and heart rate response may
improve the prognostic relevance, but these findings await inde-
pendent confirmation.119,120
Cardiopulmonary exercise testing (CPET) is usually performed as
a maximal exercise test and provides important information on ex-
ercise capacity as well as on gas exchange, ventilator efficacy and
cardiac function during exercise. Most PH centres use an incremen-
tal ramp protocol, although the test has not yet been standardized
for this patient population. Patients with PAH show a typical pattern
with a low end-tidal partial pressure of carbon dioxide (pCO2), high
ventilator equivalents for carbon dioxide (VE/VCO2), low oxygen
pulse (VO2/HR) and low peak oxygen uptake (peak VO2).
121 Sev-
eral variables determined by CPET provide prognostic information,
although peak VO2 is most widely used for therapeutic decision
making.106,122 – 125 The diagnostic and prognostic information pro-
vided by CPET add to that provided by the 6MWT.122
6.2.3 Biochemical markers
There is still no specific marker for PAH or pulmonary vascular remod-
elling, although a wide variety of biomarkers have been explored in the
field. These can be grouped into markers of vascular dysfunction
[asymmetric dimethylarginine (ADMA), endothelin-1, angiopoeitins,
von Willebrand factor],126–131 markers of inflammation (C-reactive
protein, interleukin 6, chemokines),132 – 135 markers of myocardial
stress (atrial natriuretic peptide, brain natriuretic peptide (BNP)/
NT-proBNP, troponins),97,118,136–139 markers of low CO and/or tissue
hypoxia [pCO2, uric acid, growth differentiation factor 15 (GDF15),
osteopontin]38,140–142 and markers of secondary organ damage (cre-
atinine, bilirubin).97,137 This list is constantly growing, but so far BNP
and NT-proBNP remain the only biomarkers that are widely used in
the routine practice of PH centres as well as in clinical trials. BNP/
NT-proBNP levels correlate with myocardial dysfunction and provide
prognostic information at the time of diagnosis and during follow-up
assessments.143 They are not specific for PH, but can be elevated in al-
most any heart disease. BNP/NT-proBNP levels tend to have a high
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variability and should be interpreted in the clinical context. There are
no clear advantages of using BNP versus NT-proBNP. BNP appears to
have a slightly tighter correlation with pulmonary haemodynamics and
is less affected by kidney function, whereas NT-proBNP seems to be a
stronger predictor of prognosis.137
6.2.4 Comprehensive prognostic evaluation and risk
assessment
Regular assessment of patients with PAH in expert PH centres is
strongly recommended. A comprehensive assessment is required
since there is no single variable that provides sufficient diagnostic
and prognostic information. The most important questions to be ad-
dressed at each visit are (i) is there any evidence of clinical deterior-
ation since the last assessment?; (ii) if so, is clinical deterioration
caused by progression of PH or by a concomitant illness?; (iii) is
RV function stable and sufficient?; and (iv) is the current status com-
patible with a good long-term prognosis, i.e. does the patient meet
the low-risk criteria (see below)?
In order to answer these questions, a multidimensional approach
is needed. Table 13 lists the variables that are most frequently used
in PH centres. Not all of them need to be assessed at each visit.
However, the basic programme should include determination of
the FC and at least one measurement of exercise capacity, e.g.
6MWD or CPET. It is also recommended to obtain some informa-
tion on RV function, either by measuring BNP/NT-proBNP or by
performing echocardiography. Most of the proposed variables and
cut-off values are based on expert opinion. They may provide prog-
nostic information and may be used to guide therapeutic decisions,
but application to individual patients must be done carefully.
The indicated mortality rates are crude estimates and the depicted
variables have been studied mostly in patients with IPAH. Not all
variables may be in the same risk group, and it is the comprehensive
assessment of individual patients that should guide treatment
decisions. The individual risk is further modified by other factors,
such as the rate of disease progression and the presence or absence
of signs of right heart failure, or syncope, and also by co-morbidities,
age, sex, background therapy, and PAH subtype, among others.
Finally, the assessment of PAH patients should provide information
on co-morbidities and disease complications. ECGs should be ob-
tained on a regular basis to detect clinically relevant arrhythmias,
which occur frequently in this patient population.33 Patients with
PAH occasionally present with progressive hypoxaemia and may be
candidates for long-term O2 therapy. In addition, a low PaCO2 is asso-
ciated with reduced pulmonary blood flow and has prognostic impli-
cations.38 Thus arterial or capillary blood gases provide important
information and should be part of the regular clinical assessment, at
least in cases of clinical deterioration. Alternatively the peripheral
O2 saturation may be used, but it is less reliable and does not provide
information on PaCO2. The recommended basic laboratory workup
(in addition to BNP/NT-proBNP) includes blood counts and inter-
national normalized ratio (INR) (in patients receiving vitamin K antago-
nists), as well as serum sodium, potassium, creatinine, uric acid,
aspartate aminotransferase (ASAT), alanine aminotransferase
(ALAT) (in patients receiving ERAs) and bilirubin. In addition, troponin,
uric acid, iron status and thyroid function should be checked at least
once a year or whenever the patient presents with clinical worsening.
Tables 14 and 15 provide detailed recommendations on the follow-up
assessment of patients with PAH.
Table 13 Risk assessment in pulmonary arterial hypertension
Determinants of prognosisa
(estimated 1-year mortality)
Low risk <5% Intermediate risk 5–10% High risk >10%
Clinical signs of right heart failure Absent Absent Present
Progression of symptoms No Slow Rapid
Syncope No Occasional syncopeb Repeated syncopec 
WHO functional class I, II III IV
6MWD >440 m 165–440 m <165 m
Cardiopulmonary exercise testing
Peak VO2 >15 ml/min/kg
(>65% pred.)
VE/VCO2 slope <36
Peak VO2 
11–15 ml/min/kg (35–65% pred.)
VE/VCO2 slope 36–44.9
Peak VO2 <11 ml/min/kg 
(<35% pred.)
VE/VCO2 slope ≥45
NT-proBNP plasma levels
BNP <50 ng/l
NT-proBNP <300 ng/l
BNP 50–300 ng/l
NT-proBNP 300–1400 ng/l
BNP >300 ng/l
NT-proBNP >1400 ng/l
Imaging (echocardiography, CMR imaging)
RA area <18 cm2
No pericardial effusion
RA area 18–26 cm2
No or minimal, pericardial 
effusion
RA area >26 cm2
Pericardial effusion
Haemodynamics
RAP <8 mmHg
CI ≥2.5 l/min/m2
SvO2 >65%
RAP 8–14 mmHg
CI 2.0–2.4 l/min/m2
SvO2 60–65%
RAP >14 mmHg
CI <2.0 l/min/m2
SvO2 <60%
6MWD ¼ 6-minute walking distance; BNP ¼ brain natriuretic peptide; CI ¼ cardiac index; CMR ¼ cardiac magnetic resonance; NT-proBNP ¼ N-terminal pro-brain natriuretic
peptide; pred. ¼ predicted; RA ¼ right atrium; RAP ¼ right atrial pressure; SvO2 ¼ mixed venous oxygen saturation; VE/VCO2 ¼ ventilatory equivalents for carbon dioxide;
VO2 ¼ oxygen consumption; WHO ¼World Health Organization.
aMost of the proposed variables and cut-off values are based on expert opinion. They may provide prognostic information and may be used to guide therapeutic decisions, but
application to individual patients must be done carefully. One must also note that most of these variables have been validated mostly for IPAH and the cut-off levels used above may
not necessarily apply to other forms of PAH. Furthermore, the use of approved therapies and their influence on the variables should be considered in the evaluation of the risk.
bOccasional syncope during brisk or heavy exercise, or occasional orthostatic syncope in an otherwise stable patient.
cRepeated episodes of syncope, even with little or regular physical activity.
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6.2.5 Definition of patient status
Based on the comprehensive assessment described in the last sec-
tion, the patient can be classified as low risk, intermediate risk or
high risk for clinical worsening or death (Table 13). Of course, there
are several other factors that have an impact on disease manifest-
ation and prognosis that cannot be affected by PAH therapy, includ-
ing age, sex, underlying disease and co-morbidities. Although
reliable individual predictions are always difficult, patients categor-
ized as low risk have an estimated 1-year mortality ,5%. Basically
these patients present with non-progressive disease in WHO-FC I
or II with a 6MWD .440 m and no signs of clinically relevant RV
dysfunction. The estimated 1-year mortality in the intermediate-risk
group is 5–10%. These patients typically present in WHO-FC III,
with moderately impaired exercise capacity and signs of RV dysfunc-
tion, but not with RV failure. Patients in the high-risk group have an
estimated 1-year mortality .10%. These patients present in
WHO-FC III or IV with progressive disease and signs of severe RV
dysfunction, or with RV failure and secondary organ dysfunction.
The variables shown in Table 13 may not behave consistently,
i.e. they may fall into different risk categories. Again, it is the overall
assessment that should drive therapeutic decisions.
6.2.6 Treatment goals and follow-up strategy
The overall treatment goal in patients with PAH is achieving a low-
risk status (Table 13), which is usually associated with good exer-
cise capacity, good quality of life, good RV function and a low mor-
tality risk. Specifically, this means bringing and/or keeping the
Table 14 Suggested assessment and timing for the follow-up of patients with pulmonary arterial hypertension
At baseline Every 3–6 
monthsa
Every 6–12 
monthsa
3–6 months after 
changes in therapya
In case of clinical 
worsening
Medical assessment and
determination of functional class
+ + + + +
ECG + + + + +
6MWT/Borg dyspnoea score + + + + +
CPET + + +e
Echo + + + +
Basic labb + + + + +
Extended labc + + +
Blood gas analysisd + + + +
Right heart catheterization + +f +e +e
ALAT ¼ alanine aminotransferase; ASAT ¼ aspartate aminotransferase; BGA ¼ blood gas analysis; BNP ¼ brain natriuretic peptide; CPET ¼ cardiopulmonary exercise testing;
Echo ¼ echocardiography; ECG ¼ electrocardiogram; ERAs ¼ endothelin receptor antagonists; FC ¼ functional class; INR ¼ international normalized ratio; lab ¼ laboratory
assessment; NT-proBNP ¼ N-terminal pro-brain natriuretic peptide; RHC ¼ right heart catheterization; TSH ¼ thyroid stimulating hormone; 6MWT ¼ 6-minute walking test.
aIntervals to be adjusted according to patient needs.
bBasic lab includes blood count, INR (in patients receiving vitamin K antagonists), serum creatinine, sodium, potassium, ASAT/ALAT (in patients receiving ERAs), bilirubin and BNP/
NT-proBNP.
cExtended lab includes TSH, troponin, uric acid, iron status (iron, ferritin, soluble transferrin receptor) and other variables according to individual patient needs.
dFrom arterial or arterialized capillary blood; may be replaced by peripheral oxygen saturation in stable patients or if BGA is not available.
eShould be considered.
fSome centres perform RHCs at regular intervals during follow-up.
Table 15 Recommendations for evaluation of the
severity of pulmonary arterial hypertension and
clinical response to therapy
Recommendations Classa Levelb Ref.c
It is recommended to evaluate the
severity of PAH patients with a panel of
data derived from clinical assessment,
exercise tests, biochemical markers and
echocardiographic and haemodynamic
evaluations (Tables 13 and 14)
I C
96,97,
99
It is recommended to perform regular
follow-up assessments every 3–6
months in stable patients (Table 14)
I C 98
Achievement/maintenance of a low-risk
profile (Table 13) is recommended as an
adequate treatment response for
patients with PAH
I C 96–99
Achievement/maintenance of an
intermediate-risk profile (Table 13)
should be considered an inadequate
treatment response for most patients
with PAH
IIa C 96–99
PAH ¼ pulmonary arterial hypertension.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
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patient in WHO-FC II whenever possible. In most patients, this
will be accompanied by a near-normal or normal 6MWD. Several
treatment goals for the 6MWD have been proposed including
.380 m, .440 m and .500 m.96,99,116 –118,144 All of these num-
bers are based on survival analyses from selected cohorts or on
expert opinion. The present guidelines adopt a threshold of
.440 m as suggested during the 5th World Symposium on Pul-
monary Hypertension,145 because this number was derived from
the largest cohort investigated so far.99 Nevertheless, individual
factors must be considered and lower values may be acceptable
in elderly patients or patients with co-morbidities, whereas even
values .440 m may not be sufficient in younger, otherwise
healthy patients. Especially in those patients, CPET should be regu-
larly used, as it provides more objective information on exercise
capacity and RV performance.
It should be noted that these treatment goals are not always real-
istic and may not be achievable in patients with advanced disease,
patients with severe co-morbidities or very old patients.
6.3 Therapy
The therapy for PAH patients has evolved progressively in the past
decade, increasing in complexity and in evidence for efficacy.146 – 148
The treatment process of PAH patients cannot be considered as a
mere prescription of drugs, but is characterised by a complex strat-
egy that includes the initial evaluation of severity and the subsequent
response to treatment.
The current treatment strategy for PAH patients can be divided
into three main steps:149
(1) The initial approach includes general measures (physical activity
and supervised rehabilitation, pregnancy, birth control and
post-menopausal hormonal therapy, elective surgery, infection
prevention, psychosocial support, adherence to treatments,
genetic counselling and travel), supportive therapy (oral antic-
oagulants, diuretics, O2, digoxin), referral to expert centres
and acute vasoreactivity testing for the indication of chronic
CCB therapy.
(2) The second step includes initial therapy with high-dose CCB
in vasoreactive patients or drugs approved for PAH in
non-vasoreactive patients according to the prognostic risk
(Table 13) of the patient and the grade of recommendation
and level of evidence for each individual compound or com-
bination of compounds.
(3) The third part is related to the response to the initial treatment
strategy; in the case of an inadequate response, the role of com-
binations of approved drugs and lung transplantation are
proposed.
6.3.1 General measures
Patients with PAH require sensible advice about general activities of
daily living and need to adapt to the uncertainty associated with a
serious chronic life-threatening disease. The diagnosis usually con-
fers a degree of social isolation.150 Encouraging patients and their
family members to join patient support groups can have positive ef-
fects on coping, confidence and outlook. The recommendations for
general measures are reported in the Table 16.
6.3.1.1 Physical activity and supervised rehabilitation
The 2009 PH guidelines suggested that PAH patients should be en-
couraged to be active within symptom limits.151 It was recom-
mended that patients should avoid excessive physical activity that
leads to distressing symptoms, but when physically deconditioned,
patients may undertake supervised exercise rehabilitation. This
was based on a randomized controlled trial (RCT) that demon-
strated an improvement in exercise and functional capacity and in
quality of life in patients with PH who took part in a training pro-
gramme as compared with an untrained control group.152 Since
then, additional uncontrolled experiences have supported these
data utilising different models of exercise training.153 –157 Two add-
itional RCTs have been published reporting that trained PAH pa-
tients reached higher levels of physical activity, had decreased
fatigue severity and showed improved 6MWD, cardiorespiratory
function and patient-reported quality of life as compared with un-
trained controls.158,159 The sample sizes of all these studies are quite
small (ranging from 19 to 183 patients) and all or the initial training
was highly supervised and in some instances conducted in an in-
patient setting.
This recommendation is limited by gaps in the knowledge about
the optimal method of exercise rehabilitation and the intensity and
duration of the training. In addition, the characteristics of the super-
vision and the mechanisms for the improvement of symptoms, ex-
ercise and functional capacity are unclear, as are the possible effects
Table 16 Recommendations for general measures
Recommendations Classa Levelb Ref.c
It is recommended that PAH patients
avoid pregnancy
I C
160,
161
Immunization of PAH patients against
influenza and pneumococcal infection is
recommended
I C
Psychosocial support is recommended in
PAH patients
I C 168
Supervised exercise training should be
considered in physically deconditioned
PAH patients under medical therapy
IIa B
153–
157
In-flight O2 administration should
be considered for patients in WHO-FC III
and IV and those with arterial blood O2
pressure consistently ,8 kPa (60 mmHg)
IIa C
In elective surgery, epidural rather than
general anaesthesia should be preferred
whenever possible
IIa C
Excessive physical activity that leads to
distressing symptoms is not
recommended in PAH patients
III C
O2 ¼ oxygen; PAH ¼ pulmonary arterial hypertension; WHO-FC ¼ World
Health Organization functional class.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
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on prognosis. Exercise training programmes should be implemented
by centres experienced in both PAH patient care and rehabilitation
of compromised patients. In addition, patients should be treated
with the best standard of pharmacological treatment and in stable
clinical condition before embarking on a supervised rehabilitation
programme.
6.3.1.2 Pregnancy, birth control and post-menopausal hormonal therapy
Pregnancy remains associated with a substantial mortality rate in
PAH. However, a recent report indicates that the outcome of preg-
nancies in PAH has improved, at least when PAH is well controlled,
and particularly in long-term responders to CCBs.160 During a
3-year period, the 13 participating centres reported 26 pregnancies.
Three women (12%) died and one (4%) developed right heart failure
requiring urgent heart– lung transplantation. There were eight abor-
tions; two spontaneous and six induced. Sixteen pregnancies (62%)
were successful, i.e. the women delivered healthy babies without
complications. A study from the USA from five centres between
1999 and 2009 managed 18 pregnancies with three deaths
(17%).161 These data must be confirmed by larger series before
the general recommendation to avoid pregnancy in all patients
with PAH is reconsidered. There is less consensus relating to the
most appropriate methods of birth control. Barrier contraceptive
methods are safe for the patient, but with an unpredictable effect.
Progesterone-only preparations such as medroxyprogesterone
acetate and etonogestrel are effective approaches to contraception
and avoid the potential issues of oestrogens such as those associated
with the old-generation mini-pill.162 It should be remembered that
the ERA bosentan may reduce the efficacy of oral contraceptive
agents. The levonorgestrel-releasing intrauterine coil is also effect-
ive but may rarely lead to a vasovagal reaction when inserted, which
may be poorly tolerated in severe PAH.162 A combination of two
methods may also be utilised. The patient who becomes pregnant
should be informed of the high risk of pregnancy and termination
of the pregnancy should be discussed. Those patients who choose
to continue pregnancy should be treated with disease-targeted
therapies, planned elective delivery and effective close collaboration
between obstetricians and the PAH team.163,164
It is unclear whether the use of hormonal therapy in post-
menopausal women with PAH is advisable. It may be considered
in cases of intolerable menopausal symptoms in conjunction with
oral anticoagulation.
6.3.1.3 Elective surgery
Elective surgery is expected to have an increased risk in patients
with PAH. It is unclear as to which form of anaesthesia is preferable,
but epidural is probably better tolerated than general anaesthe-
sia.165 – 167 Patients usually maintained on oral therapy may require
temporary conversion to i.v. or nebulized treatment until they are
able to both swallow and absorb drugs taken orally.
6.3.1.4 Infection prevention
Patients with PAH are susceptible to developing pneumonia, which
is the cause of death in 7% of cases.34 While there are no controlled
trials, it is recommended to vaccinate against influenza and pneumo-
coccal pneumonia.
6.3.1.5 Psychosocial support
PH is a disease with a significant impact on the psychological, social
(including financial), emotional and spiritual functioning of patients
and their families.168 Teams managing these patients should have
the skills and expertise to assess and manage issues in all of these
domains, with close links to colleagues in relevant disciplines for
those with severe problems, e.g. psychiatry, clinical psychology, wel-
fare and social work. Patient support groups may also play an im-
portant role and patients should be advised to join such groups.
PH is a disease that may be severely life-limiting. In addition to
psychological and social support there should be proactive ad-
vanced care planning with referral to specialist palliative care ser-
vices when appropriate.
6.3.1.6 Adherence to treatments
Adherence to medical treatments needs to be checked periodically
due to the complexity of the PAH therapy and possible reductions
or changes to the treatment regimen induced spontaneously by pa-
tients or non-expert physicians.
6.3.1.7 Travel
There are no studies using flight simulation to determine the need
for supplemental O2 during prolonged flights in patients with PAH.
The known physiological effects of hypoxia suggest that in-flight O2
administration should be considered for patients in WHO-FC III and
IV and those with arterial blood O2 pressure consistently ,8 kPa
(60 mmHg).169 A flow rate of 2 l/min will raise inspired O2 pressure
to values seen at sea level. Similarly, such patients should avoid going
to altitudes .1500–2000 m without supplemental O2. Patients
should be advised to travel with written information about their
PAH and be advised on how to contact local PH clinics in close
proximity to where they are travelling.
6.3.1.8 Genetic counselling
Genetic counselling should be offered to selected PAH patients
(detailed in section 5.1.12).26 Because of the psychological impact
of the positive or negative results, genetic testing and counselling
should be provided according to local regulations in the setting of
a multidisciplinary team with availability of PH specialists, genetic
counsellors, geneticists, psychologists and nurses. Affected indivi-
duals and at-risk family members may want to know their mutation
status for family planning purposes. Current reproductive options
for couples with a BMPR2 mutation carrier are to remain childless,
to have no genetic prenatal testing (reproductive chance), to under-
go prenatal or pre-implantation genetic diagnosis,170 to use gamete
donation or to adopt.
6.3.2 Supportive therapy
The recommendations for supportive therapy are reported in
Table 17.
6.3.2.1 Oral anticoagulants
There is a high prevalence of vascular thrombotic lesions at post-
mortem examination in patients with IPAH.171 Abnormalities in co-
agulation and fibrinolytic pathways have also been reported.172 – 174
This, together with the non-specific increased risk factors for ven-
ous thromboembolism, including heart failure and immobility, re-
presents the rationale for oral anticoagulation in PAH. Evidence in
favour of oral anticoagulation is confined to patients with IPAH,
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HPAH and PAH due to anorexigens and is generally retrospective
and based on single-centre experience.84,171 Registry and RCT
data appear to be heterogeneous and inconclusive.175 – 177 The po-
tential benefits of oral anticoagulation in APAH is even less clear.
Generally patients with PAH receiving therapy with long-term
i.v. prostaglandins are anticoagulated in the absence of contraindica-
tions due in part to the additional risk of catheter-associated
thrombosis. The role of the new oral anticoagulants in PAH is
unknown. Additional information on APAH is provided in the
individual chapters.
6.3.2.2 Diuretics
Decompensated right heart failure leads to fluid retention, raised
central venous pressure, hepatic congestion, ascites and peripheral
oedema. Although there are no RCTs on the use of diuretics in
PAH, clinical experience shows clear symptomatic benefit in fluid
overloaded patients treated with this therapy. The choice and
dose of diuretic therapy may be left to the PAH physician.178 The
addition of aldosterone antagonists should also be considered to-
gether with systematic assessments of electrolyte plasma levels. It
is important with diuretic use to monitor renal function and blood
biochemistry in patients to avoid hypokalaemia and the effects of
decreased intravascular volume leading to pre-renal failure.
6.3.2.3 Oxygen
Although O2 administration has been demonstrated to reduce the
PVR in patients with PAH, there are no randomised data to suggest
that long-term O2 therapy is beneficial. Most patients with PAH, ex-
cept those with CHD and pulmonary-to-systemic shunts, have min-
or degrees of arterial hypoxaemia at rest unless they have a patent
foramen ovale. There are data showing that nocturnal O2 therapy
does not modify the natural history of advanced Eisenmenger syn-
drome.179 Guidance may be based on evidence in patients with
COPD; when arterial blood O2 pressure is consistently ,8 kPa
(60 mmHg; alternatively, ,91% of arterial O2 saturation) patients
are advised to take O2 to achieve an arterial blood O2 pressure
.8 kPa.169 Ambulatory O2 may be considered when there is evi-
dence of symptomatic benefit and correctable desaturation on
exercise.
6.3.2.4 Digoxin and other cardiovascular drugs
Digoxin has been shown to improve CO acutely in IPAH, although
its efficacy is unknown when administered chronically.180 It may be
given to slow ventricular rate in patients with PAH who develop at-
rial tachyarrhythmias.
No convincing data are available on the usefulness and safety of
angiotensin-converting enzyme inhibitors, angiotensin II receptor
antagonists, beta-blockers or ivabradine in patients with PAH.
6.3.2.5 Anaemia and iron status
Iron deficiency is common in patients with PAH and has been re-
ported in 43% of patients with IPAH, 46% of patients with SSc-PAH
and 56% of patients with Eisenmenger syndrome.181 – 183 In all of
these entities, preliminary data indicate that iron deficiency may
be associated with reduced exercise capacity, and perhaps also
with a higher mortality, independent of the presence or severity
of anaemia.181,182,184,185 Based on these data, regular monitoring
of the iron status should be considered in patients with PAH and de-
tection of an iron deficiency should trigger a search for potential
reasons. Iron substitution should be considered in patients with
iron deficiency. Some studies suggest that oral iron absorption is im-
paired in patients with PAH, so i.v. iron administration may be pref-
erable.181,184,186 However, controlled trials are lacking.
6.3.3 Specific drug therapy
6.3.3.1 Calcium channel blockers
It has been increasingly recognised that only a small number of pa-
tients with IPAH who demonstrate a favourable response to acute
vasodilator testing (Table 11) at the time of RHC do well with
CCBs.84,85 The CCBs that have been predominantly used in re-
ported studies are nifedipine, diltiazem and amlodipine, with par-
ticular emphasis on nifedipine and diltiazem.84,85 The choice of
CCB is based on the patient’s heart rate at baseline, with a relative
bradycardia favouring nifedipine and amlodipine and a relative tachy-
cardia favouring diltiazem. The daily doses of these drugs that have
shown efficacy in IPAH are relatively high: 120–240 mg for nifedi-
pine, 240–720 mg for diltiazem and up to 20 mg for amlodipine. It
is advisable to start with an initial lower dose, e.g. 30 mg of slow re-
lease nifedipine twice a day or 60 mg of diltiazem three times a day
(t.i.d.) or 2.5 mg of amlodipine once a day, and increase cautiously
and progressively to the maximum tolerated dose. Limiting factors
Table 17 Recommendations for supportive therapy
Recommendations Classa Levelb Ref.c
Diuretic treatment is
recommended in PAH patients with
signs of RV failure and fluid
retention
I C 178
Continuous long-term O2 therapy is
recommended in PAH patients
when arterial blood O2 pressure is
consistently ,8 kPa (60 mmHg)d
I C 179
Oral anticoagulant treatment may
be considered in patients with
IPAH, HPAH and PAH due to use of
anorexigens
IIb C
84,171,
175–
177
Correction of anaemia and/or iron
status may be considered in PAH
patients
IIb C 184
The use of angiotensin-converting
enzyme inhibitors, angiotensin-2
receptor antagonists, beta-blockers
and ivabradine is not recommended
in patients with PAH unless
required by co-morbidities (i.e. high
blood pressure, coronary artery
disease or left heart failure)
III C
HPAH ¼ heritable pulmonary arterial hypertension; IPAH ¼ idiopathic
pulmonary arterial hypertension; O2 ¼ oxygen; PAH ¼ pulmonary arterial
hypertension; RV ¼ right ventricular.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
dSee also recommendations for PAH associated with congenital cardiac shunts.
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for dose increase are usually systemic hypotension and lower limb
peripheral oedema. Patients with IPAH who meet the criteria for a
positive vasodilator response and are treated with CCBs should be
followed closely for reasons of both safety and efficacy, with a com-
plete reassessment after 3–4 months of therapy including RHC.
If the patient does not show an adequate response, defined as
being in WHO-FC I or II and with a marked haemodynamic im-
provement (near normalization), additional PAH therapy should
be instituted. In some cases the combination of CCB with the ap-
proved PAH drugs is required because of further clinical deterior-
ation in case of CCB withdrawal attempts. Patients who have not
undergone a vasoreactivity study or those with a negative study
should not be started on CCBs because of potential severe side ef-
fects (e.g. hypotension, syncope and RV failure).187
Vasodilator responsiveness does not appear to predict a favour-
able long-term response to CCB therapy in patients with PAH in the
setting of CTD, HIV, porto-pulmonary hypertension (PoPH) and
PVOD.188,189
The recommendations for CCB therapy are reported in Table 18.
For specific approved doses of the drugs, please refer to the
updated official prescription information.
6.3.3.2 Endothelin receptor antagonists
Activation of the endothelin system has been demonstrated in both
plasma and lung tissue of PAH patients.190 Although it is unclear if
the increases in endothelin-1 plasma levels are a cause or a conse-
quence of PH,191 these data support a prominent role for the en-
dothelin system in the pathogenesis of PAH.192 Endothelin-1
exerts vasoconstrictor and mitogenic effects by binding to two dis-
tinct receptor isoforms in the pulmonary vascular smooth muscle
cells, endothelin receptors type A and B. The characteristics of
RCTs with PAH drugs interfering with the endothelin pathway are
reported in Web Table VIA.
Ambrisentan
Ambrisentan is an ERA that preferentially binds with endothelin re-
ceptor type A. Ambrisentan has been evaluated in a pilot study193
and in two large RCTs that have demonstrated efficacy on symp-
toms, exercise capacity, haemodynamics and time to clinical wor-
sening of patients with IPAH and PAH associated with CTD and
HIV infection.194 The incidence of abnormal liver function tests
ranges from 0.8 to 3%. Monthly liver function assessment is not
mandated in the USA.195 An increased incidence of peripheral
oedema has been reported with ambrisentan use.
Bosentan
Bosentan is an oral active dual endothelin receptor type A and B antag-
onist and the first molecule of its class to be synthesized. Bosentan has
been evaluated in PAH (idiopathic, associated with CTD and Eisen-
menger syndrome) in six RCTs (Study-351, BREATHE-1, BREATHE-2,
BREATHE-5, EARLY and COMPASS 2), which showed improvement
in exercise capacity, FC, haemodynamics, echocardiographic and Dop-
pler variables and time to clinical worsening.196–200 Increases in hepatic
aminotransferases occurred in approximately 10% of the patients and
were found to be dose dependent and reversible after dose reduction
or discontinuation. For these reasons, liver function testing should be
performed monthly in patients receiving bosentan.
Macitentan
The dual ERA macitentan has been evaluated in an event-driven
RCT:201 742 PAH patients were treated with 3 mg or 10 mg maciten-
tan as compared with placebo for an average of 100 weeks. The pri-
mary endpoint was the time from the initiation of treatment to the
first occurrence of a composite endpoint of death, atrial septostomy,
lung transplantation, initiation of treatment with i.v. or subcutaneous
prostanoids or worsening of PAH. Macitentan significantly reduced
this composite endpoint of morbidity and mortality among patients
with PAH and also increased exercise capacity. Benefits were shown
both for patients who had not received treatment previously and for
those receiving additional therapy for PAH. While no liver toxicity
was shown, reduction in blood haemoglobin ≤8 g/dl was observed
in 4.3% of patients receiving 10 mg of macitentan.
6.3.3.3 Phosphodiesterase type 5 inhibitors and guanylate cyclase
stimulators
Inhibition of the cyclic guanosine monophosphate (cGMP) degrading
enzyme phosphodiesterase type 5 results in vasodilation through the
NO/cGMP pathway at sites expressing this enzyme. Since the pulmon-
ary vasculature contains substantial amounts of phosphodiesterase
Table 18 Recommendations for calcium channel
blocker therapy in patients who respond to the acute
vasoreactivity test
Recommendations Classa Levelb Ref.c
High doses of CCBs are recommended in
patients with IPAH, HPAH and DPAH
who are responders to acute
vasoreactivity testing
I C 84,85
Close follow-up with complete
reassessment after 3–4 months of
therapy (including RHC) is
recommended in patients with IPAH,
HPAH and DPAH treated by high doses
of CCBs
I C 84,85
Continuation of high doses of CCBs is
recommended in patients with IPAH,
HPAH and DPAH in WHO-FC I or II
with marked haemodynamic
improvement (near normalization)
I C 84,85
Initiation of specific PAH therapy is
recommended in patients in WHO-FC III
or IV or those without marked
haemodynamic improvement (near
normalization) after high doses of CCBs
I C 84,85
High doses of CCBs are not indicated in
patients without a vasoreactivity study or
non-responders unless standard doses
are prescribed for other indications (e.g.
Raynaud’s phenomenon)
III C
CCB ¼ calcium channel blocker; DPAH ¼ drug-induced PAH; HPAH =
heritable PAH; IPAH ¼ idiopathic PAH; PAH ¼ pulmonary arterial
hypertension; RHC ¼ right heart catheterization; RV ¼ right ventricular;
WHO-FC ¼ World Health Organization functional class.
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type 5, the potential clinical benefit of phosphodiesterase type 5 inhi-
bitors (PDE-5is) has been investigated in PAH. In addition, PDE-5is ex-
ert antiproliferative effects.202,203 All three PDE-5is approved for the
treatment of erectile dysfunction—sildenafil, tadalafil and vardena-
fil—cause significant pulmonary vasodilation, with maximum effects
observed after 60, 75–90 and 40–45 minutes, respectively.204 The
characteristics of RCTs with PAH drugs interfering with the NO path-
way [soluble guanylate cyclase (sGC) stimulators, PDE-5is] are re-
ported in Web Table VIB.
Sildenafil
Sildenafil is an orally active, potent and selective inhibitor of phospho-
diesterase type 5. Four RCTs in PAH patients treated with sildenafil
have confirmed favourable results on exercise capacity, symptoms
and/or haemodynamics.205–208 An RCT addressing the effects of add-
ing sildenafil to epoprostenol showed improvements after 12 weeks
in 6MWD and time to clinical worsening. Of note, seven deaths oc-
curred in this trial, all in the placebo group.209 The approved dose of
sildenafil is 20 mg t.i.d. Most side effects of sildenafil are mild to mod-
erate and mainly related to vasodilation (headache, flushing, epistaxis).
Based on pharmacokinetic data, an i.v. formulation of sildenafil210 has
been proposed as a bridge for PAH patients on long-term oral treat-
ment who are temporarily unable to ingest tablets.
Tadalafil
Tadalafil is a once-daily dispensed selective PDE-5i. An RCT in 406
PAH patients (53% on background bosentan therapy) treated with
tadalafil 2.5, 10, 20 or 40 mg once daily has shown favourable results
on exercise capacity, symptoms, haemodynamics and time to clinical
worsening at the highest dose.211 The side-effect profile was similar
to that of sildenafil.
Vardenafil
Vardenafil is a twice-daily dispensed PDE-5i. An RCT in 66
treatment-naive PAH patients treated with vardenafil 5 mg twice
daily has shown favourable results on exercise capacity, haemo-
dynamics and time to clinical worsening.212 The side-effect profile
was similar to that of sildenafil.
Riociguat
While PDE-5is such as sildenafil, tadalafil and vardenafil enhance the
NO–cGMP pathway, slowing cGMP degradation, sGC stimulators
enhance cGMP production.213 Moreover, pre-clinical studies with
sGC stimulators have antiproliferative and antiremodelling proper-
ties in various animal models.
An RCT214 in 443 PAH patients (44% and 6% on background
therapy with ERAs or prostanoids, respectively) treated with rioci-
guat up to 2.5 mg t.i.d. has shown favourable results on exercise cap-
acity, haemodynamics, WHO-FC and time to clinical worsening.
The increase in exercise capacity was also demonstrated in patients
on background therapy. The most common serious adverse event in
the placebo group and in the 2.5-mg group was syncope (4% and 1%,
respectively). The combination of riociguat and PDE-5i is contrain-
dicated due to hypotension and other relevant side effects detected
in the open-label phase of an RCT study.215
6.3.3.4 Prostacyclin analogues and prostacyclin receptor agonists
Prostacyclin is produced predominantly by endothelial cells and in-
duces potent vasodilation of all vascular beds. This compound is the
most potent endogenous inhibitor of platelet aggregation and also
appears to have both cytoprotective and antiproliferative
activities.216 Dysregulation of the prostacyclin metabolic pathways
has been shown in patients with PAH as assessed by a reduction
of prostacyclin synthase expression in the pulmonary arteries and
of prostacyclin urinary metabolites.217 The clinical use of prostacyc-
lin in patients with PAH has been extended by the synthesis of stable
analogues that possess different pharmacokinetic properties but
share qualitatively similar pharmacodynamic effects.
The characteristics of RCTs with PAH drugs interfering with the
prostacyclin pathway (prostanoids and prostacyclin IP receptor
agonists) are reported in Web Table VIC.
Beraprost
Beraprost is the first chemically stable and orally active prostacyclin
analogue. An RCT218 in Europe and a second in the USA219
have shown an improvement in exercise capacity that persists up
to 3–6 months. There were no haemodynamic improvements or
long-term outcome benefits. The most frequent adverse events
were headache, flushing, jaw pain and diarrhoea.
Epoprostenol
Epoprostenol (synthetic prostacyclin) has a short half-life (3–5 min-
utes) and is stable at room temperature for only 8 hours; it requires
cooling and continuous administration by means of an infusion pump
and a permanent tunnelled catheter. The efficacy of continuous i.v. ad-
ministration of epoprostenol has been tested in three unblinded RCTs
in patients with WHO-FC III and IV IPAH220,221 and in those with PAH
associated with the scleroderma spectrum of diseases.222 Epoproste-
nol improves symptoms, exercise capacity and haemodynamics in
both clinical conditions and is the only treatment shown to reduce
mortality in IPAH in a single RCT study.221 The meta-analysis for total
mortality of the three epoprostenol RCTs220–222 has shown a risk re-
duction for mortality of about 70%. Long-term persistence of efficacy
has also been shown96,107 in IPAH as well as in other APAH condi-
tions223–225 and in non-operable CTEPH.226
Treatment with epoprostenol is initiated at a dose of 2–4 ng/kg/min,
with doses increasing at a rate limited by side effects (flushing, head-
ache, diarrhoea, leg pain). The optimal dose varies between individual
patients, ranging in the majority between 20 and 40 ng/kg/min.96,107
Serious adverse events related to the delivery system include pump
malfunction, local site infection, catheter obstruction and sepsis. Guide-
lines for the prevention of central venous catheter bloodstream infec-
tions have been proposed.227 Abrupt interruption of the epoprostenol
infusion should be avoided, because in some patients this may lead to a
PH rebound with symptomatic deterioration and even death. A thermo-
stable formulation of epoprostenol is also available and does not usually
require cooling packs to maintain stability beyond 8–12 hours.228
Iloprost
Iloprost is a chemically stable prostacyclin analogue available for i.v.,
oral or aerosol administration. Inhaled iloprost has been evaluated in
one RCT in which daily repetitive iloprost inhalations (six to nine
times, 2.5–5 mg/inhalation, median 30 mg daily) were compared
with placebo inhalation in patients with PAH and CTEPH.229 The
study showed an increase in exercise capacity and improvement in
symptoms, PVR and clinical events in enrolled patients. A second
RCT involving 60 patients already treated with bosentan showed
an increase in exercise capacity (P , 0.051) in the subjects rando-
mized to the addition of inhaled iloprost compared with placebo.230
Another similar study was terminated prematurely for futility.231
Overall, inhaled iloprost was well tolerated, with flushing and jaw
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pain being the most frequent side effects. Continuous i.v. administra-
tion of iloprost appeared to be as effective as epoprostenol in a
small series of patients with PAH and CTEPH.232 The effects of
oral iloprost have not been assessed in PAH.
Treprostinil
Treprostinil is a tricyclic benzidine analogue of epoprostenol, with
sufficient chemical stability to be administered at ambient tempera-
ture. These characteristics allow administration of the compound by
i.v. and subcutaneous routes. The subcutaneous administration of
treprostinil can be accomplished by a micro-infusion pump and a
small subcutaneous catheter. The effects of treprostinil in PAH
were assessed in an RCT and showed improvements in exercise
capacity, haemodynamics and symptoms.233 The greatest exercise
improvement was observed in patients who were more compro-
mised at baseline and in subjects who could tolerate the upper quar-
tile dose (.13.8 ng/kg/min). Infusion site pain was the most
common adverse effect of treprostinil, leading to discontinuation
of the treatment in 8% of cases on active drug and limiting dose
increases in an additional proportion of patients.233 Treatment
with subcutaneous treprostinil is initiated at a dose of 1–2 ng/kg/
min, with doses increasing at a rate limited by side effects (local
site pain, flushing, headache). The optimal dose varies between indi-
vidual patients, ranging in the majority between 20 and 80 ng/kg/min.
An RCT was performed with i.v. treprostinil in PAH patients, but
the enrolment of this trial was closed because of safety considera-
tions after 45 (36%) of the planned 126 patients had been rando-
mized.234 The data generated from 31 (25%) survivors after the
randomized phase (23 active and 8 placebo) are not considered re-
liable. The dose of i.v. treprostinil is two to three times higher than
the dose of i.v. epoprostenol.235,236
An RCT with inhaled treprostinil in PAH patients on background
therapy with either bosentan or sildenafil showed improvements in
the 6MWD by 20 m at peak dose and 12 m at trough dose,
NT-proBNP and quality of life measures.237
Oral treprostinil has been evaluated in two RCTs in PAH patients on
background therapy with bosentan and/or sildenafil and in both trials
the primary endpoint 6MWD did not reach statistical significance.238,239
Table 19 Recommendations for efficacy of drug monotherapy for pulmonary arterial hypertension (group 1) according to
World Health Organization functional class. The sequence is by pharmacological group, by rating and by alphabetical order
Measure/treatment Classa-Levelb Ref.c
WHO-FC II WHO-FC III WHO-FC IV
Calcium channel blockers I Cd I Cd - - 84,85
Endothelin receptor antagonists Ambrisentan I A I A IIb C 194
Bosentan
I A I A IIb C
196–
200
Macitentane I B I B IIb C 201
Phosphodiesterase type 5 inhibitors Sildenafil
I A I A IIb C
205–
208
Tadalafil I B I B IIb C 211
Vardenafilg IIb B IIb B IIb C 212
Guanylate cyclase stimulators Riociguat I B I B IIb C 214
Prostacyclin analogues Epoprostenol Intravenouse - -
I A I A
220–
222
Iloprost Inhaled - -
I B IIb C
229–
231
Intravenousg - - IIa C IIb C 232
Treprostinil Subcutaneous - - I B IIb C 233
Inhaledg - - I B IIb C 237
Intravenousf - - IIa C IIb C 234
Oralg - -
IIb B
- - 238–
240
Beraprostg - - IIb B - - 218
IP receptor agonists Selexipag (oral)g I B I B - - 241,248
EMA ¼ European Medicines Agency; PAH ¼ pulmonary arterial hypertension; RCT ¼ randomized controlled trial; WHO-FC ¼ World Health Organization functional class.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
dOnly in responders to acute vasoreactivity tests ¼ class I, for idiopathic PAH, heritable PAH and PAH due to drugs; class IIa, for conditions associated with PAH.
eTime to clinical worsening as primary endpoint in RCTs or drugs with demonstrated reduction in all-cause mortality.
fIn patients not tolerating the subcutaneous form.
gThis drug is not approved by the EMA at the time of publication of these guidelines.
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An additional RCT in treatment-naive PAH patients showed improve-
ment in the 6MWD by 26 m at peak dose and 17 m at trough dose.240
Selexipag
Selexipag is an orally available, selective prostacyclin IP receptor
agonist. Although selexipag and its metabolite have modes of action
similar to that of endogenous prostacyclin (IP receptor agonism),
they are chemically distinct from prostacyclin with a different
pharmacology. In a pilot RCT in PAH patients (receiving stable
ERA and/or PDE-5i therapy), selexipag reduced PVR after 17
weeks.241 An event-driven phase 3 RCT that enrolled 1156 patients248
has shown that selexipag alone or on top of mono- or double therapy
with ERAs and/or PDE-5i was able to reduce by 40% (hazard ratio
0.60, P, 0.001) a composite morbidity and mortality endpoint
(including death from all causes, hospitalization for worsening of
PAH, worsening of PAH resulting in the need for lung transplantation
or atrial septostomy, initiation of parenteral prostanoids or chronic
O2 for worsening of PAH and disease progression).
Recommendations for efficacy of specific drug monotherapies
are reported in the Table 19.
6.3.3.5 Experimental compounds and strategies
Despite progress in the treatment of PAH, the functional limitation and
survival of these patients remain unsatisfactory. There are three well-
known pathways that contribute to the pathogenesis of PAH: the en-
dothelin, NO and prostacyclin pathways. Treatments targeting these
pathways are well established in clinical practice, such as ERAs, PDE-5is
and prostanoids. Additional therapeutic strategies targeted at diverse
pathobiological changes are being explored in order to further improve
symptoms and prognosis. Three pathways have been explored with
unsatisfactory results using the following compounds: inhaled vaso-
active intestinal peptide, tyrosine kinase inhibitors (platelet-derived
growth factor inhibitors) and serotonin antagonists. The following
additional compounds are in an earlier stage of development: rho
kinase inhibitors, vascular endothelial growth factor receptor inhibi-
tors, angiopoietin-1 inhibitors and elastase inhibitors. Gene therapy
strategies have been tested in animal models. Stem cell therapy has
proven to be effective in the monocrotaline rat model and is currently
being tested in a proof-of-concept and dose-finding study in PAH pa-
tients. A controversial study has shown a preliminary favourable effect
of PA denervation by a radiofrequency ablation catheter.242,243
6.3.4 Combination therapy
Combination therapy—using two or more classes of drugs simul-
taneously—has been used successfully in the treatment of systemic
hypertension and heart failure. It is also an attractive option for the
management of PAH, because three separate signalling pathways
known to be involved in the disease can be addressed by specific
drugs: the prostacyclin pathway (prostanoids), the endothelin path-
way (ERAs) and the NO pathway (PDE-5is and sGCs).
The experience with combination therapy is increasing and a re-
cent meta-analysis on six RCTs with combination therapy including
858 patients has been published;244 compared with the control
group, combination therapy reduced the risk of clinical worsening
{relative risk [RR] 0.48 [95% confidence interval (CI) 0.26, 0.91],
P ¼ 0.023}, increased the 6MWD significantly by 22 m and reduced
mean PAP, RAP and PVR. The incidence of serious adverse
events was similar in the two groups [RR 1.17 (95% CI 0.40, 3.42),
P ¼ 0.77]. The reduction in all-cause mortality was not statistically
significant. However, the incidence of mortality in RCTs with PAH
medications is relatively low and to achieve statistical significance a
sample size of several thousand patients may be required.244
Combination therapy may be applied sequentially or initially
(upfront).
Sequential combination therapy is the most widely utilised strategy
both in RCTs and in clinical practice: from monotherapy there is an
addition of a second and then a third drug in cases of inadequate clin-
ical results or in cases of deterioration. A structured prospective pro-
gramme to evaluate the adequacy of clinical results is the so-called
goal-oriented therapy, a treatment strategy that uses known prognos-
tic indicators as treatment targets. The therapy is considered adequate
only if the targets are met. The key difference between goal-oriented
therapy and non-structured approaches is that patients who are stabi-
lised, or even those who improve slightly, can still receive additional
therapy if treatment goals are not met. The goal-oriented treatment
strategy utilises different targets, including WHO-FC I or II, and the
near-normalization of resting CI and/or of NT-proBNP plasma levels.
A recent study has confirmed a better prognosis in patients achieving
these goals as compared with patients who did not.97
Recommendations and evidence on the use of specific drugs for
initial combination therapy and for sequential combination therapy
for PAH according to WHO-FC are provided in Table 20 and
Table 21, respectively.
Table 20 Recommendations for efficacy of initial
drug combination therapy for pulmonary arterial
hypertension (group 1) according to World Health
Organization functional class. Sequence is by rating
Measure/
treatment
Classa-Levelb Ref.c
WHO-FC
II
WHO-FC
III
WHO-FC
IV
Ambrisentan +
tadalafild
I B I B IIb C 247
Other ERA +
PDE-5i
IIa C IIa C IIb C
-
Bosentan +
sildenafil +
i.v. epoprostenol
- -
IIa C IIa C 246
Bosentan + i.v.
epoprostenol
- -
IIa C IIa C
198,
245
Other ERA or
PDE-5i +
s.c. treprostinil
IIb C IIb C
-
Other ERA or
PDE-5i + other
i.v. prostacyclin
analogues
IIb C IIb C
-
ERA ¼ endothelin receptor antagonist; i.v. ¼ intravenous;
PDE-5i ¼ phosphodiesterase type 5 inhibitor; RCT ¼ randomized controlled trial;
s.c. ¼ subcutaneous; WHO-FC ¼ World Health Organization functional class.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
dTime to clinical failure as primary endpoint in RCTs or drugs with demonstrated
reduction in all-cause mortality (prospectively defined).
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The rationale for initial or upfront combination therapy is
based on the known mortality of PAH, which is reminiscent of
many malignancies, and the fact that malignancies and critical
medical illnesses (heart failure, malignant hypertension) are not
treated with a stepwise approach to therapy, but rather with
pre-emptive combination therapy. The experience in RCTs with
initial combination therapy started with the small BREATHE-2
(Web Table VID) study, which failed to demonstrate any signifi-
cant difference between patients treated initially with the combin-
ation epoprostenol and bosentan as compared with epoprostenol
alone.198 In a more recent experience, 23 treatment-naive PAH
patients were treated with the initial combination of epoprostenol
and bosentan and compared with a matched historical control
group treated with epoprostenol.245 The study showed a statis-
tically significant greater decrease in PVR in the initial combina-
tion therapy group, but this haemodynamic benefit did not
translate into a statistically significant difference in survival or in
transplant-free survival. A pilot study on an initial triple com-
bination in 19 WHO-FC class III and IV patients has provided
preliminary evidence of the long-term benefits of upfront triple
combination therapy in patients with severe PAH.246 A recent
multicentre, multinational, blinded, placebo-controlled trial
(Web Table VID) compared first-line monotherapy with tadalafil
or monotherapy with ambrisentan with upfront combination
therapy with tadalafil and ambrisentan in de novo WHO-FC II
and III PAH patients.247 The primary endpoint was a composite
of clinical failure events (including death, hospitalization, PAH pro-
gression and unsatisfactory clinical status). The study was positive,
with a 50% reduction in events in the combination group. In add-
ition, improvements were observed in exercise capacity, rate of
satisfactory clinical response and NT-proBNP plasma levels.247
6.3.5 Drug interactions
Significant drug interactions involving the disease-targeted
therapies for PAH are shown in Web Table VII. This table high-
lights known important interactions but does not include
theoretical untested interactions, which may still be clinically im-
portant. In addition, updated official prescribing information for
each compound should be read.
Bosentan is an inducer of cytochrome P450 isoenzymes CYP3A4
and CYP2C9. Plasma concentrations of drugs metabolised by these
isoenzymes will be reduced when co-administered with bosentan.
Bosentan is also metabolised by these enzymes so that their inhib-
ition may increase the plasma concentration of bosentan. In addition
to interactions shown in Web Table VII, a combination of a potent
CYP3A4 inhibitor (ketoconazole, ritonavir) and/or a CYP2C9 in-
hibitor (e.g. amiodarone, fluconazole) with bosentan may cause a
significant increase in plasma bosentan levels and thus is contraindi-
cated. Interactions may theoretically occur with itraconazole,
tacrolimus, sirolimus, carbamazepine, phenytoin, phenobarbitone,
dapsone and St John’s wort.
Sildenafil is metabolised by cytochrome P450 isoenzymes
CYP3A4 (major route) and CYP2C9 (minor route). There is an in-
crease in sildenafil bioavailability and reduced clearance with
CYP3A4 substrates and inhibitors and CYP3A4 substrates plus
beta-adrenoceptor blockers. CYP3A4 inducers such as carba-
mazepine, phenytoin, phenobarbital, rifampicin and St John’s
wort may significantly lower sildenafil levels. Sildenafil levels are
modestly increased by fresh grapefruit juice, a weak inhibitor of
CYP3A4.
Table 21 Recommendations for efficacy of
sequential drug combination therapy for pulmonary
arterial hypertension (group 1) according to World
Health Organization functional class. Sequence is by
rating and by alphabetical order
Measure/
treatment
Classa-Levelb Ref.c
WHO-FC
II
WHO-FC
III
WHO-FC
IV
Macitentan
added to
sildenafild
I B I B IIa C 201
Riociguat added
to bosentan
I B I B IIa C 214
Selexipage
added to ERA
and/or PDE-5id
I B I B IIa C
241,
248
Sildenafil added
to epoprostenol
– –
I B IIa B 209
Treprostinil
inhaled added
to sildenafil or
bosentan
IIa B IIa B IIa C 237
Iloprost inhaled
added to
bosentan
IIb B IIb B IIb C
230,
231
Tadalafil added
to bosentan
IIa C IIa C IIa C 211
Ambrisentan
added to
sildenafil
IIb C IIb C IIb C 249
Bosentan added
to epoprostenol
– –
IIb C IIb C 250
Bosentan
added to
sildenafil
IIb C IIb C IIb C
251,
252
Sildenafil added
to bosentan
IIb C IIb C IIb C 252
Other double
combinations
IIb C IIb C IIb C
–
Other triple
combinations
IIb C IIb C IIb C
–
Riociguat added
to sildenafil or
other PDE-5i
III B III B III B 215
EMA ¼ European Medicines Agency; ERA ¼ endothelin receptor antagonist;
PAH ¼ pulmonary arterial hypertension; PDE-5i ¼ phosphodiesterase type 5
inhibitor; RCT ¼ randomized controlled trial; WHO-FC ¼ World Health
Organization functional class.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
dTime to clinical worsening as primary endpoint in RCTs or drugs with
demonstrated reduction in all-cause mortality (prospectively defined).
eThis drug was not approved by the EMA at the time of publication of these
guidelines.
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Finally, care is needed when PAH-targeted medications
are co-administered with antihypertensive drugs such as beta-
adrenoceptor blockers, angiotensin-converting enzyme inhibitors,
etc., to avoid excessive systemic hypotension.
6.3.6 Balloon atrial septostomy
The creation of an inter-atrial right-to-left shunt can decompress
the right heart chambers and increase LV preload and CO.253,254
In addition, this improves systemic O2 transport despite arterial
O2 desaturation
253 and decreases sympathetic hyperactivity.
The recommended technique is graded balloon dilation atrial
septostomy, which produces equivalent improvements in hae-
modynamics and symptoms but reduced risk compared with the
original blade technique. Other techniques are considered
experimental.255
A careful pre-procedure risk assessment ensures reduced mor-
tality. Balloon atrial septostomy (BAS) should be avoided in end-
stage patients presenting with a baseline mean RAP .20 mmHg
and O2 saturation at rest ,85% on room air. Patients should be
on optimal medical therapy, which may include preconditioning
with i.v. inotropic drugs, prior to considering BAS. Published re-
ports suggest a benefit in patients who are in WHO-FC IV with
right heart failure refractory to medical therapy or with severe syn-
copal symptoms.253,254 It may also be considered in patients await-
ing lung transplantation with unsatisfactory clinical response on
maximal medical therapy or when medical therapy is not available.
Studies show improvements in CI and decreases in RAP with im-
provement in 6MWD.253,254 The impact of BAS on long-term sur-
vival has not been established in RCTs.253,254 BAS should be
regarded as a palliative or bridging procedure to be performed
only in centres with experience in the method.256 Since BAS is per-
formed very rarely, it has not been included in the treatment algo-
rithm (Figure 2).
6.3.7 Advanced right ventricular failure
6.3.7.1 Intensive care unit management
Patients with PH may require intensive care unit (ICU) treatment for
a co-morbid condition (including major surgery), right heart failure
or both. In a series from France, the mortality among PAH patients
admitted to the ICU was 41%,257 underscoring the poor prognosis.
Hence PAH patients requiring ICU treatment should be managed at
specialized centres whenever possible. Basic monitoring includes
vital signs (heart rate, blood pressure, body temperature and O2
saturation), urine production, central venous pressure, central
venous O2 saturation and blood lactate levels. The combination of
a low central venous O2 saturation (,60%) with rising lactate levels
and low or absent urine production signals imminent right heart fail-
ure. In certain situations, placement of a right heart catheter might be
required to allow comprehensive haemodynamic monitoring. The ba-
sic principles of ICU management of patients with PH and RV failure
include the treatment of triggering factors (such as anaemia, arrhyth-
mias, infections or other co-morbidities), optimization of fluid balance
(usually with i.v. diuretics), reduction of RV afterload (usually with
parenteral prostacyclin analogues, but sometimes also with other
PAH drugs), improvement of CO with inotropes (with dobutamine
being the preferred inotrope to treat RV failure) and maintenance
of systemic blood pressure with vasopressors, if necessary.258 – 260
Intubation should be avoided in patients with RV failure, as it frequent-
ly results in haemodynamic collapse.
6.3.7.2 Right ventricle assistance
The use of veno-arterial extracorporeal membrane oxygenation
(ECMO) should be considered for selected patients with PH and
RV failure. A veno-venous approach may improve oxygenation
but does not unload the RV, which makes it unsuitable for this pa-
tient population. There are two basic concepts for the use of ECMO
in these patients: bridge to recovery and bridge to transplantation.
Few reports have been published on the bridge to recovery con-
cept,261 which is only reasonable in patients for whom a clear thera-
peutic concept with a realistic chance of recovery exists. There are,
however, several reports on the successful use of ECMO as a bridge
to transplantation, especially when used in awake patients.261 – 263
An alternative approach involves connecting a pumpless device to
the pulmonary circulation.264,265 All of these procedures are avail-
able only in highly specialized centres.
6.3.8 Transplantation
The advent of disease-targeted therapy for severe PAH has reduced
and delayed patient referral for lung transplant programmes.256 The
long-term outcomes of medically treated patients remain uncertain
and transplantation should continue to be an important option for
those who fail on such therapy and remain in WHO-FC III or
IV.96,107 Delayed referral in combination with the length of the wait-
ing time, due to the shortage of organ donors, may increase the
mortality of patients on the waiting list and their clinical severity
at the time of transplantation.
The overall 5-year survival following transplantation for PAH was
considered to be 45–50%, with evidence of continued good quality
of life.266 More recent data show that survival is increased to 52–
75% at 5 years and to 45–66% at 10 years.267 –269
Considering the above information, it seems reasonable to consider
eligibility for lung transplantation after an inadequate clinical response
to the initial monotherapy and to refer the patient soon after an inad-
equate clinical response is confirmed on maximal combination therapy
(Figure 2). Also the aetiology of PAH may help the decision making since
the prognosis varies according to the underlying condition. In fact, PAH
associated with CTD has a worse prognosis than IPAH, even when trea-
ted with prostanoids, while patients with PAH associated with CHD
have a better survival. The poorest prognosis is seen in patients with
PVOD and PCH because of the lack of effective medical treatments;
these patients should be listed for transplantation at diagnosis.
Both heart–lung and double-lung transplantation have been per-
formed for PAH, although the threshold for unrecoverable RV systol-
ic dysfunction and/or LV diastolic dysfunction is unknown. Currently
the vast majority of patients worldwide receive bilateral lungs, as in-
dicated by the International Society for Heart and Lung Transplant-
ation Registry figures.270 Patients with Eisenmenger syndrome due
to simple shunts have been treated with isolated lung transplantation
and repair of the cardiac defect or by heart–lung transplantation.266
While registry data initially supported a survival benefit of heart–
lung transplantation for patients with PH associated with a ventricu-
lar septal defect,271 experience with isolated bilateral lung trans-
plantation has increased and more recent data support a role for
this approach combined with repair of the defect.272
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Recent reports indicate that veno-arterial ECMO may be
employed in awake end-stage PH patients for bridging to lung
transplantation.263
6.3.9 Treatment algorithm
A treatment algorithm for PAH patients is shown in Figure 2. The
classes of recommendation and levels of evidence for the PAH
treatments are shown in Tables 19 (monotherapy), 20 (initial com-
bination therapy), 21 (sequential combination therapy) and 22 (ICU
and interventions). Definitions of clinical response to treatments are
reported in Table 15. It is recognized that the therapeutic approach
to PAH may vary depending on the local availability (and expertise)
of therapeutic options in various hospitals and clinical settings.
Accordingly, Tables 19, 20, 21 and 22 provide the necessary
evidence for alternative evidence-based therapeutic strategies. In
these tables only the compounds officially approved for PAH or
undergoing regulatory approval in at least one country are included.
A four-level hierarchy for endpoints in RCTs has been proposed by
experts according to the level of evidence regarding efficacy.273,274
According to this hierarchy, drugs or combinations of drugs
with time to clinical failure or to clinical worsening as the primary
endpoint in RCTs or drugs with a demonstrated reduction in all-
cause mortality (prospectively defined) have been highlighted
with a footnote in Tables 19, 20 and 21. The PAH treatment algo-
rithm does not apply to patients in other clinical groups, and in par-
ticular it does not apply to patients with PH associated with group 2
(LHD) or group 3 (lung diseases). In addition, the different treat-
ments have been evaluated by RCTs mainly in IPAH, HPAH, PAH
due to drugs and in PAH associated with CTD or with CHD (surgi-
cally corrected or not).
Treatment algorithm description (Figure 2)
† After confirmation of the diagnosis of the treatment-naive PAH
patient in an expert centre, the suggested initial approach is the
adoption of general measures and the initiation of supportive
therapy if needed (Tables 16 and 17).
† Acute vasoreactivity testing should be performed only in patients
with IPAH, HPAH and PAH associated with drugs or toxins use.
Vasoreactive patients should be treated with high doses (pro-
gressively titrated) of CCB; adequate response should be con-
firmed after 3–4 months of treatment (Table 18). Patient
responders without an adequate clinical response to CCB treat-
ment should be treated with approved PAH medications accord-
ing to the non-vasoreactive patient’s treatment strategy.
† Non-responders to acute vasoreactivity testing who are at low or
intermediate risk (Table 13) can be treated with either initial mono-
therapy (Table 19) or initial oral combination therapy (Table 20).
† If initial monotherapy is chosen, since head-to-head comparisons
among different compounds are not available, no evidence-based
first-line monotherapy can be proposed. In this case the choice of
the drug may depend on a variety of factors, including the approv-
al status, labelling, route of administration, side-effect profile,
potential interaction with background therapies, patient prefer-
ences, co-morbidities, physician experience and cost.
† Since head-to-head comparison between initial combination
therapy with ambrisentan plus tadalafil has proven to be superior
to initial monotherapy with ambrisentan or tadalafil in delaying
clinical failure, a higher grade of recommendation has been given
to this initial combination (Table 20).247
† In non-vasoreactive and treatment-naive patients at high risk
(Table 13), initial combination therapy including i.v. prostacyclin
analogues should be considered (Table 20). I.V. epoprostenol
should be prioritised since it has reduced the 3-month rate of
mortality in high-risk PAH patients also as monotherapy
(Table 19).149 Alternative types of initial combination therapy
may be considered (Table 20).
Table 22 Recommendations for efficacy of intensive
care unit management, balloon atrial septostomy and
lung transplantation for pulmonary arterial
hypertension (group 1) according to World Health
Organization functional class
Measure/
treatment
Classa-Levelb Ref.c
WHO-FC
II
WHO-FC
III
WHO-FC
IV
Hospitalization
in ICU is
recommended in
PH patients with
high heart rate
(.110 beats/
min), low blood
pressure
(systolic blood
pressure ,90
mmHg), low
urine output and
rising lactate
levels due or
not due to
co-morbidities
– – – –
I C 257
Inotropic
support is
recommended in
hypotensive
patients
I C I C
Lung
transplantation is
recommended
soon after
inadequate
clinical response
on maximal
medical therapy
– –
I C I C 270
BAS may be
considered
where available
after failure of
maximal medical
therapy
– –
IIb C IIb C
253,
254
BAS ¼ Balloon atrial septostomy; ICU ¼ intensive care unit; PH ¼ pulmonary
hypertension; WHO-FC ¼ World Health Organization functional class.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
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† In case of inadequate clinical response to initial combination ther-
apy or initial monotherapy (Table 15), sequential double or triple
combination therapy is recommended according to Table 21. The
combination of riociguat and PDE-5i is contraindicated.
† In case of inadequate clinical response with sequential double
combination therapy, triple combination therapy should be
attempted (Tables 20 and 21).
† It seems reasonable to consider eligibility for lung transplantation
after an inadequate clinical response to the initial monotherapy
or initial combination therapy and to refer the patient for lung
transplantation soon after the inadequate clinical response is con-
firmed on maximal combination therapy. BAS should be regarded
as a palliative or bridging procedure in patients deteriorating des-
pite maximal medical therapy.
PAH confirmed by
expert center
Treatment naïve
patient
Patient already
on treatment
Acute vasoreactivity test
(IPAH/HPAH/DPAH only)
Non-vasoreactive
Inadequate clinical response
(Table 15)
Consider referral for
lung transplantation
Low or intermediate risk
(WHO FC II–III)a
High risk
(WHO FC IV)a
General measures
(Table 16)
Supportive therapy
(Table 17)
CCB Therapy
(Table 18)
Initial
monotherapy b
(Table 19)
Initial oral
combinationb
(Table 20)
Double or triple sequential combination
(Table 21)
Inadequate clinical response
(Table 15)
Consider listing for lung transplantationd
(Table 22)
Initial combination
including i.v. PCAc
(Table 20)
Vasoreactive
CCB = calcium channel blockers; DPAH = drug-induced PAH; HPAH = heritable PAH; IPAH = idiopathic PAH; i.v. = intravenous; PAH = pulmonary arterial hypertension; 
PCA = prostacyclin analogues; WHO-FC = World Health Organization functional class.
aSome WHO-FC III patients may be considered high risk (see Table 13).
b
cIntravenous epoprostenol should be prioritised as it has reduced the 3 months rate for mortality in high risk PAH patients also as monotherapy.
dConsider also balloon atrial septostomy.
Figure 2 Evidence based treatment algorithm for pulmonary arterial hypertension patients (for group 1 patients only; see description in the
text).
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6.3.10 Diagnosis and treatment of pulmonary arterial
hypertension complications
6.3.10.1 Arrhythmias
Arrhythmias are an increasing clinical problem in PAH patients. In
particular, the presence of symptomatic atrial arrhythmia might por-
tend a poor prognosis.275 In contrast to patients with LHD, malig-
nant ventricular arrhythmias such as ventricular tachycardia,
ventricular flutter and ventricular fibrillation are rare in PAH pa-
tients. In a series of 132 witnessed cardiac arrests in patients with
PAH, ventricular fibrillation was observed in only 8% of the cases.276
Another series of 231 patients with PAH or CTEPH followed over a
6-year period did not report any case of malignant ventricular ar-
rhythmia.275 In that series, supraventricular tachyarrhythmias oc-
curred with an annual incidence of 2.8%. Atrial flutter and atrial
fibrillation were equally common and both arrhythmias invariably
led to clinical deterioration with signs of right heart failure. Treat-
ment of atrial flutter proved to be more successful than treatment
of atrial fibrillation. Restoration of a stable sinus rhythm was asso-
ciated with a favourable long-term survival, while persistent atrial
fibrillation was associated with a 2-year mortality .80%.275 Supra-
ventricular arrhythmias represent an indication for oral anticoagula-
tion with vitamin K antagonists or new oral anticoagulants. Both
electric cardioversion and radiofrequency ablation in refractory
cases have proven to be effective.277
Although prospective and controlled data are lacking, these find-
ings suggest that maintenance of a stable sinus rhythm after cardio-
version should be considered an important treatment goal in
patients with PAH. In order to achieve a stable sinus rhythm,
prophylaxis with antiarrhythmic drugs without negative inotropic
effects, such as oral amiodarone (see interactions in Web
Table VII), should also be considered, even if specific data regarding
efficacy are lacking.
6.3.10.2 Haemoptysis
Haemoptysis is a recognised complication of PH, represents a risk
factor for mortality and appears to be more frequent in specific
types, such as HPAH, PAH associated with CHD and CTEPH.
Haemoptysis severity ranges from mild to very severe leading to
sudden death. Reported prevalence is variable, from 1% to 6%.278
Bronchial artery embolization is suggested as an acute emergency
procedure in the case of severe haemoptysis or as elective interven-
tion in cases of frequent mild or moderate episodes. Haemoptysis
may represent a contraindication to anticoagulant therapy.
6.3.10.3 Mechanical complications
Mechanical complications in PAH patients are usually related to pro-
gressive dilatation of the PA and include PA aneurysms, rupture and
dissection and compression of different intrathoracic structures
such as the left main coronary artery, pulmonary veins, main bronchi
and the recurrent laryngeal nerves.279 – 281 Symptoms and signs are
not specific and are variable according to the different complica-
tions, including chest pain (angina-like or not), dyspnoea, regional
lung oedema and sudden death. Contrast-enhanced and high-
resolution CT scan represent the best imaging option to detect
mechanical complications.
Treatment options are not well established in cases of PA aneur-
ysms, pseudo-aneurysms and dissection.279,280
The indications and results of a traditional surgical approach in the
presence of PH are unknown and the predictable risks may be very
high. The percutaneous approach (stenting) faces relevant technical
issues mainly due to early branching of the main and lobar PA.
A possible approach is double-lung or heart– lung transplantation,
but this solution can be applied only in chronic stabilised cases,
and clear indications are lacking. In patients with left main coronary
artery compression, a percutaneous stenting procedure should be
performed.282
6.3.11 End of life care and ethical issues
The clinical course of PH is one of progressive deterioration inter-
spersed with episodes of acute decompensation. It is difficult to pre-
dict when patients will die since death may come either suddenly or
slowly because of progressive heart failure. It has been shown that
physicians caring for patients tend to be overoptimistic in their prog-
nostication and frequently misunderstand their patients’ wishes.
Open and sensitive communication with patients allows advanced
planning and discussion of their fears, concerns and wishes, which is
essential to good care. Opportunities to discuss prognosis should be
created at the time of initial diagnosis. Recognition that cardiopul-
monary resuscitation in severe PH has a poor outcome may enable
a do-not-resuscitate order. This may increase the chance of patients
being in their preferred place of care at the end of life.
Patients approaching the end of life require frequent assessment
of their full needs by a multidisciplinary team. Attention should be
given to controlling the distressing symptoms and prescribing ap-
propriate drugs while withdrawing unnecessary medication. Well-
informed psychological, social and spiritual support is also vital. Spe-
cialist palliative care should be consulted about patients whose
needs are beyond the expertise of the PH team.
PH is a disease that may be severely life-limiting. In addition to
psychological and social support, there should be proactive ad-
vanced care planning with referral to specialist palliative care ser-
vices when appropriate.
7. Specific pulmonary (arterial)
hypertension subsets
7.1 Paediatric pulmonary arterial
hypertension
PH can present at any age from the neonatal period to adulthood.
Paediatric PH has some unique features that are not found in adult
PH, including prenatal aetiological factors, and postnatal parenchy-
mal and vascular abnormalities in lung development.283 Before the
epoprostenol era, the prognosis had been worse in children, with
a median survival estimated at 10 months, compared to 2.8 years
in adults; however, with new targeted therapies the outcome has
improved significantly.9,284
Recent data from registries have shed light on the prevalence and
incidence of paediatric PH. In the Netherlands, the incidence and
prevalence of IPAH is 0.7 and 4.4 per million children, respective-
ly.285 Similar numbers have been observed in the UK, with annual
cases of IPAH of 0.48 per million and a prevalence of 2.1 per mil-
lion.286 National and large-scale registries either including chil-
dren284 or exclusively dedicated to paediatrics287,288 have
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described the different aetiologies of PH, with IPAH, HPAH and
CHD-PAH as the most common. However, PH associated with
respiratory disease is also noted to be important and may be
underreported.287
Although the 2009 Dana Point classification included most of the
paediatric causes, it was felt that paediatric aetiologies should be
better described. The 2011 Panama classification was recently pro-
posed, with 10 different subgroups of paediatric PH.289 The 2013
Nice classification includes new groups and aetiologies specific to
children,9 such as congenital and acquired left heart inflow/outflow
tract obstruction and segmental PH; it has been further adapted for
the current ESC/ERS Guidelines (Table 4 and Web Table I) with
provision of clinical (Table 6) and anatomical–pathophysiological
classification of congenital systemic-to-pulmonary shunts associated
with PAH (Web Table II) and of developmental lung disease
(Web Table III).
PPHN remains in the PAH group but has been moved to a sub-
group, as it is considered to be a specific entity with a more transient
course (Table 4 and Web Table IV) in most cases.
7.1.1 Diagnosis
Dyspnoea, fatigue and failure to thrive are common symptoms; syn-
cope is more common in children, but overt RV failure is a late event
and the child may die of sudden death before the occurrence of RV
failure.284,287 A specific diagnostic workup has been recently recom-
mended, and even if some causes are rare, they should be excluded
before a definite diagnosis of IPAH.284 A thorough family and per-
sonal history, including pregnancy, delivery and postnatal details, is
essential.290 Diagnosis must be confirmed by heart catheterization,
and vasoreactivity testing should be performed. Recent reports sug-
gest that cardiac catheterization may be a greater risk in children
compared with adults, with younger age (,1 year) and worse FC
(WHO-FC IV) as risk factors. Cardiac catheterization performed
in expert centres is recommended.290 The general scheme of the
diagnostic algorithm for adult patients with PH (Figure 1) may also
be adopted in children, with some adaptation related to the different
epidemiology.9
As in adults, clinical evidence of RV failure, progression of symp-
toms, WHO-FC III/IV and elevated BNP levels are recognized as
being associated with higher risk of death. In children, failure to
thrive, haemodynamic parameters such as the PAPm:systemic artery
pressure ratio, RAP .10 mmHg and PVR index .20 WU/m2 have
also been associated with a higher risk of death, while the 6MWD
was not a prognostic parameter.
7.1.2 Therapy
There is a lack of randomized trials in paediatrics, making it difficult
to deliver strong guidelines.291,292 A specific treatment algorithm,
similar to that used in adults (Figure 2), has been recommended.
Determinants of risk and risk stratification have also been
suggested.9 CCBs are used in responders, but close follow-up is
mandatory, as some patients may fail long-term therapy.
Indications for epoprostenol are similar to those for adults. The
optimal dose varies between patients and thus individual adaptation
is required.293,294 Use of i.v. iloprost and trepostinil, as well as sub-
cutaneous trepostinil,295 has been reported. Oral beraprost is used
in some countries, but lack of proof of efficacy is a problem. Inhaled
iloprost is difficult to deliver, but some reports have shown efficacy,
mostly in combination with other therapies.296
Bosentan pharmacokinetics have been assessed in two stud-
ies.297,298 Several uncontrolled studies have shown positive results
similar to adults, with survival rates around 80–90% at 1 year.298
A paediatric formulation is available in Europe.299 Data with ambri-
sentan are scarce and a study is ongoing.
Sildenafil has shown efficacy300 and has been approved in Europe
for children 1–17 years of age. Increased mortality using high doses
has raised concerns; therefore high doses should not be used in chil-
dren (high individual doses of sildenafil on a three daily dosing not
recommended: .10 mg/dose with a bodyweight of 8–20 kg,
.20 mg/dose in children with a bodyweight .20 kg or .1 mg/
kg/dose in infants and small children).301
Data on tadalafil also suggest efficacy;302 a trial is currently under
way to define the specific dosage for children.
An increasing number of paediatric patients are on combination
therapies even though evidence is still limited.303
RV decompression strategies include atrioseptostomy,304 ductal
stenting in cases of patent ductus arteriosus305 and a surgical Potts
shunt.306 Transcatheter Potts shunt creation has also been pro-
posed.307 Lung transplantation remains an important option for
paediatric PH patients.
Specific goals for treatment should be applied for children. Some
have been extrapolated from defined risk factors in children but still
require validation in large cohorts.9 Recently FC, TAPSE and
NT-proBNP have been recognized as treatment goals.308
The recommendations for paediatric PH are reported in the
Table 23.
Table 23 Recommendations for paediatric
pulmonary hypertension
Recommendations Classa Levelb Ref.c
A PH diagnostic algorithm workup
is recommended for diagnosis and
definition of the specific aetiology
group in paediatric PH patientsd
I C 9,290
A PAH-specific therapeutic
algorithm is recommended in
paediatric PH patientsd
I C 9
Combination therapy should be
considered in paediatric PH patients
IIa C
295,298,
302
Specific paediatric determinants of
risk should be consideredd
IIa C 9,308
PAH ¼ pulmonary arterial hypertension; PH ¼ pulmonary hypertension.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
dSee Ivy D et al J Am Coll Cardiol 2013;62(25):D117–D126.
ESC/ERS Guidelines98
Downloaded from https://academic.oup.com/eurheartj/article-abstract/37/1/67/2887599
by Olivier Borsus user
on 26 January 2018
7.2. Pulmonary arterial hypertension
associated with adult congenital heart
disease
PAH associated with adult CHD is included in group 1 of the PH
clinical classification (Table 4) and represents a very heterogeneous
patient population. A specific clinical classification (Table 6) and an
anatomical–pathophysiological classification (Web Table II) are pro-
vided to better characterize each individual patient with PAH asso-
ciated with adult CHD.13,309 Some malformations, such as patent
ductus arteriosus, sinus venosus atrial septal defect or partial anom-
alous pulmonary venous return, are often concealed and patients
are misclassified as suffering from IPAH. Hence these congenital
anomalies should be specifically sought.
Epidemiological data remain scarce, as no studies have been de-
signed to assess the prevalence of PAH in adult CHD, although the
figure of 5–10% was reported in a European survey.310 Persistent
exposure of the pulmonary vasculature to increased blood flow
due to systemic-to-pulmonary shunts, as well as increased pressure,
may result in a typical pulmonary obstructive arteriopathy (identical
to other PAH forms) leading to an increase in PVR. If PVR ap-
proaches or exceeds systemic vascular resistance (SVR), the shunt
is reversed (Eisenmenger syndrome).311
7.2.1. Diagnosis
As indicated in Table 6, the clinical presentation of adult patients
with PAH may differ. Eisenmenger syndrome is a multisystem dis-
order and the most severe form of PAH in adult CHD. The signs
and symptoms of Eisenmenger syndrome result from PH, low arter-
ial O2 saturation and haematological changes, including secondary
erythrocytosis, thrombocytopenia and at times leucopenia. They in-
clude dyspnoea, fatigue and syncope. In patients with PAH asso-
ciated with adult CHD without reversal of the shunt, the degree
of cyanosis and erythrocytosis may be mild to moderate. Eisenmen-
ger syndrome patients also present with haemoptysis, cerebrovas-
cular accidents, brain abscesses, coagulation abnormalities and
sudden death. Subjects with Eisenmenger syndrome have reduced
life expectancy, although many survive into their third or fourth dec-
ade, with some even surviving up to their seventh decade.312 In pa-
tients listed for lung or heart– lung transplantation when no medical
treatment was available, Eisenmenger syndrome had better survival
compared with IPAH, with a 3-year survival rate of 77% compared
with 35% for untreated IPAH.313 In a recent study on the different
clinical groups of PAH patients associated with CHD (Table 6), the
worst survival was observed in patients with PAH after defect repair
or with small/coincidental defects as compared with patients with
Eisenmenger syndrome or those with prevalent systemic-to-pulmonary
shunts.314 Improved survival may result from preservation of RV func-
tion, as the RV does not undergo remodelling at birth and remains
hypertrophied.315 The RV is also relieved by the right-to-left shunt, sus-
taining CO at the expense of hypoxaemia and cyanosis.
Of all patients with CHD, those with Eisenmenger syndrome are the
most severely compromised in terms of exercise intolerance.314,316
Patients with CHD (in particular those without shunts) may also
develop PH due to LHD (group 2, Table 4) or concomitant lung dis-
eases (group 3, Table 4). In these cases, a comprehensive diagnostic
workup, as reported in the section 7.1.1, is recommended.
7.2.2. Therapy
Operability may be considered in patients with prevalent
systemic-to-pulmonary shunting (Table 6). The criteria for shunt
closure based on baseline PVR have been proposed (Table 24)
based on available literature data.317 –319 Additional criteria include
the type of the defect, age, the PVR:SVR ratio and the Qp:Qs
ratio.320 No prospective data are available on the usefulness of
vasoreactivity testing, closure test or lung biopsy for operability
assessment.320 Surgical or percutaneous intervention is contraindi-
cated in patients with Eisenmenger syndrome and likely is useless in
patients with small/coincidental defects.
The medical treatment strategy for patients with PAH associated
with CHD, and in particular for subjects with Eisenmenger syn-
drome, is mainly based on the clinical experience of experts rather
than being formally evidence-based.311 A specific treatment algo-
rithm has been proposed.309
PAH associated with CHD patients should be managed in specia-
lised centres. Patient education, behavioural modifications and
awareness of potential medical risk factors are important aspects
of management.
Patients with PAH associated with CHD may present with clinical
deterioration in different circumstances, such as during non-cardiac
surgery requiring general anaesthesia, dehydration, lung infections
and at high altitudes. It is recommended to avoid strenuous exercise,
but mild activities seem to be beneficial. Pregnancy is associated
with very high risk to both the mother and foetus and should be dis-
couraged. Hence effective contraception is mandatory. Dual contra-
ception is indicated in patients taking ERAs in light of the interaction
with progesterone-based compounds.
Long-term home O2 therapy may improve symptoms but has not
been shown to modify survival, at least when given only at night.179
The use of supplemental O2 therapy is recommended in cases in
which it produces a consistent increase in arterial O2 saturation
and reduces symptoms.
The use of oral anticoagulant treatment in Eisenmenger syn-
drome is controversial: a high incidence of PA thrombosis and
stroke is reported, but there is also an increased risk of haemor-
rhage and haemoptysis.321 No data exist on this issue and thus def-
inite recommendations cannot be made. Oral anticoagulant
treatment may be considered in patients with PA thrombosis, signs
of heart failure and absent or only mild haemoptysis.321
Secondary erythrocytosis is beneficial for adequate O2 transport
and delivery and routine phlebotomy should be avoided. If symp-
toms of hyperviscosity are present, phlebotomy with isovolumic re-
placement should be performed, usually when the haematocrit is
.65%. Iron deficiency should be corrected. No clear data support
the use of CCBs in patients with Eisenmenger syndrome and the
empirical use of CCBs is dangerous and should be avoided.
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One RCT is available with specific drug therapy in Eisenmenger
syndrome patients: bosentan has been shown to improve 6MWT
and decrease PVR after 16 weeks of treatment in WHO-FC III
patients. Although a beneficial effect of bosentan has been shown
on exercise capacity and quality of life in this group of patients,
an effect on mortality remains uncertain.200 Long-term follow-up
(40 weeks) showed sustained improvement.322 Bosentan is
currently approved in Europe for WHO-FC III Eisenmenger
syndrome patients.
Experiences with other ERAs323 and the PDE-5is sildenafil314 and
tadalafil324 show favourable functional and haemodynamic results
in patients with PAH associated with CHD and Eisenmenger
syndrome.
The use of i.v. epoprostenol has been reported in Eisenmenger
syndrome patients, with favourable effects on haemodynamics and
exercise capacity, although central lines expose the patients to the
risk of paradoxical embolism and sepsis.223 No data are available on
the use of other prostanoids.
There are a few published data on combination therapy,
but the rationale is the same as in IPAH.207,314 The use of
PAH therapy to achieve the operability criteria in PAH with
systemic-to-pulmonary cardiovascular shunts (Table 24), allowing
defect correction (‘treat-to-close’ concept), is not supported by
available data.
Heart– lung or lung transplantation with heart surgery is an
option in special cases not responsive to medical treatment, but is
limited by organ availability. Short- and long-term survival rates
following heart– lung transplantation are similar to other forms of
PAH. The prolonged estimated survival of patients with Eisenmen-
ger syndrome makes the decision as to if and when patients should
be listed difficult.309
Recommendations for PAH associated with CHD are reported in
the Table 25.
7.3 Pulmonary arterial hypertension
associated with connective tissue disease
PAH is a well-known complication of CTDs such as SSc, systemic
lupus erythematosus, mixed CTD and, to a lesser extent, rheuma-
toid arthritis, dermatomyositis and Sjo¨gren’s syndrome.325– 329 PAH
associated with CTD is the second most prevalent type of PAH after
IPAH in Western countries.10 SSc, particularly in its limited variant,
represents the main CTD associated with PAH in Europe and the
USA (systemic lupus erythematosus is more common in
Asia).325,329 The prevalence of haemodynamically proven pre-
capillary PH in large cohorts of SSc patients ranges from 5 to
12%.46,325,330,331 In these patients, PH may occur in association
Table 24 Recommendations for correction of
congenital heart disease with prevalent
systemic-to-pulmonary shunts
Recommendations Classa Levelb Ref.c
PVRi
(WU † m2)
PVR
(WU)
Correctabled
,4 ,2.3 Yes IIa C 317
.8 .4.6 No IIa C 317
4–8 2.3–
4.6
Individual
patient
evaluation in
tertiary centres
IIa C 317
PVR ¼ pulmonary vascular resistance; PVRi ¼ pulmonary vascular resistance
index; WU ¼ Wood units.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
dWith surgery or intravascular percutaneous procedure.
Table 25 Recommendations for pulmonary arterial
hypertension associated with congenital heart disease
Recommendations Classa Levelb Ref.c
Bosentan is recommended in
WHO-FC III patients with
Eisenmenger syndrome
I B 200,322
Other ERAs, PDE-5is and
prostanoids should be considered
in patients with Eisenmenger
syndrome
IIa C
223,314,
323,324
In the absence of significant
haemoptysis, oral anticoagulant
treatment may be considered in
patients with PA thrombosis or
signs of heart failure
IIb C
The use of supplemental O2
therapy should be considered
in cases in which it produces
a consistent increase in arterial
O2 saturation and reduces
symptoms
IIa C 179
If symptoms of hyperviscosity are
present, phlebotomy with
isovolumic replacement should be
considered, usually when the
haematocrit is .65%
IIa C 183
The use of supplemental iron
treatment may be considered in
patients with low ferritin plasma
levels
IIb C 184
Combination drug therapy may be
considered in patients with
Eisenmenger syndrome
IIb C 207,314
The use of CCBs is not
recommended in patients with
Eisenmenger syndrome
III C 189
CCBs ¼ calcium channel blockers; ERAs ¼ endothelin receptor antagonists;
O2 ¼ oxygen; PA ¼ pulmonary artery; PDE-5is ¼ phosphodiesterase type 5
inhibitors; WHO-FC ¼ World Health Organization functional class.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
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with interstitial lung disease or as a result of an isolated pulmonary
vascular disease, which may affect pre-capillary arterioles (PAH) and
post-capillary venules (PVOD).326,332 In addition, group 2 pulmon-
ary venous hypertension from LHD may be present.76,326,333 It is
thus imperative to determine which mechanism is operative since
this dictates treatment in the context of a multifaceted disease.
7.3.1. Diagnosis
Compared with IPAH, patients with CTD and PAH are mainly wo-
men (female:male ratio 4:1), are older (mean age at diagnosis .60
years), may present concomitant disorders (interstitial lung disease,
LHD) and have shorter survival times.326,330,334 –336 The unadjusted
risk of death for SSc-PAH compared with IPAH is 2.9 and the pre-
dictors of outcome are broadly similar as for IPAH.336 Symptoms
and clinical presentation are very similar to IPAH and occasional pa-
tients thought to have IPAH can be identified as having an associated
CTD by immunological screening tests. High-resolution tomog-
raphy of the chest is helpful for evaluating the presence of associated
interstitial lung disease and/or PVOD.326,332,337 An isolated reduc-
tion of DLCO is a frequent abnormality in SSc associated with
PAH.327,338
Resting echocardiography is recommended as a screening test in
asymptomatic SSc patients, followed by annual screening with echo-
cardiography, DLCO and biomarkers.325 A two-step composite
score has been proposed in the DETECT study to select patients
who should have RHC.327 Specific recommendations for screen-
ing/early detection are provided in Web Table IX. The cost-
effectiveness of these strategies has not been clarified as compared
with symptom-based detection. Echocardiography is recommended
in the presence of symptoms in other CTDs. As in other forms of
PAH, RHC is recommended in all cases of suspected PAH asso-
ciated with CTD to confirm the diagnosis, determine severity and
rule out left-sided heart disease.
7.3.2 Therapy
Treatment of patients with CTD-associated PAH is more complex
than that of IPAH. Immunosuppressive therapy combining
glucocorticosteroids and cyclophosphamide may result in clinical
improvement in patients with PAH associated with systemic lupus
erythematosus or mixed CTD.339
Long-term favourable response to CCB treatment is reported in
,1% of cases.189 In SSc, the long-term risk:benefit ratio of oral an-
ticoagulation is less favourable than in IPAH because of an increased
risk of bleeding.175
Treatment of patients with CTD and PAH should follow the same
treatment algorithm as in IPAH (Figure 2). This recommendation is
based on the fact that patients with CTD have been included in most
of the major RCTs for regulatory approval of PAH therapy, including
those with combination therapy.
Subgroup analysis of patients with SSc enrolled in the RCTs per-
formed with bosentan, macitentan, sildenafil, riociguat and subcuta-
neous treprostinil have shown favourable effects. In some of these
trials the magnitude of the response in the PAH subgroup associated
with CTD was lower than in IPAH.340 The choice of PAH therapy in
the context of SSc and its generalized microangiopathy must take
into account other vascular damage such as past/current digital
ulcers.
Continuous i.v. epoprostenol therapy was shown to improve ex-
ercise capacity, symptoms and haemodynamics in a 3-month RCT in
SSc-PAH.222 However, retrospective analysis shows a better effect
of i.v. epoprostenol on survival in IPAH as compared with SSc-PAH.
This may be due, at least in part, to co-morbidities such as cardio-
pulmonary involvement.
SSc should not be considered as an a priori contraindication for
lung transplantation.341 A multidisciplinary approach optimizing SSc
patient management before, during and after surgery is recom-
mended.341 Indications and contraindications for transplantation
have to be adapted to the specificities of SSc with a special focus
on digestive (gastro-oesophageal reflux disease and intestinal
disease), cardiac, renal and cutaneous involvement.
The recommendations for PAH associated with CTD are
reported in the Table 26.
7.4 Pulmonary arterial hypertension
associated with portal hypertension
PAH associated with portal hypertension is commonly referred to
as PoPH. This entity should not be confused with hepatopulmonary
syndrome, which is characterized by abnormal pulmonary vasodila-
tion and hypoxaemia.342 However, overlaps between both condi-
tions may occur.343 As implied by the term, PoPH is associated
with the presence of portal hypertension, not necessarily with the
presence of liver disease. However, as cirrhotic liver disease is by
far the most common cause of portal hypertension, PoPH is most
frequently encountered in patients with cirrhosis. Approximately
1–5% of patients with portal hypertension develop PAH344 and
the risk seems to be largely independent from the aetiology of liver
Table 26 Recommendations for pulmonary arterial
hypertension associated with connective tissue disease
Recommendations Classa Levelb Ref.c
In patients with PAH associated with
CTD, the same treatment algorithm as
for patients with IPAH is recommended
I C 46
Resting echocardiography is
recommended as a screening test in
asymptomatic patients with SSc,
followed by annual screening with
echocardiography, DLCO and
biomarkers
I C 46
RHC is recommended in all cases of
suspected PAH associated with CTD
I C 46,327
Oral anticoagulation may be considered
on an individual basis and in the
presence of thrombophilic
predisposition
IIb C 175,339
CTD ¼ connective tissue disease; DLCO ¼ diffusing capacity of the lung for carbon
monoxide; IPAH ¼ idiopathic pulmonary arterial hypertension; PAH ¼ pulmonary
arterial hypertension; RHC ¼ right heart catheterization; SSc ¼ systemic sclerosis.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
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disease and from the impairment of hepatic function.345 Although
some genetic risk factors have been described,346 the pathogenetic
link between portal and PH remains unclear.
7.4.1 Diagnosis
In general, the signs and symptoms of PoPH are similar or identical
to most other forms of PAH, with progressive dyspnoea on exertion
being the chief complaint. The clinical picture may be obscured by
the presence and severity of the underlying liver disease. The diag-
nostic assessment follows the same recommendations as for other
forms of PH, keeping in mind that the co-existence of portal hyper-
tension and PH does not mean that these patients necessarily suffer
from PoPH.344 A complete diagnostic workup including RHC is re-
quired to assess disease severity, haemodynamic profile and other
potential causes of PH, including lung disease, LHD or chronic
thromboembolic disease. As a group, patients with PoPH tend to
have a higher CI and a lower PVR than patients with IPAH,347 but
there is a wide overlap.
7.4.2 Therapy
The mortality risk of patients with PoPH is at least as high as in
IPAH347,348 and these patients should be referred to centres with
expertise in managing both PAH and liver disease. In general, treat-
ment follows the general rules for other forms of PAH, but there are
important considerations. Patients with PoPH often have an ele-
vated bleeding risk and anticoagulation is usually not recommended
for these patients. Beta-blockers, which are frequently used to
lower the portal pressure, should be avoided in patients with
PoPH, as they worsen haemodynamics and exercise in this patient
population.349
Patients with PoPH have been excluded from almost all RCTs in
the PAH field (except for the PATENT study, which included 13 pa-
tients with PoPH). Anecdotal reports suggest that ERAs, PDE-5is,
sGC stimulators and prostacyclin analogues may be used in this pa-
tient population.214,350 – 356 This includes potentially hepatotoxic
drugs such as bosentan, but it should be noted that this compound
tends to accumulate in patients with severely impaired liver function
(i.e. Child–Pugh class B and C).356 Newer ERAs (ambrisentan, ma-
citentan) have a theoretical advantage over bosentan, as the risk of
drug-associated liver toxicity is lower,194,201,357 but both drugs have
not been systematically evaluated in patients with PoPH.
The presence of PH is of particular importance in patients under-
going liver transplantation.358 Mild PH with normal or near-normal
PVR in the presence of high CO is usually well tolerated and tends to
be reversible after transplantation.359 PAH, in contrast, has been
identified as a major risk factor in the setting of liver transplantation.
In a series from the Mayo Clinic, the mortality rate was 100% in pa-
tients with a PAPm ≥50 mmHg and 50% in patients with a PAPm
between 35 and 50 mmHg and a PVR ≥250 dyn.s.cm25.359 There-
fore patients evaluated for liver transplantation should be screened
for signs of PH, even in the absence of corresponding clinical symp-
toms. In the past, significant PAH was considered a contraindication
for liver transplantation, but anecdotal reports suggest that pre-
treating these patients with PAH drugs might improve the outcome
after liver transplantation.360 – 363 There is not yet sufficient evi-
dence to allow general recommendations and the transplant deci-
sion should be made by multidisciplinary teams in expert centres.
A few specialized centres offer combined liver– lung or liver–
heart– lung transplantation for carefully selected patients.364
The recommendations for PAH associated with portal hyperten-
sion are reported in the Table 27.
7.5 Pulmonary arterial hypertension
associated with human immunodeficiency
virus infection
The use of highly active antiretroviral therapy (HAART) and
aggressive management of opportunistic infections has contributed
to increased life expectancy in HIV-infected patients.366,367 Conse-
quently, the spectrum of complications has shifted towards other
long-term conditions, including PAH. It is likely that modern HIV
management with HAART has also resulted in improved survival
and decreased incidence of HIV-associated PAH.368 Taken together,
these effects on survival and incidence have resulted in a stable
PAH prevalence in HIV-infected patients over recent decades.
A population study indicated that the minimal prevalence of HIV-
related PAH was 0.46%, very similar to the prevalence before the
HAART era.369 The pathogenesis of HIV-related PAH remains
Table 27 Recommendations for pulmonary arterial
hypertension associated with portal hypertension
Recommendations Classa Levelb Ref.c
Echocardiographic assessment for signs
of PH is recommended in symptomatic
patients with liver disease or portal
hypertension and in all candidates for
liver transplantation
I B 344
It is recommended that patients affected
by PAH associated with portal
hypertension should be referred to
centres with expertise in managing both
conditions
I C 344
It is recommended that the treatment
algorithm for patients with other forms of
PAH should be applied to patients with
PAH associated with portal hypertension,
taking into account the severity of liver
disease
I C
214,
350–
356
Anticoagulation is not recommended in
patients with PH associated with portal
hypertension
III C 365
Liver transplantation may be considered
in selected patients responding well to
PAH therapy
IIb C
361–
363
Liver transplantation is contraindicated in
patients with severe and uncontrolled
PAH
III C
361–
363
PAH ¼ pulmonary arterial hypertension; PH ¼ pulmonary hypertension.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
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unclear. The absence of viral particles in the complex plexiform le-
sions found from these patients suggests that an indirect action of
viral infection on inflammation and growth factors may act as a trig-
ger in a predisposed patient.
7.5.1 Diagnosis
HIV-associated PAH shares a similar clinical presentation with
IPAH. At the time of diagnosis, a majority of patients are in an ad-
vanced New York Heart Association (NYHA)-FC III or IV. Patients
may present with other risk factors for PAH, such as liver disease
(chronic hepatitis B or C), exposure to drugs or toxins or PE due
to i.v. drug abuse. Patients with HIV-associated PAH are more like-
ly to be male and i.v. drug abusers. Animal research supports the
notion that the additive effect of cocaine on HIV infection might
play a role in the development of pulmonary arteriopathy. Because
of its low prevalence, asymptomatic HIV-infected patients should
not be screened for PAH. However, echocardiography must be
performed in patients with unexplained dyspnoea to detect HIV-
related cardiovascular complications such as myocarditis, cardio-
myopathy or PAH. RHC confirmation is mandatory to establish
the diagnosis of HIV-related PAH and the absence of LHD.369
PAH is an independent risk factor for death in HIV-infected
patients.
7.5.2 Therapy
In the absence of specific recommendations, treatment of HIV-
PAH follows guidelines for the treatment of IPAH together with
HAART. On multivariate analysis, a CI .2.8 l/min/m2 and a
CD4 lymphocyte count .200 cells/ml are independent predictors
of survival.225 Anticoagulation is not routinely recommended be-
cause of an increased risk of bleeding, anticipated compliance is-
sues and drug interactions. Patients with HIV-related PAH
appear to be non-responders to acute vasodilator challenge and
thus should not receive CCBs.189 Uncontrolled studies suggest
that prostacyclins may improve exercise tolerance, haemodynam-
ics and symptoms in HIV-related PAH.218 An open-label study re-
ported the effects of bosentan in patients with HIV-related PAH,
showing an improvement in all efficacy measures, including 6MWT
and invasive haemodynamics.370 Sporadic cases have been in-
cluded in the ambrisentan RCTs.194 Hepatic tolerability was similar
to previously reported observations in other forms of PAH. The
interpretation of these studies is limited by the small sample size
and their open-label nature. In the case of sildenafil, the dose
should be reduced if ritonavir and saquinavir are co-administered
due to drug–drug interactions. HIV infection is generally consid-
ered an exclusion criterion for lung transplantation, even though
in some centres specific programmes have been implemented.
Of note, cases of reversible disease have been described in HIV-
PAH patients treated with HAART and specific therapies. This
finding, together with the decreased incidence of HIV-PH in the
modern management era, may indicate that aggressive manage-
ment improves outcomes in this patient population. Further stud-
ies are needed to understand the underlying reasons of improved
outcomes in these patients.
The recommendations for PAH associated with HIV infection are
reported in the Table 28.
7.6 Pulmonary veno-occlusive disease and
pulmonary capillary haemangiomatosis
Both PVOD and PCH are uncommon conditions but are increasing-
ly recognized as causes of PH.92,371 Pathologic characteristics of
PCH are found in 73% of PVOD patients and, inversely, pathologic
characteristics of PVOD are found in 80% of PCH patients.372 Simi-
larities in pathologic features and clinical characteristics and the risk
of drug-induced pulmonary oedema with PAH therapy371,373 sug-
gest that these two conditions overlap, and it has been proposed
that PCH could be a secondary angioproliferative process caused
by post-capillary obstruction of PVOD rather than a distinct dis-
ease.6,372 Thus PVOD and PCH have been classified together in a
specific subgroup of the clinical classification next to PAH (Table 4,
group 1′) because of their pathological, genetic and clinical similar-
ities and differences with PAH.6 The true incidence of PVOD/PCH
remains unknown because many cases are still misclassified as
PAH.374 The proportion of idiopathic cases of PAH that in reality
fulfil the criteria for PVOD/PCH is likely to be around 10% (lowest
estimates of PVOD/PCH incidence and prevalence are,1 case/mil-
lion).92,374 In contrast to IPAH, there is a male predominance in
PVOD and the prognosis appears to be worse.371 Familial occur-
rence of PVOD has been reported, but BMPR2 mutations have rare-
ly been found in patients with this disease.28,371,375 While PAH that
is due to BMPR2 mutations segregates as an autosomal dominant
trait with incomplete penetrance, familial cases of PVOD/PCH typ-
ically occur in the young siblings of one generation with unaffected
parents, indicating that the disease segregates as a recessive trait.28
In these families, PVOD/PCH is caused by bi-allelic mutations in
EIF2AK4.28 Like PAH, PVOD/PCH may complicate the course of
associated conditions (SSc, HIV infection, etc.) and exposure to
drugs or toxins (cyclophosphamide, mitomycin, etc.).
Table 28 Recommendations for pulmonary arterial
hypertension associated with human
immunodeficiency virus infection
Recommendations Classa Levelb Ref.c
Echocardiographic screening in
asymptomatic HIV patients to detect PH
is not recommended
III C 369
In patients with PAH associated with
HIV infection, the same treatment
algorithm used for patients with PAH
should be considered, taking into
consideration co-morbidities and drug–
drug interactions
IIa C
194,
367
Anticoagulation is not recommended
because of a lack of data on the
efficacy:risk ratio
III C 175,367
HIV ¼ human immunodeficiency virus; IPAH ¼ idiopathic pulmonary arterial
hypertension; PAH ¼ pulmonary arterial hypertension.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
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7.6.1 Diagnosis
The diagnosis of PVOD/PCH can be established with a high prob-
ability by the combination of clinical suspicion, physical examination,
bronchoscopy and radiological findings.371 This non-invasive ap-
proach may avoid the need to perform a hazardous lung biopsy
(the gold standard to confirm a histological diagnosis of PVOD/
PCH), which is no longer recommended in most cases.371 In herit-
able cases, identification of a bi-allelic EIF2AK4 mutation is sufficient
to confirm a diagnosis of PVOD/PCH without histological confirm-
ation.28,376 Most patients complain of dyspnoea on exertion and fa-
tigue, a clinical presentation that is indistinguishable from
PAH.371,374 Physical examination may reveal digital clubbing and bi-
basal crackles on lung auscultation, these being unusual in PAH.371
Case series indicate that patients with PVOD/PCH are more severe-
ly hypoxaemic and have much lower DLCO levels than in other
forms of PAH.92,371 This can be explained by the presence of chron-
ic interstitial pulmonary oedema and pulmonary capillary prolifer-
ation typical of PVOD/PCH.
Chest radiography may reveal Kerley B lines, mediastinal lymph
node enlargement and peripheral interstitial infiltrate, in addition
to other signs of PH.92,371 High-resolution CT of the chest is the in-
vestigation of choice. Typical findings suggestive of PVOD/PCH are
the presence of subpleural thickened septal lines, centrilobular
ground-glass opacities and mediastinal lymphadenopathy.92,371 The
association of these three findings was found to be 100% specific for
PVOD/PCH in cases of PAH, with 66% sensitivity. In addition, their
presence appears to closely correlate with the risk of pulmonary oe-
dema with PAH drugs. V/Q lung scanning is not useful in discrimin-
ating PVOD/PCH from IPAH.377
Because PVOD/PCH may be associated with occult alveolar
haemorrhage, bronchoscopy with bronchoalveolar lavage may be
a useful tool in the diagnostic strategy. In a retrospective study,
the results of bronchoalveolar lavage performed in 19 patients
with PAH or PVOD/PCH were analysed. Compared with IPAH,
the eight cases of PVOD presented with a significantly elevated
cell count, a higher percentage of hemosiderin-laden macrophages
and a markedly elevated Golde score.378
The haemodynamic presentation of PVOD is similar to
IPAH.92,371 Importantly, PAWP is almost invariably normal, because
the pathological changes occur in small venulae and capillaries and
do not affect the larger pulmonary veins.92,371 Vasoreactivity testing
may be complicated by acute pulmonary oedema.92,371
7.6.2 Therapy
There is no established medical therapy for PVOD/PCH.92 Most im-
portantly, vasodilators and, in particular, i.v. epoprostenol must be
used with great caution because of the high risk of severe
drug-induced pulmonary oedema.92,373 However, there are reports
of sustained clinical improvement in individual patients treated with
these medications.379 High-dose diuretics, O2 therapy and slow in-
creases in epoprostenol doses are recommended.379 Therefore
therapy for PVOD/PCH should be undertaken only at centres
with extensive experience in the management of PH and patients
should be fully informed about the risks. Investigational use of angio-
genesis inhibitors such as interferon alfa-2a has been considered in
these patients but is not currently recommended.379 The only cura-
tive therapy for PVOD/PCH is lung transplantation, and there are no
reports of recurrence of disease following transplantation. Eligible
patients with PVOD/PCH should be referred to a transplant centre
for evaluation as soon as the diagnosis is established.379
The recommendations for PVOD/PCH are reported in the
Table 29.
8. Pulmonary hypertension due
to left heart disease (group 2)
PH is a common complication of LHDs (PH-LHD), frequently occur-
ring as a ‘symptom’ of the underlying condition4,380 and often related
to disease severity. PH-LHD can complicate any left heart disorder,
such as valvular heart diseases and congenital defects. However, it
has been most often studied in patients with heart failure and with
preserved or reduced ejection fraction.4,380 When present, PH-LHD
results in more severe symptoms and worse exercise tolerance and
exerts a negative impact on outcome.4,380,381 Compared with PAH,
patients with PH-LHD [especially in the case of heart failure with pre-
served LV ejection fraction (HF-pEF)] are often older, female, with a
higher prevalence of cardiovascular co-morbidities382 and most, if not
all, of the features of metabolic syndrome.383
The true prevalence of PH-LHD in heart failure remains un-
known, mostly because the definition of PH in epidemiological stud-
ies has been based on echocardiography, with a variety of cut-off
values.4,384 Invasive haemodynamics were reported in a limited
Table 29 Recommendations for pulmonary
veno-occlusive disease and pulmonary capillary
haemangiomatosis
Recommendations Classa Levelb Ref.c
A combination of clinical findings,
physical examination,
bronchoscopy and radiological
findings is recommended to
diagnose PVOD/PCH
I C
92,371,
378
Identification of a bi-allelic EIF2AK4
mutation is recommended to
confirm a diagnosis of heritable
PVOD/PCH without histological
confirmation
I B 28,376
Referral of eligible patients with
PVOD/PCH to a transplant centre
for evaluation is indicated as soon as
the diagnosis is established
I C 371
Patients with PVOD/PCH should be
managed only in centres with
extensive experience in PH due to
the risk of lung oedema after the
initiation of PAH therapy
IIa C
371,373,
379
PAH ¼ pulmonary arterial hypertension; PCH ¼ pulmonary capillary
haemangiomatosis; PH ¼ pulmonary hypertension; PVOD ¼ pulmonary
veno-occlusive disease.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
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number of single-centre reports.4 In a retrospective analysis per-
formed in a large PH centre, LHD was identified as the cause of
PH in 36% of all patients referred for evaluation, of which 55%
had ‘passive’ PH, defined as a TPG ,12 mmHg.151,385
PH develops in LHD in response to a passive backward transmis-
sion of filling pressures, mainly driven by LV diastolic function, en-
hanced by exercise-induced mitral regurgitation and a loss of LA
compliance.4 In some patients, these purely mechanical compo-
nents of venous congestion may trigger a superimposed compo-
nent, combining pulmonary vasoconstriction, decreased NO
availability, increased endothelin expression, desensitization to
natriuretic peptide– induced vasodilation and vascular remodel-
ling.4,380,386 This results in a further increase in PAPm in excess of
the elevation of PAWP that may lead to pulmonary vascular disease,
increased RV afterload and RV failure.4
The definitions of PH and the difference between pre- and post-
capillary PH are based on pressure cut-off. This explains why TPG,
i.e. the difference between PAPm and PAWP, has been used to
distinguish ‘passive’ PH (TPG ,12 mmHg) from ‘reactive’ PH (TPG
≥12 mmHg).151 However, this definition and the associated
terminology have been unsatisfactory, to such an extent that
‘out-of-proportion’ PH-LHD has often been used to characterize a
subset of patients with significant changes in pulmonary circula-
tion.4,151 Ideally the latter should be defined by a haemodynamic vari-
able that would (i) be a marker of disease, (ii) be least dependent on
changes in PAWP and stroke volume and (iii) take into account the
pulsatile nature of the pulmonary circulation.4,81 The TPG is influenced
by all the determinants of PAPm, including flow, resistance and left
heart filling pressure.4,81,82 In contrast, diastolic PAP when compared
with PAPs and PAPm is less influenced by PAWP at any level of stroke
volume.4,81 Therefore the DPG (defined as diastolic PAP2 mean
PAWP) appears to best approach the characteristics required to de-
termine pulmonary vascular disease.4,81 In normal subjects, DPG lies in
the 1–3 mmHg range, and in patients evaluated for cardiac disease
(excluding shunts), DPG remains ,5 mmHg in most cases.4,81,387
The role of DPG and TPG in predicting outcome in heart failure
has recently been reported.83,385,388 In a single-centre study of 3107
patients, a DPG.7 mmHg has been reported to be associated with
a worse prognosis in a subgroup of patients with increased TPG
.12 mmHg.385 In another study on 463 patients with LV ejection
fraction ,40%, the risk of death was higher in patients with PH
when the definition was based on PVR (P , 0.01), with a higher
mortality rate in patients with a PVR ≥3 WU.387 However, the out-
come was not different whether the TPG was less than or greater
than 12 mmHg,83 suggesting that the latter could be less discrimin-
ant than PVR when PH is present. Interestingly, the authors re-
ported that pulmonary arterial compliance was an independent
marker of prognosis. Other investigators have also reported this ob-
servation, suggesting that PA compliance is altered in heart fail-
ure,389 even in the absence of PH.390 In 25 450 patients receiving
a heart transplant in the USA, 22.6% were found to have a TPG
.12 mmHg.83 In this specific setting, the DPG was not found to pre-
dict a worse outcome at any level studied. Another recent study re-
ported the lack of prognostic value of the DPG even if significant
methodological limitations were raised.391 Although limited by their
retrospective nature, these studies do not provide a clear answer to
the question of what is the best variable to predict outcome in
PH-LHD. Therefore, for consistency with the general PH definition,
it is recommended to use a combination of DPG and PVR to define
the different types of PH-LHD, i.e. isolated post-capillary pulmonary
hypertension (Ipc-PH) and combined post-capillary and pre-
capillary pulmonary hypertension (Cpc-PH) (Table 3).
8.1 Diagnosis
In LHDs, and more specifically in left heart failure, PH can easily be
suspected by a stepwise approach, combining clinical presentation,
specific echocardiographic features and other modalities such as
ECG and other imaging techniques. Although no single variable
can differentiate PH-LHD from pre-capillary PH, the presence of
multiple risk factors and findings should raise suspicion for PH-LHD
(Table 30). PH should be suspected when patients present with
otherwise unexplained symptoms, signs of right heart failure and co-
morbidities associated with PH, such as sleep apnoea syndrome,
COPD, previous PE and risk factors for PAH.
The respective role of fluid loading and exercise testing to un-
cover PH-LHD in patients with HF-pEF is currently not standardized
and normal values are lacking to provide a clear recommendation to
clinicians. In addition, it has been suggested that patients with a diag-
nosis of PAH may present an abnormal increase in PAWP in re-
sponse to fluid loading.77
Table 30 Examples of key factors suggestive of group
2 pulmonary hypertension
Clinical 
presentation
Echocardiography
Other 
features
Age >65 years Structural left heart 
abnormality
• Disease of left heart valves 
• LA enlargement (>4.2 cm)
• Bowing of the IAS to the 
 right
• LV dysfunction 
• Concentric LV hypertrophy 
 and/or increased LV mass 
ECG
• LVH and/or LAH
• 
• LBBB
• Presence of Q 
 waves
Symptoms of left 
heart failure
Doppler indices of increased 
• Increased E/e’
• >T
 abnormality
Other imaging
• Kerley B lines
• Pleural effusion
• Pulmonary oedema
• LA enlargement
Features of 
metabolic 
syndrome
Absence of 
• RV dysfunction
• Mid systolic notching of 
 the P
• Pericardial effusion
History of heart 
disease 
(past or current)
Persistent atrial 
AF ¼ atrial flutter; Afib ¼ atrial fibrillation; ECG ¼ electrocardiogram;
IAS ¼ inter-atrial septum; LA ¼ left atrium; LAH ¼ left atrial hypertrophy/
dilatation; LBBB ¼ left bundle branch block; LV ¼ left ventricle; LVH ¼ left
ventricular hypertrophy; PA ¼ pulmonary artery; RV ¼ right ventricle.
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The indications for RHC in PH-LHD, preferably electively in
stable condition, are reported in Table 10.
8.2 Therapy
The primary goal of therapy in PH-LHD must be to improve global
management of the underlying condition prior to considering specif-
ic measures to treat PH. This includes repair of valvular heart disease
when indicated and aggressive therapy for heart failure with reduced
systolic function.4,392 Some patients may also benefit from non-
specific vasodilators such as nitrates and hydralazine, although
evidence supporting this strategy is limited.4,392 In severe heart fail-
ure, optimizing volume status is of critical importance and may re-
quire invasive monitoring.4,393 In addition, the implantation of an
LV assist device has been shown to lower pulmonary pressures
through LV unloading without increasing the risk of post-
implantation RV failure.4,394,395 Risk factors for cardiovascular dis-
eases and features of metabolic syndrome should be controlled.4,392
Concomitant disorders leading to PH should be identified and trea-
ted, including COPD, sleep apnoea syndrome and PE. In contrast,
there is no strong evidence-based recommendation for the treat-
ment for HF-pEF.392
The rationale to use PAH therapies in PH-LHD has been sup-
ported by acute or short-term studies using prostanoids, ERAs and
PDE-5is. Most of these studies consistently reported improvements
in haemodynamics, exercise capacity and symptoms.4,396 However,
these studies carry significant methodological limitations (small sam-
ple size, single centre, unclear or no randomization process) that do
not provide enough evidence to support the use of these drugs in the
clinical management of patients.4 In addition, there is no evidence sug-
gesting that acute changes in pulmonary circulation may have a value
outside of the setting of major cardiac surgery such as heart trans-
plantation and/or LV assist device implantation.4,380
In a recent multicentre, placebo-controlled trial,397 201 patients
with PH due to systolic heart failure were randomized in four arms
comparing three doses of riociguat (0.5, 1 and 2 mg t.i.d.) with pla-
cebo over 16 weeks. No effect on the primary endpoint (a change in
PAPm after 16 weeks) was observed at any dose of riociguat com-
pared with placebo.397
Two multicentre clinical trials in PH-LHD are currently under
way with sildenafil [SilHF (NCT01616381)] and macitentan
[Melody-1 (NCT02070991)], the latter being the only study requir-
ing RHC validation.
Therefore there is no new evidence supporting the use of PAH
therapies in PH-LHD, due in part to the absence of studies specific-
ally stratifying patients for PH and/or targeting this specific condi-
tion. Such trials are necessary to address this area of unmet
medical need and patients with Cpc-PH should be included in clin-
ical trials. Recommendations for the management of PH-LHD are
listed in Table 31.
9. Pulmonary hypertension due
to lung diseases and/or hypoxia
(group 3)
The pathology, pathophysiology and epidemiology of these condi-
tions have been discussed previously (see section 4). The most
common lung diseases associated with PH are COPD, interstitial
lung disease and combined pulmonary fibrosis and emphysema
(CPFE). Rare conditions such as Langerhans cell granulomatosis
or sarcoidosis are reported in Web Table VIII. In any lung disease,
the development of PH is accompanied by a deterioration of exer-
cise capacity, worsening of hypoxaemia and shorter survival.398 –400
The severity of PH is usually poorly associated with the severity of
the underlying lung disease.401,402 The most common indicators for
the presence of PH in these patients are a disproportionally low
DLCO and a low pCO2.
401,402
The haemodynamic classification of PH associated with lung dis-
ease is shown in Table 32.20 In case of severe PH, other potential
causes such as LHD or CTEPH should be excluded. In some patients
with lung disease and PH, especially in patients with mild lung
disease but severe PH, it may be difficult to determine whether
PH is due to lung disease or whether the patient suffers from two
diseases, i.e. PAH and chronic lung disease. Those patients should
be referred to a PH centre where there is also expertise in lung
diseases.
Table 31 Management of pulmonary hypertension
in left heart disease
Recommendations Classa Levelb Ref.c
Optimization of the treatment of the
underlying condition is recommended
before considering assessment of PH-LHD
(i.e. treating structural heart disease)
I B 396
It is recommended to identify other
causes of PH (i.e. COPD, sleep apnoea
syndrome, PE, CTEPH) and to treat them
when appropriate before considering
assessment of PH-LHD
I C 396
It is recommended to perform invasive
assessment of PH in patients on
optimized volume status
I C
Patients with PH-LHD and a severe
pre-capillary component as indicated by a
high DPG and/or high PVR should be
referred to an expert PH centre for a
complete diagnostic workup and an
individual treatment decision
IIa C
The importance and role of
vasoreactivity testing is not established in
PH-LHD, except in patients who are
candidates for heart transplantation and/
or LV assist device implantation
III C 396
The use of PAH-approved therapies is
not recommended in PH-LHD
III C 396
COPD ¼ chronic obstructive pulmonary disease; CTEPH ¼ chronic
thromboembolic pulmonary hypertension; DPG ¼ diastolic pressure gradient;
LHD ¼ left heart disease; LV ¼ left ventricular; PE ¼ pulmonary embolism;
PH ¼ pulmonary hypertension; PVR ¼ pulmonary vascular resistance.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
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9.1 Diagnosis
Clinical symptoms and physical signs of PH may be difficult to identify
in patients with respiratory disorders. In addition, in patients with lung
disease, peripheral oedema may not necessarily indicate RV failure, as
it may also result from the effects of hypoxaemia and hypercapnia on
the renin-angiotensin-aldosterone system. Furthermore, concomi-
tant LHD, which is frequently found in patients with chronic respira-
tory diseases, may also contribute to PH. As a general rule, patients
presenting with symptoms that are more severe than expected based
on their PFT results should be further evaluated, in particular by echo-
cardiography, to search for concomitant LHD or PH.
Echocardiography remains the most widely used non-invasive
diagnostic tool for the assessment of PH. Indications for echocardi-
ography in patients with lung diseases include the clinical suspicion
of significant PH or the evaluation of concomitant LHD. It should be
noted, however, that the accuracy of echocardiography in patients
with advanced respiratory diseases is low.403 –405 Patients with clin-
ical or echocardiographic signs of severe PH and/or severe RV dys-
function should be referred to a PH centre.
A definite diagnosis of PH relies on measurements obtained dur-
ing RHC. Potential indications for RHC in advanced lung disease are
(i) proper diagnosis or exclusion of PH in candidates for surgical
treatments (transplantation, lung volume reduction), (ii) suspected
PAH or CTEPH, (iii) episodes of RV failure and (iv) inconclusive
echocardiographic findings in cases with a high level of suspicion
and potential therapeutic implications.
9.2 Therapy
Currently there is no specific therapy for PH associated with lung
diseases. Long-term O2 administration has been shown to partially
reduce the progression of PH in COPD. Nevertheless, PAP rarely
returns to normal values and the structural abnormalities of pul-
monary vessels remain unaltered.169 In interstitial lung diseases,
the role of long-term O2 therapy on PH progression is less clear.
Treatment with conventional vasodilators such as CCBs is not re-
commended because they may impair gas exchange due to the in-
hibition of hypoxic pulmonary vasoconstriction406 – 408 and
because of their lack of efficacy after long-term use.409,410
Published experience with targeted PAH drug therapy is scarce, and
so far there is no evidence from RCTs suggesting that PAH drugs result
in improved symptoms or outcomes in patients with lung disease.411–416
In summary, patients with lung disease and PH who are hypoxae-
mic should receive long-term O2 therapy, adapting the general
recommendations for COPD. Treatment of the underlying lung dis-
ease should be optimized. The use of drugs approved for PAH is not
recommended for patients with PH due to lung disease. Patients
with suspected PAH in addition to their lung diseases (characterized
by mild lung parenchymal abnormalities, symptoms insufficiently
explained by lung mechanical disturbances and a haemodynamic
‘PAH phenotype’, i.e. severe PH with high PVR and low CO) may
be treated according to the recommendations for PAH, keeping
in mind the potential implications of the co-existing lung disease
on symptoms and response to therapy.
The recommendations for PH due to lung diseases are reported
in the Table 33.
Table 32 Haemodynamic classification of pulmonary
hypertension due to lung disease9
Terminology Haemodynamics (right 
heart catheterization)
COPD/IPF/CPFE without PH PAPm <25 mmHg
COPD/IPF/CPFE with PH PAPm ≥25 mmHg 
COPD/IPF/CPFE with severe PH PAPm >35 mmHg, or 
PAPm ≥25 mmHg in the presence 
of a low cardiac output 
(CI <2.5 L/min, not explained by 
other causes)
CI ¼ cardiac index; COPD ¼ chronic obstructive pulmonary disease;
CPFE ¼ combined pulmonary fibrosis and emphysema; IPF ¼ idiopathic
pulmonary fibrosis; PAP ¼ pulmonary artery pressure; PAPm ¼ mean pulmonary
arterial pressure; PH ¼ pulmonary hypertension.
Table 33 Recommendations for pulmonary
hypertension due to lung diseases
Recommendations Classa Levelb Ref.c
Echocardiography is recommended for
the non-invasive diagnostic assessment
of suspected PH in patients with lung
disease
I C
403,
405
Referral to an expert centre is
recommendedd in patients with
echocardiographic signs of severe PH
and/or severe right ventricular
dysfunction
I C
The optimal treatment of the underlying
lung disease, including long-term O2
therapy in patients with chronic
hypoxaemia, is recommended in
patients with PH due to lung diseases
I C 169
Referral to PH expert center should be
considered for patients with signs of
severe PH/severe RV failure for
individual-based treatment
IIa C
RHC is not recommended for suspected
PH in patients with lung disease, unless
therapeutic consequences are to be
expected (e.g. lung transplantation,
alternative diagnoses such as PAH or
CTEPH, potential enrolment in a clinical
trial)
III C 169
The use of drugs approved for PAH is
not recommended in patients with PH
due to lung diseases
III C
411–
416
CTEPH ¼ chronic thromboembolic pulmonary hypertension;
PAH ¼ pulmonary arterial hypertension; PH ¼ pulmonary hypertension;
RHC ¼ right heart catheterization.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
dThis recommendation does not apply to patients with end-stage lung disease
who are not considered candidates for lung transplantation.
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10. Chronic thromboembolic
pulmonary hypertension (group 4)
CTEPH is a disease of obstructive PA remodelling as a consequence
of major vessel thromboembolism. CTEPH has been reported with
a cumulative incidence of 0.1–9.1% within the first 2 years after a
symptomatic PE event.417 The large margin of error is probably
due to referral bias, a paucity of early symptoms and difficulty in
differentiating acute PE from symptoms of pre-existing CTEPH.418
Although the exact prevalence and annual incidence of CTEPH
are unknown, some data suggest that this condition may occur in
approximately 5 individuals per million population per year.419
In the differential diagnosis of CTEPH the following conditions
have to be considered and treated according to current best knowl-
edge. These conditions include PA sarcoma, tumour cell embolism,
parasites (hydatid cyst), foreign body embolism and congenital or
acquired PA stenosis (Table 4).
10.1 Diagnosis
Routine screening for CTEPH after PE is not supported by current
evidence; a significant number of CTEPH cases develop in the ab-
sence of previous acute PE.
The median age of patients at diagnosis is 63 years and both gen-
ders are equally affected;25 paediatric cases are rare.287,420 Clinical
symptoms and signs are non-specific or absent in early CTEPH,
with signs of right heart failure only becoming evident in advanced
disease. Thus early diagnosis remains a challenge in CTEPH, with a
median time of 14 months between symptom onset and diagnosis in
expert centres.421 When present, the clinical symptoms of CTEPH
may resemble those of acute PE or IPAH; in the latter context, oe-
dema and haemoptysis occur more often in CTEPH, while syncope
is more common in IPAH.422
The diagnosis of CTEPH is based on findings obtained after at
least 3 months of effective anticoagulation in order to discriminate
this condition from ‘subacute’ PE. These findings are mean PAP ≥25
mmHg with PAWP ≤15 mmHg, mismatched perfusion defects on
lung scan and specific diagnostic signs for CTEPH seen by multide-
tector CT angiography, MR imaging or conventional pulmonary
cineangiography, such as ring-like stenoses, webs/slits and chronic
total occlusions (pouch lesions or tapered lesions).
Some patients, particularly those with complete unilateral ob-
struction, may present with normal pulmonary haemodynamics at
rest despite symptomatic disease. These patients are also consid-
ered to have CTEPH and are managed accordingly. A suitable ter-
minology to describe this condition of chronic thromboembolic
pulmonary vascular disease is still lacking.
An algorithm for CTEPH diagnosis is shown in Figure 3. While CT
pulmonary angiography is the investigation of choice for the
Symptoms, signs, history suggestive of CTEPH
Echocardiographic probability of PH (Table 8)
High or intermediate probability of PH
V/Q scana
Mismatched perfusion defects?
CTEPH ruled out
Work-up for PH/¨PAH
(Figure 1)
CTEPH possible
Refer to PH/CTEPH
expert centre
CT pulmonary angiography
Right heart catheterization
+/- Pulmonary angiography
Yes No
CT = computed thomography; CTEPH = chronic thromboembolic pulmonary hypertension; PAH = pulmonary arterial hypertension; PH = pulmonary hypertension;
V/Q = ventilation/perfusion.
aCT pulmonary angiography alone may miss diagnosis of chronic thromboembolic pulmonary hypertension.
Figure 3 Diagnostic algorithm for chronic thromboembolic pulmonary hypertension.
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diagnosis of acute PE, planar V/Q lung scan remains the main first-
line imaging modality for CTEPH, as it carries a 96–97% sensitivity
and a 90–95% specificity for the diagnosis.47 In contrast, in IPAH and
PVOD, perfusion scans typically show non-segmental defects or are
normal.377 More recent work suggests that both V/Q scanning and
modern CT pulmonary angiography may be accurate methods for
the detection of CTEPH, with excellent diagnostic efficacy in expert
hands (100% sensitivity, 93.7% specificity and 96.5% accuracy for
V/Q and 96.1%, 95.2% and 95.6%, respectively, for CT pulmonary
angiography).93,423,424
Multidetector CT pulmonary angiography has become an estab-
lished imaging modality for confirming CTEPH,93 however, this investi-
gation alone cannot exclude the disease.47 CT pulmonary angiography
may help to identify complications of the disease such as PA dilatation
resulting in left main coronary artery compression and hypertrophied
bronchial arterial collaterals, which may lead to haemoptysis.
A high-resolution CT scan of the chest delivers images of the lung
parenchyma and identifies emphysema, bronchial disease or intersti-
tial lung disease, as well as infarcts, vascular and pericardial malfor-
mations and thoracic wall deformities. Perfusion inequalities
manifest as a mosaic parenchymal pattern, with dark areas corre-
sponding to relatively decreased perfusion. Although a mosaic pat-
tern is frequent in CTEPH, it can also be observed in up to 12% of
patients with PAH.425 MR imaging of the pulmonary vasculature is
still considered inferior to CT,426 but this modality, as well as
cone beam CT,427 angioscopy,428 intravascular ultrasound or optical
coherence tomography, may be complimentary and used according
to local experience and practice.
RHC is an essential diagnostic tool. Preoperative and immediate
postoperative PVR is a long-term predictor of prognosis.429 The
final step in the diagnostic pathway is selective pulmonary angiog-
raphy in the anterior–posterior and lateral projections illustrating
ring-like stenosis, webs (‘slits’), pouches, wall irregularities, com-
plete vascular obstructions as well as bronchial collaterals, and sup-
ports the technical assessment of operability.
10.2 Therapy
10.2.1 Surgical
PEA is the treatment of choice for CTEPH (Figure 4). In Europe, in-
hospital mortality is currently as low as 4.7%,430 and even lower in
Diagnosis confirmed by
CTEPH expert center
Lifelong anticoagulation
Operability assessment
by a multidisciplinary CTEPH team
Non-acceptable
risk/benefit ratioa
Acceptable
risk/benefit ratio
Pulmonary
endarterectomy
Persistent
symptomatic PH
Consider lung
transplantation
Technically non-operable
Persistent severe
symptomatic PH
Targeted medical
therapy
Consider BPA in
expert centerb
Technically operable
BPA = balloon pulmonary angioplasty; CTEPH = chronic thromboembolic pulmonary hypertension; PH = pulmonary hypertension.
a
bIn some centers medical therapy and BPA are initiated concurrently.
Figure 4 Treatment algorithm for chronic thromboembolic pulmonary hypertension.
ESC/ERS Guidelines 109
Downloaded from https://academic.oup.com/eurheartj/article-abstract/37/1/67/2887599
by Olivier Borsus user
on 26 January 2018
high-volume single centres.431 The majority of patients experience
substantial relief from symptoms and near normalization of haemo-
dynamics.430 – 432 In contrast to surgical embolectomy for acute PE,
treatment of CTEPH necessitates a true bilateral endarterectomy
through the medial layer of the pulmonary arteries, which is per-
formed under deep hypothermia and circulatory arrest,431 without
the need for cerebral perfusion.433
Operability of patients with CTEPH is determined by multiple fac-
tors that cannot easily be standardized; these are related to the suit-
ability of the patient, the expertise of the surgical team and available
resources. General criteria include preoperative WHO-FC II– IV
and surgical accessibility of thrombi in the main, lobar or segmental
pulmonary arteries. Advanced age per se is not a contraindication for
surgery. There is no PVR threshold or measure of RV dysfunction
that can be considered to preclude PEA.
Postoperative ECMO is recommended as a standard of care
in PEA centres for severe cases.434 –436 Early postoperative reperfu-
sion oedema may require veno-arterial ECMO, and severe persist-
ent PH may be bridged to emergency lung transplantation with
veno-venous ECMO.
Patients who do not undergo PEA or suffer from persistent or
recurrent PH after PEA (post-PEA PH) face a poor prognosis.
10.2.2 Medical
Optimal medical treatment for CTEPH consists of anticoagulants
and diuretics, and O2 in cases of heart failure or hypoxaemia.
Lifelong anticoagulation is recommended, even after PEA, though
no data exist on the efficacy and safety of new oral anticoagu-
lants. Although there is no consensus, routine cava filter place-
ment is not justified by the available evidence. Pulmonary
microvascular disease in CTEPH has provided the rationale for
off-label use of drugs approved for PAH.25 Some non-randomized
studies have provided evidence for improvement in exercise cap-
acity and haemodynamics.437 – 439 Medical treatment of CTEPH
with targeted therapy may be justified in technically non-operable
patients or in the presence of an unacceptable surgical risk:bene-
fit ratio (Figure 2). Patients with persistent or recurrent PH after
PEA may also be candidates for targeted medical therapy. The
use of targeted therapy in operable patients with severe haemo-
dynamic compromise as a bridge to PEA has not yet been sup-
ported by scientific evidence.
The dual endothelin antagonist bosentan was evaluated in 157 pa-
tients with inoperable CTEPH or persistent/recurrent PH after PEA
over 16 weeks; the primary combined endpoint of a decrease in PVR
and an increase in the 6MWD was not met.440 However, an oral
sGC stimulator, riociguat, was administered to 261 of 446 screened
patients with non-operable CTEPH or persistent/recurrent PH after
PEA for 16 weeks and led to a mean increase of 39 m in the 6MWD
(P , 0.001, primary endpoint) and to a least squares mean differ-
ence of 246 dyn.cm.s25 in PVR (P, 0.001, secondary endpoint);
the time to clinical worsening remained unchanged.441
Preoperative medical treatment is uncertain because the magni-
tude of effects was small in one RCT.442 One retrospective study in-
dicated no difference in outcome, but there was a delay in surgery
for patients treated medically.442 Prospective RCTs are needed in
patients with potential treatment benefit; for example, patients
with a high PVR and technically challenging anatomy.
After PEA, patients should be followed in CTEPH centres, with at
least one haemodynamic assessment to be considered at 6–12
months after the intervention.
10.2.3 Interventional
In 2001 Feinstein et al.443 published a series of 18 patients with
non-operable CTEPH who had been subjected to balloon dilata-
tion of the pulmonary arteries. Despite a significant decrease in
PAPm, 11 patients developed reperfusion pulmonary oedema
and 3 required mechanical ventilation. Recently, Japanese investiga-
tors have refined BPA by using smaller balloons, by cautiously lim-
iting the number of balloon inflations per session to one or two
pulmonary vascular segments and by the use of intravascular
imaging.444 – 446 An average number of 4.8 sessions is needed per
patient to improve parameters of RV function.57 A careful ap-
proach with targeting only one lobe during each session and
very cautious balloon sizing have reduced the incidence of reper-
fusion pulmonary oedema to 2% in individual centres.447 While
BPA is still not extensively used,448 it is rapidly gaining attention
worldwide. BPA should only be performed in experienced and
high-volume CTEPH centres.
The recommendations for CTEPH are summarised in Table 34.
Table 34 Recommendations for chronic
thromboembolic pulmonary hypertension
Recommendations Classa Levelb Ref.c
In PE survivors with exercise
dyspnoea, CTEPH should be
considered
IIa C 449
Life-long anticoagulation is
recommended in all patients with
CTEPH
I C 91
It is recommended that in all patients with
CTEPH the assessment of operability and
decisions regarding other treatment
strategies should be made by a
multidisciplinary team of experts
I C 91
Surgical PEA in deep hypothermia
circulatory arrest is recommended for
patients with CTEPH
I C 91
Riociguat is recommended in
symptomatic patients who have been
classified as having persistent/recurrent
CTEPH after surgical treatment or
inoperable CTEPH by a CTEPH team
including at least one experienced PEA
surgeon
I B 441
Off-label use of drugs approved for PAH
may be considered in symptomatic
patients who have been classified as
having inoperable CTEPH by a CTEPH
team including at least one experienced
PEA surgeon
IIb B
437–
440
Continued
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An algorithm for the treatment of CTEPH is provided in Figure 4.
11. Pulmonary hypertension with
unclear and/or multifactorial
mechanisms (group 5)
PH with unclear and/or multifactorial mechanisms (group 5, Table 4)
includes several disorders with multiple patho-aetiologies. A com-
mon feature of these diseases is that the mechanisms of PH are
poorly understood and may include pulmonary vasoconstriction,
proliferative vasculopathy, extrinsic compression, intrinsic occlu-
sion, high-output cardiac failure, vascular obliteration and left heart
failure as causes (Web Table VIII).
These patients need careful diagnosis. Treatment is tailored for
that diagnosis; treatment of PH is secondary. The axiom should
be ‘Treat the lung not the pressure’. There are no RCTs regarding
the use of PAH-approved drugs in the treatment of group 5 disor-
ders.450 Of particular importance is that some of the diseases de-
scribed in Web Table VII may have a venous component (PVOD)
that could be made worse by the use of pulmonary arterial
vasodilators.
12. Definition of a pulmonary
hypertension expert referral
centre
PAH is a rare disease. Since, in general, medical centres with a high
volume of patients tend to obtain the best outcomes, the establish-
ment of expert referral centres is clinically and economically highly
desirable and supported by patient organisations. The purpose of a
expert referral centre is to receive new referrals and undertake
assessment and investigation of all causes of PH, routinely manage
appropriate patients with PAH- and CTEPH-specific drug therap-
ies, work closely with other healthcare providers to obtain the
best outcomes for patients and undertake audits, research and
education.
Expert referral centres should have sufficient patients on chronic
therapy as well as new referrals to warrant this status. The ideal
number of patients seen by an adult centre each year is recom-
mended to be no fewer than 200, of which at least half have a final
diagnosis of PAH. In countries with a population .10 million, adult
centres should ideally expand to accommodate .300 patients
annually. It is recommended that a expert referral centre, as a
minimum, should follow at least 50 patients with PAH or CTEPH
and receive at least two new referrals per month with documented
PAH or CTEPH. Paediatric centres are recommended to see 30–50
patients per year. These numbers can be adapted according to spe-
cific country characteristics (population distribution, geographical
constraints, etc.).
12.1 Facilities and skills required for a
expert referral centre
1. Expert referral centres are recommended to provide care by
an interprofessional team that should, as a minimum,
comprise:451 – 456
(a) two consultant physicians (normally from either or both car-
diology and respiratory medicine) experienced in and with a
special interest in PH with dedicated PH clinical sessions for
outpatients, inpatients and a multidisciplinary team meeting
(b) clinical nurse specialist
(c) radiologist with expertise in pulmonary hypertension imaging
(d) cardiologist or PH physician with expertise in echocardiography
(e) cardiologist or PH physician with expertise in RHC and va-
soreactivity testing
(f) access to psychological and social work support
(g) appropriate on-call cover and expertise
2. For expert referral centres, access to the following facilities is
recommended:
(a) a ward where staff has special expertise in PH
(b) an intensive therapy unit with relevant expertise
(c) a specialist outpatient service
(d) emergency care
(e) diagnostic investigations including echocardiography, CT
scanning, nuclear scanning, MR imaging, ultrasound, exercise
testing, lung function testing and a cardiac catheterization
laboratory
(f) access to the full range of specific PAH and CTEPH drug ther-
apy available in their country
3. Expert referral centres are recommended to have established
networks (e.g. expert referral criteria, patient pathway and
clinical management protocols) with other services that may
not necessarily be on the same site:452
(a) genetics
(b) CTD
(c) family planning
(d) PEA
(e) lung transplantation
(f) adult CHD
Table 34 Continued
Recommendations Classa Levelb Ref.c
Interventional BPA may be considered in
patients who are technically
non-operable or carry an unfavourable
risk:benefit ratio for PEA
IIb C
57,
444–
446,
448
Screening for CTEPH in asymptomatic
survivors of PE is currently not
recommended
III C 417
BPA ¼ balloon pulmonary angioplasty; CTEPH ¼ chronic thromboembolic
pulmonary hypertension; PAH ¼ pulmonary arterial hypertension;
PE ¼ pulmonary embolism; PEA ¼ pulmonary endarterectomy.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
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4. Expert referral centres should consider undertaking a pro-
gramme of clinical audit of adherence to guidelines and clinical
outcomes that includes survival analysis. Audits should also carry
out comparisons within the same country where there is more
than one expert referral centre.
5. Expert referral centres should consider participating in collab-
orative clinical research in PAH and CTEPH that includes phase
II and phase III clinical trials.
6. Expert referral centres should consider raising awareness about
expert referral criteria and provide regular education about all
aspects of PH to appropriate healthcare professionals. In parti-
cular, education should be aimed at junior doctors in training
as well as senior colleagues.
7. Expert referral centres should consider participating in the devel-
opment and running of a network of PH centres within their own
country where there is more than one expert referral centre.
8. Expert referral centres should consider having a link to their
national and/or European PH patients’ associations.
The recommendations for pulmonary hypertension expert referral
centres are reported in the Table 35.
13. To do and not to do messages
from the guidelines
Table 35 Recommendations for pulmonary
hypertension expert referral centres
Recommendations Classa Levelb
It is recommended for expert referral centres
to provide care by a multiprofessional team
(cardiology and respiratory medicine
physicians, clinical nurse specialist,
radiologists, psychological and social work
support, appropriate on-call expertise)
I C
It is recommended for expert referral centres
to have direct links and quick referral patterns
to other services (such as CTD, family
planning, PEA, lung transplantation, adult
congenital heart disease)
I C
It should be considered that a expert referral
centre follow at least 50 patients with PAH
or CTEPH and should receive at least two
new referrals per month with documented
PAH or CTEPH
IIa C
It should be considered that a expert referral
centre perform at least 20 vasoreactivity
tests in IPAH, HPAH or DPAH patients per
year
IIa C
Expert referral centres should participate in
collaborative clinical research in PAH,
including phase II and phase III clinical trials
IIa C
CTD ¼ connective tissue disease; CTEPH ¼ chronic thromboembolic
pulmonary hypertension; DPAH ¼ drug-induced pulmonary arterial
hypertension; HPAH ¼ heritable pulmonary arterial hypertension;
IPAH ¼ idiopathic pulmonary arterial hypertension; PAH ¼ pulmonary arterial
hypertension; PEA ¼ pulmonary endarterectomy.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendations.
Pulmonary hypertension diagnosis
Right heart catheterization is recommended to
confirm the diagnosis of pulmonary arterial
hypertension (PAH - Group 1) and to support
treatment decisions
I C
Vasoreactivity testing is recommended in patients
with IPAH, HPAH and PAH induced by drugs use
to detect patients who can be treated with high
doses of a calcium channel blocker
I C
Pulmonary arterial hypertension severity
It is recommended to evaluate the severity of
PAH patients with a panel of data derived from
clinical assessment, exercise tests, biochemical
markers, and echocardiographic and
haemodynamic evaluation (Tables 13 and 14) and
to perform regular follow-up assessments every
3-6 months in stable patients /Table 14)
I C
Pulmonary arterial hypertension general measures
It is recommended to avoid pregnancy in patients
with PAH
I C
Pulmonary arterial hypertension therapy
It is recommended for expert referral centres to
providecarebyamulti-professional team(cardiology
and respiratory medicine physicians, clinical nurse
specialist, radiologists, psychological and social work
support, appropriate on-call expertise)
I C
Initial approved drugs monotherapy is
recommended in treatment naı¨ve, low or
intermediate risk patients with pulmonary arterial
hypertension (Table 19)
I A
Initial approved oral drugs combination therapy is
recommended in treatment naı¨ve, low or
intermediate risk patients with pulmonary arterial
hypertension (Table 20)
I B
Sequential drugs combination therapy is
recommended in patients with inadequate
treatment response to initial monotherapy or to
initial double combination therapy (Table 21)
I B
Recommendations for left heart disease and lung diseases
The use of PAH approved therapies is not
recommended in patients with pulmonary
hypertension due to left heart disease or lung diseases
III C
Recommendations for chronic thromboembolic
pulmonary hypertension
Surgical pulmonary endarterectomy in deep
hypothermia circulatory arrest is recommended
for patients with CTEPH and it is recommended
that the assessment of operability and decisions
regarding other treatment strategies (drugs
therapy or balloon pulmonary angioplasty) be
made by a multidisciplinary team of experts
I C
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14. Web addenda
All Web figures and Web tables are available in the Web addenda at:
http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-
Guidelines/Pulmonary-Hypertension-Guidelines-on-Diagnosis-
and-Treatment-of
15. Appendix
ESC Committee for Practice Guidelines (CPG): Jose Luis
Zamorano (Chairperson) (Spain), Victor Aboyans (France), Stephan
Achenbach (Germany), Stefan Agewall (Norway), Lina Badimon
(Spain), Gonzalo Baro´n-Esquivias (Spain), Helmut Baumgartner
(Germany), Jeroen J. Bax (The Netherlands), He´ctor Bueno (Spain),
Scipione Carerj (Italy), Veronica Dean (France), Çetin Erol (Turkey),
Donna Fitzsimons (UK), Oliver Gaemperli (Switzerland), Paulus
Kirchhof (Germany/UK), Philippe Kolh (Belgium), Patrizio Lancellot-
ti (Belgium), Gregory Y.H. Lip (UK), Petros Nihoyannopoulos (UK),
Massimo F. Piepoli (Italy), Piotr Ponikowski (Poland), Marco Roffi
(Switzerland), Adam Torbicki (Poland), Antonio Vaz Carneiro (Por-
tugal), Stephan Windecker (Switzerland).
ESC National Cardiac Societies actively involved in the re-
view process of the 2015 ESC/ERS Guidelines for the diagnosis
and treatment of pulmonary hypertension:
Albania: Albanian Society of Cardiology, Sokol Myftiu;
Austria: Austrian Society of Cardiology, Diana Bonderman;
Azerbaijan: Azerbaijan Society of Cardiology, Ibrahimov Firdovsi;
Belarus: Belorussian Scientific Society of Cardiologists, Irina
Lazareva; Belgium: Belgian Society of Cardiology, Michel De
Pauw; Bosnia & Herzegovina: Association of Cardiologists of
Bosnia & Herzegovina, Sˇekib Sokolovic´; Bulgaria: Bulgarian
Society of Cardiology, Vasil Velchev; Croatia: Croatian Cardiac
Society, Maja Cˇikesˇ; Cyprus: Cyprus Society of Cardiology, Josef
Antoniou Moutiris; Czech Republic: Czech Society of Cardi-
ology, Pavel Jansa; Denmark: Danish Society of Cardiology, Jens
Erik Nielsen-Kudsk; Estonia: Estonian Society of Cardiology, Ly
Anton; Finland: Finnish Cardiac Society, Pertti Ja¨a¨skela¨inen;
France: French Society of Cardiology, Fabrice Bauer; Georgia:
Georgian Society of Cardiology, Archil Chukhrukidze; Germany:
German Cardiac Society, Christian Opitz; Greece: Hellenic Car-
diological Society, George Giannakoulas; Hungary: Hungarian
Society of Cardiology, Kristo´f Karlo´cai; Iceland: Icelandic Society
of Cardiology, Hjo¨rtur Oddsson; Ireland: Irish Heart Foundation,
Sean Gaine; Israel: Israel Heart Society, Doron Menachemi; Italy:
Italian Federation of Cardiology, Michele Emdin; Kyrgyzstan:
Kyrgyz Society of Cardiology, Talant Sooronbaev; Latvia: Latvian
Society of Cardiology, Ainars Rudzıtis; Lithuania: Lithuanian Soci-
ety of Cardiology, Lina Gumbiene; Luxembourg: Luxembourg
Society of Cardiology, Frederic Lebrun; Malta: Maltese Cardiac
Society, Josef Micallef; Moldavia: Moldavian Society of Cardiology,
Victor Botnaru; Morocco: Moroccan Society of Cardiology, Latifa
Oukerraj; Norway: Norwegian Society of Cardiology, Arne
K. Andreassen; Poland: Polish Cardiac Society, Marcin Kurzyna;
Portugal: Portuguese Society of Cardiology, Maria Joa˜o Ribeiro
Leite Baptista; Romania: Romanian Society of Cardiology,
Ioan Mircea Coman; Russia: Russian Society of Cardiology, Olga
Moiseeva; Serbia: Cardiology Society of Serbia, Branislav
S. Stefanovic´; Slovakia: Slovak Society of Cardiology, Iveta Sˇimko-
va´; Sweden: Swedish Society of Cardiology, Gerhard Wikstro¨m;
Switzerland: Swiss Society of Cardiology, Markus Schwerzmann;
The Former Yugoslav Republic of Macedonia: Macedonian
FYR Society of Cardiology, Elizabeta Srbinovska-Kostovska;
The Netherlands: Netherlands Society of Cardiology, Arie
P. J. van Dijk; Tunisia: Tunisian Society of Cardiology and Cardio-
Vascular Surgery, Abdallah Mahdhaoui; Turkey: Turkish Society of
Cardiology, Cihangir Kaymaz; UK: British Cardiovascular Society,
Gerry Coghlan; Ukraine: Ukrainian Association of Cardiology,
Yuriy Sirenko.
16. References
1. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D,
Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. Definitions and diagnosis of
pulmonary hypertension. J Am Coll Cardiol 2013;62(Suppl):D42–D50.
2. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure dur-
ing rest and exercise in healthy subjects A systematic review. Eur Respir J 2009;34:
888–894.
3. Herve P, Lau E, Sitbon O, Savale L, Montani D, Godinas L, Lador F, Jaı¨s X, Parent F,
Gu¨nther S, Humbert M, Simonneau G, Chemla D. Criteria for diagnosis of exer-
cise pulmonary hypertension. Eur Respir J 2015;46:728–737.
4. Vachiery JL, Adir Y, Barbera JA, Champion HC, Coghlan JG, Cottin V, DeMarco T,
Galie` N, Ghio S, Gibbs JS, Martinez FJ, Semigran MJ, Simonneau G, Wells AU,
Seeger W. Pulmonary hypertension due to left heart disease. J Am Coll Cardiol
2013;62:D100–D108.
5. Simonneau G, Galie` N, Rubin LJ, Langleben D, Seeger W, Domenighetti G,
Gibbs S, Lebrec D, Speich R, Beghetti M. Clinical classification of pulmonary
hypertension. J Am Coll Cardiol 2004;43(Suppl 1):S5–S12.
6. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A,
Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF,
Olschewski H, Robbins IM, Souza R. Updated clinical classification of pulmonary
hypertension. J Am Coll Cardiol 2013;62:D34–D41.
7. Dhillon R. The management of neonatal pulmonary hypertension. Arch Dis Child
Fetal Neonatal Ed 2012;97:F223–F228.
8. Porta NF, Steinhorn RH. Pulmonary vasodilator therapy in the NICU: inhaled ni-
tric oxide, sildenafil, and other pulmonary vasodilating agents. Clin Perinatol 2012;
39:149–164.
9. Ivy DD, Abman SH, Barst RJ, Berger RMF, Bonnet D, Fleming TR, Haworth SG,
Raj JU, Rosenzweig EB, Schulze Neick I, Steinhorn RH, Beghetti M. Pediatric pul-
monary hypertension. J Am Coll Cardiol 2013;62:D117–D126.
10. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A,
Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C,
Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G. Pulmonary
arterial hypertension in France: results from a national registry. Am J Respir Crit
Care Med 2006;173:1023–1030.
The CME text ‘2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension’ is accredited by the European Board for Accreditation in Cardiology (EBAC).
EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of
Medical Specialists (UEMS). In compliance with EBAC/EACCME Guidelines, all authors participating in this programme have disclosed any potential conflicts of interest that might cause
a bias in the article. The Organizing Committee is responsible for ensuring that all potential conflicts of interest relevant to the programme are declared to the participants prior to the
CME activities.
CME questions for this article are available at: European Heart Journal http://www.oxforde-learning.com/eurheartj and European Society of Cardiology http://www.escardio.
org/guidelines.
ESC/ERS Guidelines 113
Downloaded from https://academic.oup.com/eurheartj/article-abstract/37/1/67/2887599
by Olivier Borsus user
on 26 January 2018
11. Peacock AJ, Murphy NF, McMurray JJV, Caballero L, Stewart S. An epidemiological
study of pulmonary arterial hypertension. Eur Respir J 2007;30:104–109.
12. McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ,
Pepke-Zaba J, Pulido T, Rich S, Rosenkranz S, Suissa S, Humbert M. Pulmonary
arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013;
62(Suppl):D51–D59.
13. Simonneau G, Robbins I, Beghetti M, Channick RN, Delcroix M, Denton CP,
Elliott CG, Gaine S, Gladwin MT, Jing ZC, Krowka MJ, Langleben D,
Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension.
J Am Coll Cardiol 2009;54(Suppl):S43–S54.
14. Montani D, Bergot E, Gu¨nther S, Savale L, Bergeron A, Bourdin A, Bouvaist H,
Canuet M, Pison C, Macro M, Poubeau P, Girerd B, Natali D, Guignabert C,
Perros F, O’Callaghan DS, Jaı¨s X, Tubert-Bitter P, Zalcman G, Sitbon O,
Simonneau G, Humbert M. Pulmonary arterial hypertension in patients treated
by dasatinib. Circulation 2012;125:2128–2137.
15. Savale L, Chaumais MC, Cottin V, Bergot E, Frachon I, Prevot G, Pison C,
Dromer C, Poubeau P, Lamblin N, Habib G, Reynaud-Gaubert M, Bourdin A,
Sanchez O, Tubert-Bitter P, Jaı¨s X, Montani D, Sitbon O, Simonneau G,
Humbert M. Pulmonary hypertension associated with benfluorex exposure. Eur
Respir J 2012;40:1164–1172.
16. Savale L, Sattler C, Gunther S, Montani D, Chaumais MC, Perrin S, Jaı¨s X,
Seferian A, Jovan R, Bulifon S, Parent F, Simonneau G, Humbert M, Sitbon O. Pul-
monary arterial hypertension in patients treated with interferon. Eur Respir J 2014;
44:1627–1634.
17. Badesch BD, Champion HC, Gomez-Sanchez MA, Hoeper M, Loyd J, Manes A,
McGoon M, Naeije R, Olschewski H, Oudiz R, Torbicki A. Diagnosis and assess-
ment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(Suppl):S55–
S56.
18. Oudiz RJ. Pulmonary hypertension associated with left-sided heart disease. Clin
Chest Med 2007;28:233–241.
19. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G,
Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V,
Iung B, Lancellotti P, Pierard L, Price S, Schafers HJ, Schuler G, Stepinska J,
Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL,
Zembala M. Guidelines on the management of valvular heart disease (version
2012). Eur Heart J 2012;33:2451–2496.
20. Seeger W, Adir Y, Barbera` JA, Champion H, Coghlan JG, Cottin V, De Marco T,
Galie` N, Ghio S, Gibbs S, Martinez FJ, Semigran MJ, Simonneau G, Wells AU,
Vachie´ry JL. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol
2013;62(Suppl):D109–D116.
21. Hurdman J, Condliffe R, Elliot CA, Swift A, Rajaram S, Davies C, Hill C,
Hamilton N, Armstrong IJ, Billings C, Pollard L, Wild JM, Lawrie A, Lawson R,
Sabroe I, Kiely DG. Pulmonary hypertension in COPD: results from the ASPIRE
registry. Eur Respir J 2013;41:1292–1301.
22. Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I,
Israel-Biet D, Court-Fortune, Valeyre D, Cordier JF. Combined pulmonary fibro-
sis and emphysema: a distinct underrecognised entity. Eur Respir J 2005;26:
586–593.
23. Escribano-Subias P, Blanco I, Lopez-Meseguer M, Lopez-Guarch CJ, Roman A,
Morales P, Castillo-Palma MJ, Segovia J, Gomez-Sanchez MA, Barbera JA. Survival
in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J
2012;40:596–603.
24. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P,
Biasiolo A, Pegoraro C, Iliceto S, Prandoni P. Incidence of chronic thromboembol-
ic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:
2257–2264.
25. Pepke-Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D, Treacy C,
D’Armini AM, Morsolini M, Snijder R, Bresser P, Torbicki A, Kristensen B,
Lewczuk J, Simkova I, Barbera` JA, de Perrot M, Hoeper MM, Gaine S, Speich R,
Gomez-Sanchez MA, Kovacs G, Hamid AM, Jaı¨s X, Simonneau G. Chronic
thromboembolic pulmonary hypertension (CTEPH): results from an internation-
al prospective registry. Circulation 2011;124:1973–1981.
26. Soubrier F, Chung WK, Machado R, Grunig E, Aldred M, Geraci M, Loyd JE,
Elliott CG, Trembath RC, Newman JH, Humbert M. Genetics and genomics of
pulmonary arterial hypertension. J Am Coll Cardiol 2013;62(Suppl):D13–D21.
27. Ma L, Roman-Campos D, Austin ED, Eyries M, Sampson KS, Soubrier F,
Germain M, Tregouet DA, Borczuk A, Rosenzweig EB, Girerd B, Montani D,
Humbert M, Loyd JE, Kass RS, Chung WK. A novel channelopathy in pulmonary
arterial hypertension. N Engl J Med 2013;369:351–361.
28. Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C, Chelghoum N,
Coulet F, Bonnet D, Dorfmuller P, Fadel E, Sitbon O, Simonneau G,
Tregouet DA, Humbert M, Soubrier F. EIF2AK4 mutations cause pulmonary
veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet
2014;46:65–69.
29. Eddahibi S, Chaouat A, Morrell N, Fadel E, Fuhrman C, Bugnet AS, Dartevelle P,
Housset B, Hamon M, Weitzenblum E, Adnot S. Polymorphism of the serotonin
transporter gene and pulmonary hypertension in chronic obstructive pulmonary
disease. Circulation 2003;108:1839–1844.
30. Bonderman D, Wexberg P, Martischnig AM, Heinzl H, Lang MB, Sadushi R,
Skoro-Sajer N, Lang IM. A noninvasive algorithm to exclude pre-capillary pulmon-
ary hypertension. Eur Respir J 2011;37:1096–1103.
31. Rich JD, Thenappan T, Freed B, Patel AR, Thisted RA, Childers R, Archer SL. QTc
prolongation is associated with impaired right ventricular function and predicts
mortality in pulmonary hypertension. Int J Cardiol 2013;167:669–676.
32. Sun PY, Jiang X, Gomberg-Maitland M, Zhao QH, He J, Yuan P, Zhang R, Jing ZC.
Prolonged QRS duration: a new predictor of adverse outcome in idiopathic pul-
monary arterial hypertension. Chest 2012;141:374–380.
33. Olsson KM, Nickel NP, Tongers J, Hoeper MM. Atrial flutter and fibrillation in pa-
tients with pulmonary hypertension. Int J Cardiol 2013;167:2300–2305.
34. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM,
Fishman AP, Goldring RM, Groves BM, Koerner SK. Primary pulmonary hyperten-
sion: a national prospective study. Ann Intern Med 1987;107:216–223.
35. Milne EN. Forgotten gold in diagnosing pulmonary hypertension: the plain chest
radiograph. Radiographics 2012;32:1085–1087.
36. Trip P, Nossent EJ, de Man FS, van den Berk IA, Boonstra A, Groepenhoff H,
Leter EM, Westerhof N, Grunberg K, Bogaard HJ, Vonk-Noordegraaf A. Severely
reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient
characteristics and treatment responses. Eur Respir J 2013;42:1575–1585.
37. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Pulmonary function in primary pul-
monary hypertension. J Am Coll Cardiol 2003;41:1028–1035.
38. Hoeper MM, Pletz MW, Golpon H, Welte T. Prognostic value of blood gas ana-
lyses in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2007;
29:944–950.
39. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van
der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N,
McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies
for lung function tests. Eur Respir J 2005;26:948–968.
40. Holverda S, Bogaard HJ, Groepenhoff H, Postmus PE, Boonstra A,
Vonk-Noordegraaf A. Cardiopulmonary exercise test characteristics in patients
with chronic obstructive pulmonary disease and associated pulmonary hyperten-
sion. Respiration 2008;76:160–167.
41. Jilwan FN, Escourrou P, Garcia G, Jaı¨s X, Humbert M, Roisman G. High occurrence
of hypoxemic sleep respiratory disorders in precapillary pulmonary hypertension
and mechanisms. Chest 2013;143:47–55.
42. Rafanan AL, Golish JA, Dinner DS, Hague LK, Arroliga AC. Nocturnal hypoxemia
is common in primary pulmonary hypertension. Chest 2001;120:894–899.
43. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K,
Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assess-
ment of the right heart in adults: a report from the American Society of Echocar-
diography endorsed by the European Association of Echocardiography, a
registered branch of the European Society of Cardiology, and the Canadian Soci-
ety of Echocardiography. J Am Soc Echocardiogr 2010;23:685–713.
44. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L,
Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D,
Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommen-
dations for cardiac chamber quantification by echocardiography in adults: an up-
date from the American Society of Echocardiography and the European
Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:
233–271.
45. Foale R, Nihoyannopoulos P, McKenna W, Kleinebenne A, Nadazdin A,
Rowland E, Smith G. Echocardiographic measurement of the normal adult right
ventricle. Br Heart J 1986;56:33–44.
46. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, Kahan A, Cabane J,
Frances C, Launay D, Mouthon L, Allanore Y, Kiet PT, Clerson P, de Groote P,
Humbert M. Early detection of pulmonary arterial hypertension in systemic scler-
osis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:
3792–3800.
47. Tunariu N, Gibbs SJR, Win Z, Gin-Sing W, Graham A, Gishen P, AL-Nahhas A.
Ventilation-perfusion scintigraphy Is more sensitive than multidetector CTPA in
detecting chronic thromboembolic pulmonary disease as a treatable cause of pul-
monary hypertension. J Nucl Med 2007;48:680–684.
48. Meng JJ, Zhang LJ, Wang Q, Fang W, Dai HJ, Yan J, Wang T, Yao ZM, He J, Li M,
Mi HZ, Jiao J, Zheng YM. [A comparison of ventilation/perfusion single photon
emission CT and CT pulmonary angiography for diagnosis of pulmonary embol-
ism]. Zhonghua Jie He He Hu Xi Za Zhi 2013;36:177–181.
49. Rajaram S, Swift AJ, Telfer A, Hurdman J, Marshall H, Lorenz E, Capener D,
Davies C, Hill C, Elliot C, Condliffe R, Wild JM, Kiely DG. 3D contrast-enhanced
lung perfusion MRI is an effective screening tool for chronic thromboembolic
ESC/ERS Guidelines114
Downloaded from https://academic.oup.com/eurheartj/article-abstract/37/1/67/2887599
by Olivier Borsus user
on 26 January 2018
pulmonary hypertension: results from the ASPIRE Registry. Thorax 2013;68:
677–678.
50. Rajaram S, Swift AJ, Condliffe R, Johns C, Elliot CA, Hill C, Davies C, Hurdman J,
Sabroe I, Wild JM, Kiely DG. CT features of pulmonary arterial hypertension and
its major subtypes: a systematic CT evaluation of 292 patients from the ASPIRE
Registry. Thorax 2015;70:382–387.
51. Shen Y, Wan C, Tian P, Wu Y, Li X, Yang T, An J, Wang T, Chen L, Wen F. CT-base
pulmonary artery measurement in the detection of pulmonary hypertension: a
meta-analysis and systematic review. Medicine (Baltimore) 2014;93:e256.
52. Tan RT, Kuzo R, Goodman LR, Siegel R, Haasler GB, Presberg KW. Utility of CT
scan evaluation for predicting pulmonary hypertension in patients with parenchy-
mal lung disease. Chest 1998;113:1250–1256.
53. Resten A, Maitre S, Humbert M, Rabiller A, Sitbon O, Capron F, Simonneau G,
Musset D. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive
disease. Am J Roentgenol 2004;183:65–70.
54. Dartevelle P, Fadel E, Mussot S, Chapelier A, Herve P, de Perrot M, Cerrina J,
Ladurie FL, Lehouerou D, Humbert M, Sitbon O, Simonneau G. Chronic
thromboembolic pulmonary hypertension. Eur Respir J 2004;23:637–648.
55. Reichelt A, Hoeper MM, Galanski M, Keberle M. Chronic thromboembolic pul-
monary hypertension: evaluation with 64-detector row CT versus digital sub-
straction angiography. Eur J Radiol 2008;71:49–54.
56. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary
hypertension. N Engl J Med 2001;345:1465–1472.
57. Fukui S, Ogo T, Morita Y, Tsuji A, Tateishi E, Ozaki K, Sanda Y, Fukuda T, Yasuda S,
Ogawa H, Nakanishi N. Right ventricular reverse remodelling after balloon pul-
monary angioplasty. Eur Respir J 2014;43:1394–1402.
58. Castaner E, Alguersuari A, Andreu M, Gallardo X, Spinu C, Mata JM. Imaging find-
ings in pulmonary vasculitis. Semin Ultrasound CT MR 2012;33:567–579.
59. Nawaz A, Litt HI, Stavropoulos SW, Charagundla SR, Shlansky-Goldberg RD,
Freiman DB, Chittams J, Pyeritz RE, Trerotola SO. Digital subtraction pulmonary
arteriography versus multidetector CT in the detection of pulmonary arterioven-
ous malformations. J Vasc Interv Radiol 2008;19:1582–1588.
60. Peacock AJ, Vonk Noordegraaf A. Cardiac magnetic resonance imaging in pul-
monary arterial hypertension. Eur Respir Rev 2013;22:526–534.
61. Swift AJ, Rajaram S, Condliffe R, Capener D, Hurdman J, Elliot CA, Wild JM,
Kiely DG. Diagnostic accuracy of cardiovascular magnetic resonance imaging of
right ventricular morphology and function in the assessment of suspected pul-
monary hypertension results from the ASPIRE registry. J Cardiovasc Magn Reson
2012;14:40–50.
62. Swift AJ, Rajaram S, Hurdman J, Hill C, Davies C, Sproson TW, Morton AC,
Capener D, Elliot C, Condliffe R, Wild JM, Kiely DG. Noninvasive estimation of
PA pressure, flow, and resistance with CMR imaging: derivation and prospective
validation study from the ASPIRE registry. JACC Cardiovasc Imaging 2013;6:
1036–1047.
63. Ley S, Kauczor HU, Heussel CP, Kramm T, Mayer E, Thelen M, Kreitner KF. Value
of contrast-enhanced MR angiography and helical CT angiography in chronic
thromboembolic pulmonary hypertension. Eur Radiol 2003;13:2365–2371.
64. van Wolferen SA, Marcus JT, Boonstra A, Marques KMJ, Bronzwaer JGF,
Spreeuwenberg MD, Postmus PE, Vonk-Noordegraaf A. Prognostic value of right
ventricular mass, volume, and function in idiopathic pulmonary arterial hyperten-
sion. Eur Heart J 2007;28:1250–1257.
65. Peacock AJ, Crawley S, McLure L, Blyth K, Vizza CD, Poscia R, Francone M,
Iacucci I, Olschewski H, Kovacs G, VonkNoordegraaf A, Marcus JT, van de
Veerdonk MC, Oosterveer FPT. Changes in right ventricular function measured
by cardiac magnetic resonance imaging in patients receiving pulmonary arterial
hypertension–targeted therapy: the EURO-MR Study. Circ Cardiovasc Imaging
2014;7:107–114.
66. van de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ,
Boonstra A, Marques KM, Westerhof N, Vonk-Noordegraaf A. Progressive right
ventricular dysfunction in patients with pulmonary arterial hypertension respond-
ing to therapy. J Am Coll Cardiol 2011;58:2511–2519.
67. Albrecht T, Blomley MJ, Cosgrove DO, Taylor-Robinson SD, Jayaram V,
Eckersley R, Urbank A, Butler-Barnes J, Patel N. Non-invasive diagnosis of hepatic
cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999;353:
1579–1583.
68. Naeije R. Hepatopulmonary syndrome and portopulmonary hypertension. Swiss
Med Wkly 2003;133:163–169.
69. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jaı¨s X, Marinelli A, Barst RJ,
Ghofrani HA, Jing ZC, Opitz C, Seyfarth HJ, Halank M, McLaughlin V, Oudiz RJ,
Ewert R, Wilkens H, Kluge S, Bremer HC, Baroke E, Rubin LJ. Complications of
right heart catheterization procedures in patients with pulmonary hypertension
in experienced centers. J Am Coll Cardiol 2006;48:2546–2552.
70. Kovacs G, Avian A, Pienn M, Naeije R, Olschewski H. Reading pulmonary vascular
pressure tracings. How to handle the problems of zero leveling and respiratory swings.
Am J Respir Crit Care Med 2014;190:252–257.
71. Hoeper MM, Maier R, Tongers J, Niedermeyer J, Hohlfeld JM, Hamm M, Fabel H.
Determination of cardiac output by the Fick method, thermodilution, and acetyl-
ene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med 1999;160:
535–541.
72. Frost AE, Farber HW, Barst RJ, Miller DP, Elliott CG, McGoon MD. Demographics
and outcomes of patients diagnosed with pulmonary hypertension with pulmon-
ary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry.
Chest 2013;143:185–195.
73. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW,
Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, Shavelle D, Jeffries B,
Yadav JS. Wireless pulmonary artery haemodynamic monitoring in chronic heart
failure: a randomised controlled trial. Lancet 2011;377:658–666.
74. Prasad A, Hastings JL, Shibata S, Popovic ZB, Arbab-Zadeh A, Bhella PS, Okazaki K,
Fu Q, Berk M, Palmer D, Greenberg NL, Garcia MJ, Thomas JD, Levine BD. Char-
acterization of static and dynamic left ventricular diastolic function in patients with
heart failure with a preserved ejection fraction. Circ Heart Fail 2010;3:617–626.
75. Fujimoto N, Borlaug BA, Lewis GD, Hastings JL, Shafer KM, Bhella PS,
Carrick-Ranson G, Levine BD. Hemodynamic responses to rapid saline loading:
the impact of age, sex, and heart failure. Circulation 2013;127:55–62.
76. Fox BD, Shimony A, Langleben D, Hirsch A, Rudski L, Schlesinger R, Eisenberg MJ,
Joyal D, Hudson M, Boutet K, Serban A, Masetto A, Baron M. High prevalence of
occult left heart disease in scleroderma-pulmonary hypertension. Eur Respir J
2013;42:1083–1091.
77. Robbins IM, Hemnes AR, Pugh ME, Brittain EL, Zhao DX, Piana RN, Fong PP,
Newman JH. High prevalence of occult pulmonary venous hypertension revealed
by fluid challenge in pulmonary hypertension. Circ Heart Fail 2014;7:116–122.
78. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemo-
dynamics enhance diagnosis of early heart failure with preserved ejection fraction.
Circ Heart Fail 2010;3:588–595.
79. Hager WD, Collins I, Tate JP, Azrin M, Foley R, Lakshminarayanan S, Rothfield NF.
Exercise during cardiac catheterization distinguishes between pulmonary and left
ventricular causes of dyspnea in systemic sclerosis patients. Clin Respir J 2013;7:
227–236.
80. Halpern SD, Taichman DB. Misclassification of pulmonary hypertension due to re-
liance on pulmonary capillary wedge pressure rather than left ventricular end-
diastolic pressure. Chest 2009;136:37–43.
81. Naeije R, Vachiery JL, Yerly P, Vanderpool R. The transpulmonary pressure gradi-
ent for the diagnosis of pulmonary vascular disease. Eur Respir J 2013;41:217–223.
82. Provencher S, Herve P, Sitbon O, Humbert M, Simonneau G, Chemla D. Changes
in exercise haemodynamics during treatment in pulmonary arterial hypertension.
Eur Respir J 2008;32:393–398.
83. Tedford RJ, Beaty CA, Mathai SC, Kolb TM, Damico R, Hassoun PM, Leary PJ,
Kass DA, Shah AS. Prognostic value of the pre-transplant diastolic pulmonary ar-
tery pressure-to-pulmonary capillary wedge pressure gradient in cardiac trans-
plant recipients with pulmonary hypertension. J Heart Lung Transplant 2014;33:
289–297.
84. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers
on survival in primary pulmonary hypertension [see comments]. N Engl J Med
1992;327:76–81.
85. Sitbon O, Humbert M, Jaı¨s X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F,
Herve P, Simonneau G. Long-term response to calcium channel blockers in idio-
pathic pulmonary arterial hypertension. Circulation 2005;111:3105–3111.
86. Barst R, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski A, Gaine S.
Diagnosis and differential assessment of pulmonary arterial hypertension. J Am
Coll Cardiol 2004;43(Suppl 1):S40–S47.
87. Morgan JM, McCormack DG, Griffiths MJ, Morgan CJ, Barnes PJ, Evans TW.
Adenosine as a vasodilator in primary pulmonary hypertension [see comments].
Circulation 1991;84:1145–1149.
88. Nootens M, Schrader B, Kaufmann E, Vestal R, Long W, Rich S. Comparative acute
effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest
1995;107:54–57.
89. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM,
Niedermeyer J, Fabel H, Seeger W. A comparison of the acute hemodynamic ef-
fects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hyper-
tension. J Am Coll Cardiol 2000;35:176–182.
90. Opitz CF, Wensel R, Bettmann M, Schaffarczyk R, Linscheid M, Hetzer R, Ewert R.
Assessment of the vasodilator response in primary pulmonary hypertension. Com-
paring prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J
2003;24:356–365.
91. Kim NH, Delcroix M, Jenkins DP, Channick R, Dartevelle P, Jansa P, Lang I,
Madani MM, Ogino H, Pengo V, Mayer E. Chronic thromboembolic pulmonary
hypertension. J Am Coll Cardiol 2013;62:D92–D99.
92. Montani D, Price LC, Dorfmuller P, Achouh L, Jaı¨s X, Yaici A, Sitbon O, Musset D,
Simonneau G, Humbert M. Pulmonary veno-occlusive disease. Eur Respir J 2009;
33:189–200.
ESC/ERS Guidelines 115
Downloaded from https://academic.oup.com/eurheartj/article-abstract/37/1/67/2887599
by Olivier Borsus user
on 26 January 2018
93. He J, Fang W, Lv B, He JG, Xiong CM, Liu ZH, He ZX. Diagnosis of chronic
thromboembolic pulmonary hypertension: comparison of ventilation/perfusion
scanning and multidetector computed tomography pulmonary angiography
with pulmonary angiography. Nucl Med Commun 2012;33:459–463.
94. Cottin V, Le Pavec J, Prevot G, Mal H, Humbert M, Simonneau G, Cordier JF.
Pulmonary hypertension in patients with combined pulmonary fibrosis and
emphysema syndrome. Eur Respir J 2010;35:105–111.
95. Taichman DB, McGoon MD, Harhay MO, Archer-Chicko C, Sager JS,
Murugappan M, Chakinali MM, Palevsky HI, Gallop R. Wide variation in clinicians’
assessment of New York Heart Association/World Health Organization func-
tional class in patients with pulmonary arterial hypertension. Mayo Clin Proc
2009;84:586–592.
96. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, Rainisio M,
Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmon-
ary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:
780–788.
97. Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, Westerkamp V, Welte T,
Hoeper MM. The prognostic impact of follow-up assessments in patients with
idiopathic pulmonary arterial hypertension. Eur Respir J 2012;39:589–596.
98. Barst RJ, Chung L, Zamanian RT, Turner M, McGoon MD. Functional class im-
provement and 3-year survival outcomes in patients with pulmonary arterial
hypertension in the REVEAL Registry. Chest 2013;144:160–168.
99. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS,
Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD. Predicting sur-
vival in pulmonary arterial hypertension: insights from the Registry to Evaluate
Early and Long-Term Pulmonary Arterial Hypertension Disease Management
(REVEAL). Circulation 2010;122:164–172.
100. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galie` N, Rainisio M,
Simonneau G, Rubin LJ. Survival with first-line bosentan in patients with primary
pulmonary hypertension. Eur Respir J 2005;25:244–249.
101. Sachdev A, Villarraga HR, Frantz RP, McGoon MD, Hsiao JF, Maalouf JF,
Ammash NM, McCully RB, Miller FA, Pellikka PA, Oh JK, Kane GC. Right ventricu-
lar strain for prediction of survival in patients with pulmonary arterial hyperten-
sion. Chest 2011;139:1299–1309.
102. Raymond RJ, Hinderliter AL, Willis PW, Ralph D, Caldwell EJ, Williams W,
Ettinger NA, Hill NS, Summer WR, de Boisblanc B, Schwartz T, Koch G,
Clayton LM, Jobsis MM, Crow JW, Long W. Echocardiographic predictors of ad-
verse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002;39:
1214–1219.
103. Bustamante-Labarta M, Perrone S, De La Fuente RL, Stutzbach P, De La Hoz RP,
Torino A, Favaloro R. Right atrial size and tricuspid regurgitation severity predict
mortality or transplantation in primary pulmonary hypertension. J Am Soc Echocar-
diogr 2002;15:1160–1164.
104. Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA,
Chamera E, Corretti MC, Champion HC, Abraham TP, Girgis RE, Hassoun PM.
Tricuspid annular displacement predicts survival in pulmonary hypertension.
Am J Respir Crit Care Med 2006;174:1034–1041.
105. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in
pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equa-
tion. Eur Respir J 2010;35:1079–1087.
106. Wensel R, Opitz CF, Anker SD, Winkler J, Hoffken G, Kleber FX, Sharma R,
Hummel M, Hetzer R, Ewert R. Assessment of survival in patients with primary
pulmonary hypertension: importance of cardiopulmonary exercise testing. Circu-
lation 2002;106:319–324.
107. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension:
the impact of epoprostenol therapy. Circulation 2002;106:1477–1482.
108. Fine NM, Chen L, Bastiansen PM, Frantz RP, Pellikka PA, Oh JK, Kane GC. Out-
come prediction by quantitative right ventricular function assessment in 575 sub-
jects evaluated for pulmonary hypertension. Circ Cardiovasc Imaging 2013;6:
711–721.
109. Shimada YJ, Shiota M, Siegel RJ, Shiota T. Accuracy of right ventricular volumes and
function determined by three-dimensional echocardiography in comparison with
magnetic resonance imaging: a meta-analysis study. J Am Soc Echocardiogr 2010;23:
943–953.
110. Smith BC, Dobson G, Dawson D, Charalampopoulos A, Grapsa J,
Nihoyannopoulos P. Three-dimensional speckle tracking of the right ventricle: to-
ward optimal quantification of right ventricular dysfunction in pulmonary hyper-
tension. J Am Coll Cardiol 2014;64:41–51.
111. Grunig E, Tiede H, Enyimayew EO, Ehlken N, Seyfarth HJ, Bossone E, D’Andrea A,
Naeije R, Olschewski H, Ulrich S, Nagel C, Halank M, Fischer C. Assessment and
prognostic relevance of right ventricular contractile reserve in patients with se-
vere pulmonary hypertension. Circulation 2013;128:2005–2015.
112. Swift AJ, Rajaram S, Marshall H, Condliffe R, Capener D, Hill C, Davies C,
Hurdman J, Elliot CA, Wild JM, Kiely DG. Black blood MRI has diagnostic and
prognostic value in the assessment of patients with pulmonary hypertension.
Eur Radiol 2012;22:695–702.
113. Swift AJ, Rajaram S, Campbell MJ, Hurdman J, Thomas S, Capener D, Elliot C,
Condliffe R, Wild JM, Kiely DG. Prognostic value of cardiovascular magnetic res-
onance imaging measurements corrected for age and sex in idiopathic pulmonary
arterial hypertension. Circ Cardiovasc Imaging 2014;7:100–106.
114. Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galie` N, Humbert M,
Rainisio M, Rubin LJ, Simonneau G. Survival in patients with class III idiopathic pul-
monary arterial hypertension treated with first line oral bosentan compared with
an historical cohort of patients started on intravenous epoprostenol. Thorax 2005;
60:1025–1030.
115. Rich JD, Archer SL, Rich S. Noninvasive cardiac output measurements in patients
with pulmonary hypertension. Eur Respir J 2013;42:125–133.
116. Savarese G, Paolillo S, Costanzo P, D’Amore C, Cecere M, Losco T, Musella F,
Gargiulo P, Marciano C, Perrone-Filardi P. Do changes of 6-minute walk distance
predict clinical events in patients with pulmonary arterial hypertension?: a
meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012;60:1192–1201.
117. Gabler NB, French B, Strom BL, Palevsky HI, Taichman DB, Kawut SM,
Halpern SD. Validation of 6-minute walk distance as a surrogate end point in pul-
monary arterial hypertension trials. Circulation 2012;126:349–356.
118. Fritz JS, Blair C, Oudiz RJ, Dufton C, Olschewski H, Despain D, Gillies H,
Kawut SM. Baseline and follow-up 6-min walk distance and brain natriuretic pep-
tide predict 2-year mortality in pulmonary arterial hypertension. Chest 2013;143:
315–323.
119. Paciocco G, Martinez F, Bossone E, Pielsticker E, Gillespie B, Rubenfire M. Oxygen
desaturation on the six-minute walk test and mortality in untreated primary pul-
monary hypertension. Eur Respir J 2001;17:647–652.
120. Provencher S, Chemla D, Herve P, Sitbon O, Humbert M, Simonneau G. Heart
rate responses during the 6-minute walk test in pulmonary arterial hypertension.
Eur Respir J 2006;27:114–120.
121. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Exercise pathophysiology in patients
with primary pulmonary hypertension. Circulation 2001;104:429–435.
122. Wensel R, Francis DP, Meyer FJ, Opitz CF, Bruch L, Halank M, Winkler J,
Seyfarth HJ, Glaser S, Blumberg F, Obst A, Dandel M, Hetzer R, Ewert R. Incre-
mental prognostic value of cardiopulmonary exercise testing and resting haemo-
dynamics in pulmonary arterial hypertension. Int J Cardiol 2013;167:1193–1198.
123. Blumberg FC, Arzt M, Lange T, Schroll S, Pfeifer M, Wensel R. Impact of right ven-
tricular reserve on exercise capacity and survival in patients with pulmonary
hypertension. Eur J Heart Fail 2013;15:771–775.
124. Diller GP, Dimopoulos K, Okonko D, Li W, Babu-Narayan SV, Broberg CS,
Johansson B, Bouzas B, Mullen MJ, Poole-Wilson PA, Francis DP, Gatzoulis MA.
Exercise intolerance in adult congenital heart disease: comparative severity, cor-
relates, and prognostic implication. Circulation 2005;112:828–835.
125. Arena R, Lavie CJ, Milani RV, Myers J, Guazzi M. Cardiopulmonary exercise testing
in patients with pulmonary arterial hypertension: an evidence-based review.
J Heart Lung Transplant 2010;29:159–173.
126. Pullamsetti S, Kiss L, Ghofrani HA, Voswinckel R, Haredza P, Klepetko W,
Aigner C, Fink L, Muyal JP, Weissmann N, Grimminger F, Seeger W,
Schermuly RT. Increased levels and reduced catabolism of asymmetric and sym-
metric dimethylarginines in pulmonary hypertension. FASEB J 2005;19:
1175–1177.
127. Kielstein JT, Bode-Boger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D,
Hoeper MM. Asymmetrical dimethylarginine in idiopathic pulmonary arterial
hypertension. Arterioscler Thromb Vasc Biol 2005;25:1414–1418.
128. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC,
Hoeper MM, Haller H, Fliser D. Cardiovascular effects of systemic nitric oxide
synthase inhibition with asymmetrical dimethylarginine in humans. Circulation
2004;109:172–177.
129. Kawut SM, Horn EM, Berekashvili KK, Widlitz AC, Rosenzweig EB, Barst RJ. von
Willebrand factor independently predicts long-term survival in patients with pul-
monary arterial hypertension. Chest 2005;128:2355–2362.
130. Kumpers P, Nickel N, Lukasz A, Golpon H, Westerkamp V, Olsson KM, Jonigk D,
Maegel L, Bockmeyer CL, David S, Hoeper MM. Circulating angiopoietins in idio-
pathic pulmonary arterial hypertension. Eur Heart J 2010;31:2291–2300.
131. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP,
Hoeffken G. Big endothelin-1 and endothelin-1 plasma levels are correlated
with the severity of primary pulmonary hypertension. Chest 2001;120:
1562–1569.
132. Quarck R, Nawrot T, Meyns B, Delcroix M. C-reactive protein: a new predictor of
adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 2009;53:
1211–1218.
133. Balabanian K, Foussat A, Dorfmuller P, Durand-Gasselin I, Capel F,
Bouchet-Delbos L, Portier A, Marfaing-Koka A, Krzysiek R, Rimaniol AC,
Simonneau G, Emilie D, Humbert M. CX(3)C chemokine fractalkine in pulmonary
arterial hypertension. Am J Respir Crit Care Med 2002;165:1419–1425.
ESC/ERS Guidelines116
Downloaded from https://academic.oup.com/eurheartj/article-abstract/37/1/67/2887599
by Olivier Borsus user
on 26 January 2018
134. Dorfmuller P, Zarka V, Durand-Gasselin I, Monti G, Balabanian K, Garcia G,
Capron F, Coulomb-Lhermine A, Marfaing-Koka A, Simonneau G, Emilie D,
Humbert M. Chemokine RANTES in severe pulmonary arterial hypertension.
Am J Respir Crit Care Med 2002;165:534–539.
135. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P,
Galanaud P, Simonneau G, Emilie D. Increased interleukin-1 and interleukin-6 ser-
um concentrations in severe primary pulmonary hypertension. Am J Respir Crit
Care Med 1995;151:1628–1631.
136. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M,
Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K. Plasma brain natri-
uretic peptide as a prognostic indicator in patients with primary pulmonary hyper-
tension. Circulation 2000;102:865–870.
137. Leuchte HH, El NM, Tuerpe JC, Hartmann B, Baumgartner RA, Vogeser M,
Muehling O, Behr J. N-terminal pro-brain natriuretic peptide and renal insuffi-
ciency as predictors of mortality in pulmonary hypertension. Chest 2007;131:
402–409.
138. Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P,
Szturmowicz M. Serum N-terminal brain natriuretic peptide as a prognostic par-
ameter in patients with pulmonary hypertension. Chest 2006;129:1313–1321.
139. Torbicki A, Kurzyna M, Kuca P, Fijalkowska A, Sikora J, Florczyk M, Pruszczyk P,
Burakowski J, Wawrzynska L. Detectable serum cardiac troponin T as a marker
of poor prognosis among patients with chronic precapillary pulmonary hyperten-
sion. Circulation 2003;108:844–848.
140. Nickel N, Kempf T, Tapken H, Tongers J, Laenger F, Lehmann U, Golpon H,
Olsson K, Wilkins MR, Gibbs JS, Hoeper MM, Wollert KC. Growth differentiation
factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med
2008;178:534–541.
141. Nagaya N, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Nakanishi N, Yamagishi M,
Kunieda T, Miyatake K. Serum uric acid levels correlate with the severity and the
mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999;160:
487–492.
142. Lorenzen JM, Nickel N, Kramer R, Golpon H, Westerkamp V, Olsson KM,
Haller H, Hoeper MM. Osteopontin in patients with idiopathic pulmonary hyper-
tension. Chest 2011;139:1010–1017.
143. Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. Eur
Respir J 2008;32:503–512.
144. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J.
Goal-oriented treatment and combination therapy for pulmonary arterial hyper-
tension. Eur Respir J 2005;26:858–863.
145. McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S,
Palazzini M, Park MH, Tapson VF, Sitbon O. Treatment goals of pulmonary hyper-
tension. J Am Coll Cardiol 2013;62(Suppl):D73–D81.
146. Galie` N, Manes A, Negro L, Palazzini M, Bacchi Reggiani ML, Branzi A. A
meta-analysis of randomized controlled trials in pulmonary arterial hypertension.
Eur Heart J 2009;30:394–403.
147. Bai Y, Sun L, Hu S, Wei Y. Combination therapy in pulmonary arterial hyperten-
sion: a meta-analysis. Cardiology 2011;120:157–165.
148. Galie` N, Simonneau G. The Fifth World Symposium on Pulmonary Arterial
Hypertension. J Am Coll Cardiol 2013;62(Suppl):D1–D3.
149. Galie` N, Corris P, Frost A, Girgis R, Granton J, Jing ZC, Klepetko W, McGoon M,
McLaughlin VV, Preston RJ, Rubin LJ, Sandoval J, Seeger W, Keogh AM. Updated
treatment algorithm of pulmonary hypertension. J Am Coll Cardiol 2013;
62(Suppl):D60–D72.
150. Lo¨we B, Gra¨fe K, Ufer C, Kroenke K, Gru¨nig E, Herzog W, Borst MM. Anxiety and
depression in patients with pulmonary hypertension. Psychosom Med 2004;66:
831–836.
151. Galie` N, Hoeper M, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M,
Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Klepetko W, Joendeau G,
Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines on diagnosis
and treatment of pulmonary hypertension: the Task Force on Diagnosis and
Treatment of Pulmonary Hypertension of the European Society of Cardiology
and of the European Respiratory Society. Eur Heart J 2009;30:2493–2537.
152. Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, Meyer FJ,
Karger G, Buss J, Juenger J, Holzapfel N, Opitz C, Winkler J, Herth FF, Wilkens H,
Katus HA, Olschewski H, Grunig E. Exercise and respiratory training improve ex-
ercise capacity and quality of life in patients with severe chronic pulmonary hyper-
tension. Circulation 2006;114:1482–1489.
153. de Man FS, Handoko ML, Groepenhoff H, van ’t Hul AJ, Abbink J, Koppers RJH,
Grotjohan HP, Twisk JWR, Bogaard HJ, Boonstra A, Postmus PE, Westerhof N,
Van Der Laarse WJ, Vonk-Noordegraaf A. Effects of exercise training in patients
with idiopathic pulmonary arterial hypertension. Eur Respir J 2009;34:669–675.
154. Grunig E, Ehlken N, Ghofrani A, Staehler G, Meyer FJ, Juenger J, Opitz CF, Klose H,
Wilkens H, Rosenkranz S, Olschewski H, Halank M. Effect of exercise and respira-
tory training on clinical progression and survival in patients with severe chronic
pulmonary hypertension. Respiration 2011;81:394–401.
155. Grunig E, Maier F, Ehlken N, Fischer C, Lichtblau M, Blank N, Fiehn C, Stockl F,
Prange F, Staehler G, Reichenberger F, Tiede H, Halank M, Seyfarth HJ,
Wagner S, Nagel C. Exercise training in pulmonary arterial hypertension asso-
ciated with connective tissue diseases. Arthritis Res Ther 2012;14:R148.
156. Grunig E, Lichtblau M, Ehlken N, Ghofrani HA, Reichenberger F, Staehler G,
Halank M, Fischer C, Seyfarth HJ, Klose H, Meyer A, Sorichter S, Wilkens H,
Rosenkranz S, Opitz C, Leuchte H, Karger G, Speich R, Nagel C. Safety and effi-
cacy of exercise training in various forms of pulmonary hypertension. Eur Respir J
2012;40:84–92.
157. Becker-Grunig T, Klose H, Ehlken N, Lichtblau M, Nagel C, Fischer C, Gorenflo M,
Tiede H, Schranz D, Hager A, Kaemmerer H, Miera O, Ulrich S, Speich R, Uiker S,
Grunig E. Efficacy of exercise training in pulmonary arterial hypertension asso-
ciated with congenital heart disease. Int J Cardiol 2013;168:375–381.
158. Weinstein AA, Chin LMK, Keyser RE, Kennedy M, Nathan SD,
Woolstenhulme JG, Connors G, Chan L. Effect of aerobic exercise training on fa-
tigue and physical activity in patients with pulmonary arterial hypertension. Respir
Med 2013;107:778–784.
159. Chan L, Chin LM, Kennedy M, Woolstenhulme JG, Nathan SD, Weinstein AA,
Connors G, Weir NA, Drinkard B, Lamberti J, Keyser RE. Benefits of intensive
treadmill exercise training on cardiorespiratory function and quality of life in pa-
tients with pulmonary hypertension. Chest 2013;143:333–343.
160. Jaı¨s X, Olsson KM, Barbera JA, Blanco I, Torbicki A, Peacock A, Vizza CD,
Macdonald P, Humbert M, Hoeper MM. Pregnancy outcomes in pulmonary arter-
ial hypertension in the modern management era. Eur Respir J 2012;40:881–885.
161. Duarte AG, Thomas S, Safdar Z, Torres F, Pacheco LD, Feldman J, deBoisblanc B.
Management of pulmonary arterial hypertension during pregnancy: a retrospect-
ive, multicenter experience. Chest 2013;143:1330–1336.
162. Thorne S, Nelson-Piercy C, MacGregor AJ, Gibbs S, Crowhurst J, Panay N,
Rosenthal E, Walker F, Williams D, de Swiet M, Guillebaud J. Pregnancy and
contraception in heart disease and pulmonary arterial hypertension. J Fam Plann
Reprod Health Care 2006;32:75–81.
163. Bendayan D, Hod M, Oron G, Sagie A, Eidelman L, Shitrit D, Kramer MR. Preg-
nancy outcome in patients with pulmonary arterial hypertension receiving pros-
tacyclin therapy. Obstet Gynecol 2005;106:1206–1210.
164. Bonnin M, Mercier FJ, Sitbon O, Jaı¨s X, Humbert M, Audibert F, Frydman R,
Simonneau G, Benhamou D. Severe pulmonary hypertension during pregnancy:
mode of delivery and anesthetic management of 15 consecutive cases. Anesthesi-
ology 2005;102:1133–1137.
165. Meyer S, McLaughlin VV, Seyfarth HJ, Bull TM, Vizza CD, Gomberg-Maitland M,
Preston IR, Barbera` JA, Hassoun PM, Halank M, Jaı¨s X, Nickel N, Hoeper MM,
Humbert M. Outcomes of noncardiac, nonobstetric surgery in patients with
PAH: an international prospective survey. Eur Respir J 2013;41:1302–1307.
166. Olofsson C, Bremme K, Forssell G, Ohqvist G. Cesarean section under epidural
ropivacaine 0.75% in a parturient with severe pulmonary hypertension. Acta
Anaesthesiol Scand 2001;45:258–260.
167. Raines DE, Liberthson RR, Murray JR. Anesthetic management and outcome fol-
lowing noncardiac surgery in nonparturients with Eisenmenger’s physiology. J Clin
Anesth 1996;8:341–347.
168. Guillevin L, Armstrong I, Aldrighetti R, Howard LS, Ryftenius H, Fischer A,
Lombardi S, Studer S, Ferrari P. Understanding the impact of pulmonary arterial
hypertension on patients’ and carers’ lives. Eur Respir Rev 2013;22:535–542.
169. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A. Long-term
oxygen therapy can reverse the progression of pulmonary hypertension in pa-
tients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985;131:
493–498.
170. Frydman N, Steffann J, Girerd B, Frydman R, Munnich A, Simonneau G,
Humbert M. Pre-implantation genetic diagnosis in pulmonary arterial hyperten-
sion due to BMPR2 mutation. Eur Respir J 2012;39:1534–1535.
171. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pul-
monary hypertension: natural history and the importance of thrombosis. Circula-
tion 1984;70:580–587.
172. Herve P, Humbert M, Sitbon O, Parent F, Nunes H, Legal C, Garcia G,
Simonneau G. Pathobiology of pulmonary hypertension: the role of platelets
and thrombosis. Clin Chest Med 2001;22:451–458.
173. Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with se-
vere primary pulmonary hypertension. Eur Respir J 1998;12:1446–1449.
174. Huber K, Beckmann R, Frank H, Kneussl M, Mlczoch J, Binder BR. Fibrinogen, t-PA,
and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit
Care Med 1994;150:929–933.
175. Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, Gru¨nig E,
Staehler G, Rosenkranz S, Halank M, Held M, Lange TJ, Behr J, Klose H,
Claussen M, Ewert R, Opitz CF, Vizza CD, Scelsi L, Vonk-Noordegraaf A,
Kaemmerer H, Gibbs JS, Coghlan G, Pepke-Zaba J, Schulz U, Gorenflo M,
Pittrow D, Hoeper MM. Anticoagulation and survival in pulmonary arterial hyper-
tension: results from the Comparative, Prospective Registry of Newly Initiated
ESC/ERS Guidelines 117
Downloaded from https://academic.oup.com/eurheartj/article-abstract/37/1/67/2887599
by Olivier Borsus user
on 26 January 2018
Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014;129:
57–65.
176. Galie` N, Delcroix M, Ghofrani A, Jansa P, Minai OA, Perchenet L, Rubin LJ,
Sastry BKS, Torbicki A, Simonneau G. Anticoagulant therapy does not influence
long-term outcomes in patients with pulmonary arterial hypertension (PAH): in-
sights from the randomised controlled SERAPHIN trial of macitentan. Eur Heart J
2014;35:10.
177. Preston RJ, Roberts KE, Miller DP, Hill NS, Farber HW. Effect of warfarin treat-
ment on survival of patients with pulmonary arterial hypertension (PAH) in the
Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL).
Am J Respir Crit Care Med 2014;189:A2464.
178. Cohn JN. Optimal diuretic therapy for heart failure. Am J Med 2001;111:577.
179. Sandoval J, Aguirre JS, Pulido T, Martinez-Guerra ML, Santos E, Alvarado P,
Rosas M, Bautista E. Nocturnal oxygen therapy in patients with the Eisenmenger
syndrome. Am J Respir Crit Care Med 2001;164:1682–1687.
180. Rich S, Seidlitz M, Dodin E, Osimani D, Judd D, Genthner D, McLaughlin V,
Francis G. The short-term effects of digoxin in patients with right ventricular dys-
function from pulmonary hypertension. Chest 1998;114:787–792.
181. Ruiter G, Lankhorst S, Boonstra A, Postmus PE, Zweegman S, Westerhof N, Van
Der Laarse WJ, Vonk-Noordegraaf A. Iron deficiency is common in idiopathic pul-
monary arterial hypertension. Eur Respir J 2011;37:1386–1391.
182. Ruiter G, Lanser IJ, de Man FS, Van Der Laarse WJ, Wharton J, Wilkins MR,
Howard LS, Vonk-Noordegraaf A, Voskuyl AE. Iron deficiency in systemic scler-
osis patients with and without pulmonary hypertension. Rheumatology (Oxford)
2014;53:285–292.
183. Broberg CS, Bax BE, Okonko DO, Rampling MW, Bayne S, Harries C, Davidson SJ,
Uebing A, Khan AA, Thein S, Gibbs JS, Burman J, Gatzoulis MA. Blood viscosity
and its relationship to iron deficiency, symptoms, and exercise capacity in adults
with cyanotic congenital heart disease. J Am Coll Cardiol 2006;48:356–365.
184. Rhodes CJ, Howard LS, Busbridge M, Ashby D, Kondili E, Gibbs JS, Wharton J,
Wilkins MR. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial
hypertension clinical prevalence, outcomes, and mechanistic insights. J Am Coll
Cardiol 2011;58:300–309.
185. Van De Bruaene A, Delcroix M, Pasquet A, De BJ, De PM, Naeije R, Vachiery JL,
Paelinck B, Morissens M, Budts W. Iron deficiency is associated with adverse out-
come in Eisenmenger patients. Eur Heart J 2011;32:2790–2799.
186. Viethen T, Gerhardt F, Dumitrescu D, Knoop-Busch S, ten Freyhaus H,
Rudolph TK, Baldus S, Rosenkranz S. Ferric carboxymaltose improves exercise
capacity and quality of life in patients with pulmonary arterial hypertension and
iron deficiency: a pilot study. Int J Cardiol 2014;175:233–239.
187. Galie´ N, Ussia G, Passarelli P, Parlangeli R, Branzi A, Magnani B. Role of pharma-
cologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol
1995;75:55A–62A.
188. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, Black CM,
Coghlan JG. Prevalence and outcome in systemic sclerosis associated pulmonary
arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:
1088–1093.
189. Montani D, Savale L, Natali D, Jaı¨s X, Herve P, Garcia G, Humbert M,
Simonneau G, Sitbon O. Long-term response to calcium-channel blockers in non-
idiopathic pulmonary arterial hypertension. Eur Heart J 2010;31:1898–1907.
190. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S,
Masaki T, Duguid WP, Stewart DJ. Expression of endothelin-1 in the lungs of pa-
tients with pulmonary hypertension. N Engl J Med 1993;328:1732–1739.
191. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in
pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;
114:464–469.
192. Galie´ N, Manes A, Branzi A. The endothelin system in pulmonary arterial hyper-
tension. Cardiovasc Res 2004;61:227–237.
193. Galie´ N, Badesch BD, Oudiz R, Simonneau G, McGoon M, Keogh A, Frost A,
Zwicke D, Naeije R, Shapiro RS, Olschewski H, Rubin L. Ambrisentan therapy
for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529–535.
194. Galie´ N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB,
McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL,
Rubin LJ. Ambrisentan for the treatment of pulmonary arterial hypertension. Re-
sults of the ambrisentan in pulmonary arterial hypertension, randomized, double-
blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation
2008;117:3010–3019.
195. McGoon M, Frost A, Oudiz R, Badesch BD, Galie` N, Olschewski H,
McLaughlin VV, Gerber MJ, Dufton C, Despain DJ, Rubin LJ. Ambrisentan therapy
in patients with pulmonary arterial hypertension who discontinued bosentan or
sitaxsentan due to liver function test abnormalities. Chest 2009;135:122–129.
196. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF,
Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ. Effects of the dual endothelin-
receptor antagonist bosentan in patients with pulmonary hypertension: a rando-
mised placebo-controlled study. Lancet 2001;358:1119–1123.
197. Rubin LJ, Badesch DB, Barst RJ, Galie` N, Black CM, Keogh A, Pulido T, Frost A,
Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary
arterial hypertension. N Engl J Med 2002;346:896–903.
198. Humbert M, Barst RJ, Robbins IM, Channick RN, Galie` N, Boonstra A, Rubin LJ,
Horn EM, Manes A, Simonneau G. Combination of bosentan with epoprostenol
in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353–359.
199. Galie` N, Rubin LJ, Hoeper M, Jansa P, Al-Hiti H, Meyer GMB, Chiossi E,
Kusic-Pajic A, Simonneau G. Treatment of patients with mildly symptomatic pul-
monary arterial hypertension with bosentan (EARLY study): a double-blind, ran-
domised controlled trial. Lancet 2008;371:2093–2100.
200. Galie` N, Beghetti M, Gatzoulis MA, Granton J, Berger RMF, Lauer A, Chiossi E,
Landzberg M. Bosentan therapy in patients with Eisenmenger syndrome: a multi-
center, double-blind, randomized, placebo-controlled study. Circulation 2006;114:
48–54.
201. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie` N, Ghofrani HA, Jansa P,
Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BKS,
Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G. Macitentan and
morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;
369:809–818.
202. Wharton J, Strange JW, Moller GMO, Growcott EJ, Ren X, Franklyn AP,
Phillips SC, Wilkins MR. Antiproliferative effects of phosphodiesterase type 5 in-
hibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005;172:
105–113.
203. Tantini B, Manes A, Fiumana E, Pignatti C, Guarnieri G, Zannoli R, Branzi A,
Galie` N. Antiproliferative effect of sildenafil on human pulmonary artery smooth
muscle cells. Basic Res Cardiol 2005;100:131–138.
204. Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadas B,
Schermuly RT, Weissmann N, Seeger W, Grimminger F. Differences in hemo-
dynamic and oxygenation responses to three different phosphodiesterase-5 inhibi-
tors in patients with pulmonary arterial hypertension: a randomized prospective
study. J Am Coll Cardiol 2004;44:1488–1496.
205. Galie` N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T,
Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G, the Silde-
nafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil cit-
rate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:
2148–2157.
206. Sastry BKS, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in pri-
mary pulmonary hypertension: a randomized, placebo-controlled, double-blind,
crossover study. J Am Coll Cardiol 2004;43:1149–1153.
207. Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Søndergaard L. Combination ther-
apy with bosentan and sildenafil in Eisenmenger syndrome: a randomized,
placebo-controlled, double-blinded trial. Eur Heart J 2010;31:1124–1131.
208. Singh T, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebo-
controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil
therapy in severe pulmonary artery hypertension. Am Heart J 2006;151:851.e1–
851.e5.
209. Simonneau G, Rubin L, Galie` N, Barst RJ, Fleming T, Frost A, Engel PJ, Kramer MR,
Burgess G, Collings L, Cossons N, Sitbon O, Badesch BD. Addition of sildenafil to
long-term intravenous epoprostenol therapy in patients with pulmonary arterial
hypertension. Ann Intern Med 2008;149:521–530.
210. Vachiery JL, Huez S, Gillies H, Layton G, Hayashi N, Gao X, Naeije R. Safety, tol-
erability and pharmacokinetics of an intravenous bolus of sildenafil in patients with
pulmonary arterial hypertension. Br J Clin Pharmacol 2011;71:289–292.
211. Galie` N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S,
White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ. Tadalafil therapy for pul-
monary arterial hypertension. Circulation 2009;119:2894–2903.
212. Jing ZC, Yu ZX, Shen JY, Wu BX, Xu KF, Zhu XY, Pan L, Zhang ZL, Liu XQ,
Zhang YS, Jiang X, Galie` N. Vardenafil in pulmonary arterial hypertension: a ran-
domized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2011;
183:1723–1729.
213. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the
lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214–221.
214. Ghofrani HA, Galie` N, Grimminger F, Grunig E, Humbert M, Jing ZC, Keogh AM,
Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ. Riociguat for the treat-
ment of pulmonary arterial hypertension. N Engl J Med 2013;369:330–340.
215. Galie` N, Muller K, Scalise AV, Grunig E. PATENT PLUS: a blinded, randomised and
extension study of riociguat plus sildenafil in PAH. Eur Respir J 2015;45:
1314–1322.
216. Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prosta-
cyclin receptors elicits opposing effects on vascular smooth muscle cell growth
and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 1995;48:
890–896.
217. Galie` N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J
Respir Med 2003;2:123–137.
ESC/ERS Guidelines118
Downloaded from https://academic.oup.com/eurheartj/article-abstract/37/1/67/2887599
by Olivier Borsus user
on 26 January 2018
218. Galie` N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, Sitbon O,
Torbicki A, Delcroix M, Naeije R, Hoeper M, Chaouat A, Morand S, Besse B,
Simonneau G. Effects of beraprost sodium, an oral prostacyclin analogue, in pa-
tients with pulmonary arterial hypertension: a randomised, double-blind placebo-
controlled trial. J Am Coll Cardiol 2002;39:1496–1502.
219. Barst RJ, McGoon M, McLaughlin VV, Tapson V, Rich S, Rubin L, Wasserman K,
Oudiz R, Shapiro S, Robbins I, Channick R, Badesch BD, Rayburn BK,
Flinchbaugh R, Sigman J, Arneson K, Jeffs R. Beraprost therapy for pulmonary ar-
terial hypertension. J Am Coll Cardiol 2003;41:2119–2125.
220. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, Diehl JH, Crow J,
Long W. Treatment of primary pulmonary hypertension with continuous intra-
venous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern
Med 1990;112:485–491.
221. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM,
Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller C,
Murali S, Uretsky BF, Clayton LM, Jo¨bsis MM, Blackburn SD, Shortino D,
Crow JW. A comparison of continuous intravenous epoprostenol (prostacyclin)
with conventional therapy for primary pulmonary hypertension [see comments].
N Engl J Med 1996;334:296–302.
222. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S,
Barst RJ, Barrett PS, Kral KM, Jobsis MM, Loyd JE, Murali S, Frost A, Girgis R,
Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ,
McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA Jr. Continuous
intravenous epoprostenol for pulmonary hypertension due to the scleroderma
spectrum of disease. A randomized, controlled trial [see comments]. Ann Intern
Med 2000;132:425–434.
223. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary
hypertension with associated congenital heart defects. Circulation 1999;99:
1858–1865.
224. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Im-
provement in pulmonary hemodynamics during intravenous epoprostenol (pros-
tacyclin): a study of 15 patients with moderate to severe portopulmonary
hypertension. Hepatology 1999;30:641–648.
225. Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA, Le Gall C,
Parent F, Garcia G, Herve P, Barst RJ, Simonneau G. Prognostic factors for survival
in human immunodeficiency virus-associated pulmonary arterial hypertension.
Am J Respir Crit Care Med 2003;167:1433–1439.
226. Cabrol S, Souza R, Jaı¨s X, Fadel E, Ali RHS, Humbert M, Dartevelle P,
Simonneau G, Sitbon O. Intravenous epoprostenol in inoperable chronic
thromboembolic pulmonary hypertension. J Heart Lung Transplant 2007;26:
357–362.
227. Doran AK, Ivy DD, Barst RJ, Hill N, Murali S, Benza RL. Guidelines for the preven-
tion of central venous catheter-related blood stream infections with prostanoid
therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl 2008;160:5–9.
228. Sitbon O, Delcroix M, Bergot E, Boonstra AB, Granton J, Langleben D, Subı´as PE,
Galie` N, Pfister T, Lemarie´ JC, Simonneau G. EPITOME-2: an open-label study as-
sessing the transition to a new formulation of intravenous epoprostenol in pa-
tients with pulmonary arterial hypertension. Am Heart J 2014;167:210–217.
229. Olschewski H, Simonneau G, Galie` N, Higenbottam T, Naeije R, Rubin LJ,
Nikkho S, Sitbon O, Speich R, Hoeper M, Behr J, Winkler J, Seeger W. Inhaled
iloprost in severe pulmonary hypertension. N Engl J Med 2002;347:322–329.
230. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN,
Badesch DB, Barst RJ, Hsu HH, Rubin LJ. Randomized study of adding inhaled ilo-
prost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care
Med 2006;174:1257–1263.
231. Hoeper M, Leuchte H, Halank M, Wilkens H, Meyer FJ, Seyfarth HJ, Wensel R,
Ripken F, Bremer H, Kluge S, Hoeffken G, Behr J. Combining inhaled iloprost
with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Re-
spir J 2006;4:691–694.
232. Higenbottam T, Butt AY, McMahon A, Westerbeck R, Sharples L. Long-term
intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pul-
monary hypertension. Heart 1998;80:151–155.
233. Simonneau G, Barst RJ, Galie` N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R,
Frost A, Blackburn SD, Crow JW, Rubin LJ. Continuous subcutaneous infusion of
treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hyperten-
sion. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med
2002;165:800–804.
234. Hiremath J, Thanikachalam S, Parikh K, Shanmugasundaram S, Bangera S,
Shapiro L, Pott GB, Vnencak-Jones CL, Arneson C, Wade M, White RJ. Exercise
improvement and plasma biomarker changes with intravenous treprostinil ther-
apy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung
Transplant 2010;29:137–149.
235. Tapson VF, Gomberg-Maitland M, McLaughlin VV, Benza RL, Widlitz AC,
Krichman A, Barst RJ. Safety and efficacy of IV treprostinil for pulmonary arterial
hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 2006;
129:683–688.
236. Sitbon O, Manes A, Jaı¨s X, Pallazini M, Humbert M, Presotto L, Paillette L,
Zaccardelli D, Davis G, Jeffs R, Simonneau G, Galie` N. Rapid switch from intraven-
ous epoprostenol to intravenous treprostinil in patients with pulmonary arterial
hypertension. J Cardiovasc Pharmacol 2007;49:1–5.
237. McLaughlin V, Rubin L, Benza RL, Channick R, Vosswinkel R, Tapson V, Robbins I,
Olschewski H, Seeger W. Addition of inhaled treprostinil to oral therapy for pul-
monary arterial hypertension: a randomized controlled clinical trial. J Am Coll Car-
diol 2010;55:1915–1922.
238. Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, Badesch DB,
Frost AE, Shapiro SM, Laliberte K, Sigman J, Arneson C, Galie` N. Oral treprostinil
for the treatment of pulmonary arterial hypertension in patients on background
endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor ther-
apy (the FREEDOM-C study): a randomized controlled trial. Chest 2012;142:
1383–1390.
239. Tapson VF, Jing ZC, Xu KF, Pan L, Feldman J, Kiely DG, Kotlyar E, McSwain CS,
Laliberte K, Arneson C. Oral treprostinil for the treatment of pulmonary arterial
hypertension in patients on background endothelin receptor antagonist and/or
phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a rando-
mized controlled trial. Chest 2013;144:952–958.
240. Jing ZC, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, Torbicki A, Xu KF,
Yehle D, Laliberte K, Arneson C, Rubin LJ. Efficacy and safety of oral treprostinil
monotherapy for the treatment of pulmonary arterial hypertension: a rando-
mized, controlled trial. Circulation 2013;127:624–633.
241. Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlocai K, Galie` N,
Degano B, Bonderman D, Kurzyna M, Efficace M, Giorgino R, Lang IM. Selexipag,
an oral, selective prostacyclin receptor agonist for the treatment of pulmonary
arterial hypertension. Eur Respir J 2012;40:874–880.
242. Chen SL, Zhang FF, Xu J, Xie DJ, Zhou L, Nguyen T, Stone GW. Pulmonary artery
denervation to treat pulmonary arterial hypertension: the single-center, pro-
spective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation
for treatment of pulmonary artery hypertension). J Am Coll Cardiol 2013;62:
1092–1100.
243. Galie` N, Manes A. New treatment strategies for pulmonary arterial hypertension:
hopes or hypes? J Am Coll Cardiol 2013;62:1101–1102.
244. Galie` N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom
of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 2010;31:
2080–2086.
245. Kemp K, Savale L, O’Callaghan DS, Jaı¨s X, Montani D, Humbert M, Simonneau G,
Sitbon O. Usefulness of first-line combination therapy with epoprostenol and bo-
sentan in pulmonary arterial hypertension: an observational study. J Heart Lung
Transplant 2012;31:150–158.
246. Sitbon O, Jaı¨s X, Savale L, Cottin V, Bergot E, Macari EA, Bouvaist H, Dauphin C,
Picard F, Bulifon S, Montani D, Humbert M, Simonneau G. Upfront triple combin-
ation therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014;
43:1691–1697.
247. Galie` N, Barbera JA, Frost A, Ghofrani A, Hoeper M, Mc Laughlin VV, Peacock A,
Simonneau G, Vachiery JL, Grunig E, Oudiz RG, Vonk-Nordegraaf A, White J,
Blair C, Gillies HC, Miller L, Harris JHN, Langley J, Rubin LJ. Initial Use of Ambri-
sentan plus Tadalafil in Pulmonary Arterial Hypertension. New Engl J Med 2015;
379(9):834–844.
248. Sitbon O, Channick R, Kelly C, Frey A, Gaine S, Galie N, Ghofrani A, Hoeper M,
Lang I, Preiss R, Rubin L, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O,
Zeng X, Simonneau G, McLaughlin V. Selexipag for the Treatment of Pulmonary
Arterial Hypertension. New Engl J Med 2015;373:2522–2533.
249. Badesch BD, Feldman J, Keogh A, Mathier MA, Oudiz R, Shapiro S, Farber HW,
McGoon M, Frost A, Allard M, Despain D, Dufton C, Rubin LJ. ARIES-3: ambrisen-
tan therapy in a diverse population of patients with pulmonary hypertension.
Cardiovasc Ther 2012;30:93–99.
250. Provencher S, Sitbon O, Humbert M, Cabrol S, Jaı¨s X, Simonneau G. Long-term
outcome with first-line bosentan therapy in idiopathic pulmonary arterial hyper-
tension. Eur Heart J 2006;27:589–595.
251. McLaughlin V, Channick RN, Ghofrani HA, Lemarie´ JC, Naeije R, Packer M,
Souza R, Tapson VF, Tolson J, Al Hit Hi, Meyer G, Hoeper M.M. Bosentan added
to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J
2015;46:405–413.
252. Dardi F, Manes A, Palazzini M, Bachetti C, Mazzanti G, Rinaldi A, Albini A, Gotti E,
Monti E, Bacchi Reggiani ML, Galie` N. Combining bosentan and sildenafil in
pulmonary arterial hypertension patients failing monotherapy: real-world insights.
Eur Respir J 2015;46:414–421.
253. Sandoval J, Gaspar J, Pulido T, Bautista E, Martı´nez Guerra ML, Zeballos M,
Palomar A, Go´mez A. Graded balloon dilation atrial septostomy in severe pri-
mary pulmonary hypertension. A therapeutic alternative for patients nonresponsive
to vasodilator treatment. J Am Coll Cardiol 1998;32:297–304.
ESC/ERS Guidelines 119
Downloaded from https://academic.oup.com/eurheartj/article-abstract/37/1/67/2887599
by Olivier Borsus user
on 26 January 2018
254. Kurzyna M, Dabrowski M, Bielecki D, Fijalkowska A, Pruszczyk P, Opolski G,
Burakowski J, Florczyk M, Tomkowski WZ, Wawrzynska L, Szturmowicz M,
Torbicki A. Atrial septostomy in treatment of end-stage right heart failure in
Patients with pulmonary hypertension. Chest 2007;131:977–983.
255. Althoff TF, Knebel F, Panda A, McArdle J, Gliech V, Franke I, Witt C, Baumann G,
Borges AC. Long-term follow-up of a fenestrated Amplatzer atrial septal occluder
in pulmonary arterial hypertension. Chest 2008;133:283–285.
256. Keogh A, Benza RL, Corris P, Dartevelle P, Frost A, Kim NH, Lang I, Pepke-Zaba J,
Sandoval J, Mayer E. Interventional and surgical modalities of treatment in pulmon-
ary arterial hypertension. J Am Coll Cardiol 2009;54(Suppl):S67–S77.
257. Sztrymf B, Souza R, Bertoletti I, Jaı¨s X, Price LC, Simonneau G, Humbert M. Prog-
nostic factors of acute heart failure in patients with pulmonary arterial hyperten-
sion. Eur Respir J 2010;35:1286–1293.
258. Zamanian RT, Haddad F, Doyle RL, Weinacker AB. Management strategies for pa-
tients with pulmonary hypertension in the intensive care unit. Crit Care Med 2007;
35:2037–2050.
259. Price LC, Wort SJ, Finney SJ, Marino PS, Brett SJ. Pulmonary vascular and right ven-
tricular dysfunction in adult critical care: current and emerging options for man-
agement: a systematic literature review. Crit Care 2010;14:R169.
260. Hoeper MM, Granton J. Intensive care unit management of patients with severe
pulmonary hypertension and right heart failure. Am J Respir Crit Care Med 2011;
184:1114–1124.
261. Rosenzweig EB, Brodie D, Abrams DC, Agerstrand CL, Bacchetta M. Extracor-
poreal membrane oxygenation as a novel bridging strategy for acute right heart
failure in group 1 pulmonary arterial hypertension. ASAIO J 2014;60:129–133.
262. Olsson KM, Simon A, Strueber M, Hadem J, Wiesner O, Gottlieb J, Fuehner T,
Fischer S, Warnecke G, Kuhn C, Haverich A, Welte T, Hoeper MM. Extracorpor-
eal membrane oxygenation in nonintubated patients as bridge to lung transplant-
ation. Am J Transplant 2010;10:2173–2178.
263. Fuehner T, Kuehn C, Hadem J, Wiesner O, Gottlieb J, Tudorache I, Olsson KM,
Greer M, Sommer W, Welte T, Haverich A, Hoeper MM, Warnecke G. Extracor-
poreal membrane oxygenation in awake patients as bridge to lung transplantation.
Am J Respir Crit Care Med 2012;185:763–768.
264. de Perrot M, Granton JT, McRae K, Cypel M, Pierre A, Waddell TK, Yasufuku K,
Hutcheon M, Chaparro C, Singer L, Keshavjee S. Impact of extracorporeal life
support on outcome in patients with idiopathic pulmonary arterial hypertension
awaiting lung transplantation. J Heart Lung Transplant 2011;30:997–1002.
265. Strueber M, Hoeper MM, Fischer S, Cypel M, Warnecke G, Gottlieb J, Pierre A,
Welte T, Haverich A, Simon AR, Keshavjee S. Bridge to thoracic organ transplant-
ation in patients with pulmonary arterial hypertension using a pumpless lung assist
device. Am J Transplant 2009;9:853–857.
266. Trulock EP, Edwards LB, Taylor DO, Trulock EP, Waltz DA, Keck BM, Hertz MI.
Registry of the International Society for Heart and Lung Transplantation:
twenty-third official adult lung and heart lung transplantation report—2006.
J Heart Lung Transplant 2006;25:880–892.
267. Toyoda Y, Thacker J, Santos R, Nguyen D, Bhama J, Bermudez C, Kormos R,
Johnson B, Crespo M, Pilewski J, Teuteberg J, Alvarez R, Mathier M,
McNamara D, McCurry K, Zenati M, Hattler B. Long-term outcome of lung
and heart-lung transplantation for idiopathic pulmonary arterial hypertension.
Ann Thorac Surg 2008;86:1116–1122.
268. Fadel E, Mercier O, Mussot S, Leroy-Ladurie F, Cerrina J, Chapelier A,
Simonneau G, Dartevelle P. Long-term outcome of double-lung and heart2lung
transplantation for pulmonary hypertension: a comparative retrospective study of
219 patients. Eur J Cardiothorac Surg 2010;38:277–284.
269. de Perrot M, Granton JT, McRae K, Pierre AF, Singer LG, Waddell TK, Keshavjee S.
Outcome of patients with pulmonary arterial hypertension referred for lung
transplantation: a 14-year single-center experience. J Thorac Cardiovasc Surg
2012;143:910–918.
270. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F,
Kirk R, Rahmel AO, Stehlik J, Hertz MI. The Registry of the International Society
for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant re-
port—2012. J Heart Lung Transplant 2012;31:1073–1086.
271. Waddell TK, Bennett L, Kennedy R, Todd TR, Keshavjee SH. Heart-lung or lung
transplantation for Eisenmenger syndrome. J Heart Lung Transplant 2002;21:
731–737.
272. Choong CK, Sweet SC, Guthrie TJ, Mendeloff EN, Haddad FJ, Schuler P,
De LaMorena M, Huddleston CB. Repair of congenital heart lesions combined
with lung transplantation for the treatment of severe pulmonary hypertension:
a 13-year experience. J Thorac Cardiovasc Surg 2005;129:661–669.
273. Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat-
istic Med 2012;31:2973–2984.
274. Fleming TR. Surrogate endpoints and FDA accelerated approval process. Health
Affairs 2005;24:67–78.
275. Tongers J, Schwerdtfeger B, Klein G, Kempf T, Schaefer A, Knapp JM, Niehaus M,
Korte T, Hoeper MM. Incidence and clinical relevance of supraventricular tachyar-
rhythmias in pulmonary hypertension. Am Heart J 2007;153:127–132.
276. Hoeper MM, Galie` N, Murali S, Olschewski H, Rubenfire M, Robbins IM,
Farber HW, McLaughlin V, Shapiro S, Pepke-Zaba J, Winkler J, Ewert R,
Opitz C, Westerkamp V, Vachiery JL, Torbicki A, Behr J, Barst RJ. Outcome after
cardiopulmonary resuscitation in patients with pulmonary arterial hypertension.
Am J Respir Crit Care Med 2002;165:341–344.
277. Showkathali R, Tayebjee MH, Grapsa J, Alzetani M, Nihoyannopoulos P,
Howard LS, Lefroy DC, Gibbs JS. Right atrial flutter isthmus ablation is feasible
and results in acute clinical improvement in patients with persistent atrial flutter
and severe pulmonary arterial hypertension. Int J Cardiol 2011;149:279–280.
278. Zylkowska J, Kurzyna M, Pietura R, Fijalkowska A, Florczyk M, Czajka C,
Torbicki A. Recurrent hemoptysis: an emerging life-threatening complication in
idiopathic pulmonary arterial hypertension. Chest 2011;139:690–693.
279. Zylkowska J, Kurzyna M, Florczyk M, Burakowska B, Grzegorczyk F, Burakowski J,
Wieteska M, Oniszh K, Biederman A, Wawrzynska L, Szturmowicz M,
Fijalkowska A, Torbicki A. Pulmonary artery dilatation correlates with the risk
of unexpected death in chronic arterial or thromboembolic pulmonary hyperten-
sion. Chest 2012;142:1406–1416.
280. Russo V, Zompatori M, Galie` N. Extensive right pulmonary artery dissection in a
young patient with chronic pulmonary hypertension. Heart 2012;98:265–266.
281. Demerouti EA, Manginas AN, Athanassopoulos GD, Karatasakis GT. Complica-
tions leading to sudden cardiac death in pulmonary arterial hypertension. Respira-
tory Care 2013;58:1246–1254.
282. Lee MS, Oyama J, Bhatia R, Kim YH, Park SJ. Left main coronary artery compres-
sion from pulmonary artery enlargement due to pulmonary hypertension: a con-
temporary review and argument for percutaneous revascularization. Catheter
Cardiovasc Interv 2010;76:543–550.
283. Barst RJ, Ertel SI, Beghetti M, Ivy DD. Pulmonary arterial hypertension: a compari-
son between children and adults. Eur Respir J 2011;37:665–677.
284. Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD. Survival in child-
hood pulmonary arterial hypertension. Circulation 2012;125:113–122.
285. van Loon RL, Roofthooft MTR, Hillege HL, ten Harkel ADJ, van Osch-Gevers M,
Delhaas T, Kapusta L, Strengers JLM, Rammeloo L, Clur SA, Mulder BJM,
Berger RMF. Pediatric pulmonary hypertension in the Netherlands: epidemiology
and characterization during the period 1991 to 2005. Circulation 2011;124:
1755–1764.
286. Moledina S, Hislop AA, Foster H, Schulze-Neick I, Haworth SG. Childhood idio-
pathic pulmonary arterial hypertension: a national cohort study. Heart 2010;96:
1401–1406.
287. Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, Bonnet D,
Schulze-Neick I, Barst RJ. Clinical features of paediatric pulmonary hypertension:
a registry study. Lancet 2012;379:537–546.
288. Hansmann G, Hoeper MM. Registries for paediatric pulmonary hypertension. Eur
Respir J 2013;42:580–583.
289. Cerro MJ, Abman S, Diaz G, Freudenthal AH, Freudenthal F, Harikrishnan S,
Haworth SG, Ivy D, Lopes AA, Raj JU, Sandoval J, Stenmark K, Adatia I. A consen-
sus approach to the classification of pediatric pulmonary hypertensive vascular
disease: report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ
2011;1:286–298.
290. Beghetti M, Berger RM, Schulze-Neick I, Day RW, Pulido T, Feinstein J, Barst RJ,
Humpl T. Diagnostic evaluation of paediatric pulmonary hypertension in current
clinical practice. Eur Respir J 2013;42:689–700.
291. Schulze-Neick I, Beghetti M. Issues related to the management and therapy of
paediatric pulmonary hypertension. Eur Respir Rev 2010;19:331–339.
292. Adatia I, Haworth SG, Wegner M, Barst RJ, Ivy D, Stenmark KR, Karkowsky A,
Rosenzweig E, Aguilar C. Clinical trials in neonates and children: report of the Pul-
monary Hypertension Academic Research Consortium Pediatric Advisory Com-
mittee. Pulm Circ 2013;3:252–266.
293. Lammers AE, Hislop AA, Flynn Y, Haworth SG. Epoprostenol treatment in chil-
dren with severe pulmonary hypertension. Heart 2007;93:739–743.
294. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary
hypertension in children. Circulation 1999;99:1197–1208.
295. Levy M, Celermajer DS, Bourges-Petit E, Del Cerro MJ, Bajolle F, Bonnet D.
Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmon-
ary hypertension. J Pediatr 2011;158:584–588.
296. Ivy DD, Doran AK, Smith KJ, Mallory GB Jr, Beghetti M, Barst RJ, Brady D, Law Y,
Parker D, Claussen L, Abman SH. Short- and long-term effects of inhaled iloprost
therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008;
51:161–169.
297. Barst R, Ivy D, Widlitz AC, Moore K, Doran A, Nguyen N, Gaitonde M. Pharma-
cokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary
arterial hypertension. Clin Pharmacol Ther 2003;73:372–382.
ESC/ERS Guidelines119a
Downloaded from https://academic.oup.com/eurheartj/article-abstract/37/1/67/2887599
by Olivier Borsus user
on 26 January 2018
298. Rosenzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D, Abman SH,
Morganti A, Nguyen N, Barst RJ. Effects of long-term bosentan in children with
pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:697–704.
299. Beghetti M, Haworth SG, Bonnet D, Barst RJ, Acar P, Fraisse A, Ivy DD, Jaı¨s X,
Schulze-Neick I, Galie` N, Morganti A, Dingemanse J, Kusic-Pajic A, Berger RM.
Pharmacokinetic and clinical profile of a novel formulation of bosentan in children
with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol
2009;68:948–955.
300. Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, Sastry BKS,
Pulido T, Layton GR, Serdarevic-Pehar M, Wessel DL. A randomized, double-
blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in
treatment-naive children with pulmonary arterial hypertension. Circulation 2012;
125:324–334.
301. Barst RJ, Beghetti M, Pulido T, Layton G, Konourina I, Zhang M, Ivy DD.
STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-
naive pediatric pulmonary arterial hypertension. Circulation 2014;129:
1914–1923.
302. Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pul-
monary arterial hypertension. Pediatr Cardiol 2012;33:683–688.
303. Douwes JM, Roofthooft MT, Van Loon RL, Ploegstra MJ, Bartelds B, Hillege HL,
Berger RM. Sildenafil add-on therapy in paediatric pulmonary arterial hyperten-
sion, experiences of a national referral centre. Heart 2014;100:224–230.
304. Micheletti A, Hislop AA, Lammers A, Bonhoeffer P, Derrick G, Rees P,
Haworth SG. Role of atrial septostomy in the treatment of children with pulmon-
ary arterial hypertension. Heart 2006;92:969–972.
305. Boudjemline Y, Patel M, Malekzadeh-Milani S, Szezepanski I, Levy M, Bonnet D.
Patent ductus arteriosus stenting (transcatheter Potts shunt) for palliation of su-
prasystemic pulmonary arterial hypertension: a case series. Circ Cardiovasc Interv
2013;6:e18–e20.
306. Baruteau AE, Belli E, Boudjemline Y, Laux D, Levy M, Simonneau G, Carotti A,
Humbert M, Bonnet D. Palliative Potts shunt for the treatment of children with
drug-refractory pulmonary arterial hypertension: updated data from the first 24
patients. Eur J Cardiothorac Surg 2015;47:e105–e110.
307. Esch JJ, Shah PB, Cockrill BA, Farber HW, Landzberg MJ, Mehra MR, Mullen MP,
Opotowsky AR, Waxman AB, Lock JE, Marshall AC. Transcatheter Potts shunt
creation in patients with severe pulmonary arterial hypertension: initial clinical
experience. J Heart Lung Transplant 2013;32:381–387.
308. Ploegstra MJ, Douwes JM, Roofthooft MT, Zijlstra WM, Hillege HL, Berger RM.
Identification of treatment goals in paediatric pulmonary arterial hypertension.
Eur Respir J 2014;44:1616–1626.
309. Galie` N, Manes A, Palazzini M, Negro L, Marinelli A, Gambetti S, Mariucci E,
Donti A, Branzi A, Picchio FM. Management of pulmonary arterial hypertension
associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s syn-
drome. Drugs 2008;68:1049–1066.
310. Engelfriet PM, Duffels MGJ, Moller T, Boersma E, Tijssen JGP, Thaulow E,
Gatzoulis MA, Mulder BJM. Pulmonary arterial hypertension in adults born with
a heart septal defect: the Euro Heart Survey on adult congenital heart disease.
Heart 2007;93:682–687.
311. Beghetti M, Galie` N. Eisenmenger syndrome: a clinical perspective in a new thera-
peutic era of pulmonary arterial hypertension. J Am Coll Cardiol 2009;53:733–740.
312. Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, Stone S.
Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 1998;
19:1845–1855.
313. Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemo-
dynamics and survival of adults with severe primary pulmonary hypertension or
Eisenmenger syndrome. J Heart Lung Transplant 1996;15:100–105.
314. Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galie` N. Current era
survival of patients with pulmonary arterial hypertension associated with congeni-
tal heart disease: a comparison between clinical subgroups. Eur Heart J 2014;35:
716–724.
315. Hopkins WE. The remarkable right ventricle of patients with Eisenmenger syn-
drome. Coron Artery Dis 2005;16:19–25.
316. Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital
heart disease. Circulation 2007;115:1039–1050.
317. Moller JH, Patton C, Varco RL, Lillehei CW. Late results (30 to 35 years) after op-
erative closure of isolated ventricular septal defect from 1954 to 1960. Am J Car-
diol 1991;68:1491–1497.
318. van Albada ME, Berger RM. Pulmonary arterial hypertension in congenital cardiac
disease—the need for refinement of the Evian-Venice classification. Cardiol Young
2008;18:10–17.
319. Schulze-Neick I, Beghetti M. Classifying pulmonary hypertension in the setting of
the congenitally malformed heart—cleaning up a dog’s dinner. Cardiol Young 2008;
18:22–25.
320. Lopes AA, Leary PW. Measurement, interpretation and use of hemodynamic
parameters. Cardiol Young 2009;19(Suppl 1):8–12.
321. Broberg CS, Ujita M, Prasad S, Li W, Rubens M, Bax BE, Davidson SJ, Bouzas B,
Gibbs JS, Burman J, Gatzoulis MA. Pulmonary arterial thrombosis in Eisenmenger
syndrome is associated with biventricular dysfunction and decreased pulmonary
flow velocity. J Am Coll Cardiol 2007;50:634–642.
322. Gatzoulis MA, Beghetti M, Galie` N, Granton J, Berger RMF, Lauer A, Chiossi E,
Landzberg M. Longer-term bosentan therapy improves functional capacity in
Eisenmenger syndrome: results of the BREATHE-5 open-label extension study.
Int J Cardiol 2007;127:27–32.
323. Zuckerman WA, Leaderer D, Rowan CA, Mituniewicz JD, Rosenzweig EB. Ambri-
sentan for pulmonary arterial hypertension due to congenital heart disease. J Am
Coll Cardiol 2011;107:1381–1385.
324. Mukhopadhyay S, Sharma M, Ramakrishnan S, Yusuf J, Gupta MD, Bhamri N,
Trehan V, Tyagi S. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a
preliminary observational study. Circulation 2006;114:1807–1810.
325. Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, Hachulla E,
Humbert M, Langleben D, Mathai SC, Saggar R, Visovatti S, Altorok N,
Townsend W, FitzGerald J, McLaughlin VV. Recommendations for screening
and detection of connective tissue disease-associated pulmonary arterial hyper-
tension. Arthritis Rheum 2013;65:3194–3201.
326. Gashouta MA, Humbert M, Hassoun PM. Update in systemic sclerosis-associated
pulmonary arterial hypertension. Presse Med 2014;43:e293–e304.
327. Coghlan JG, Denton CP, Gruenig E, Bonderman D, Distler O, Khanna D,
Muller-Ladner U, Pope JE, Vonk MC, Doelberg M, Chadha-Boreham H,
Heinzl H, Rosenberg DM, McLaughlin VV, Seibold JR. Evidence-based detection
of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.
Ann Rheum Dis 2014;73:1340–1349.
328. Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D, Gressin V,
Guillevin L, Clerson P, Simonneau G, Hachulla E. Screening for pulmonary arterial
hypertension in patients with systemic sclerosis: clinical characteristics at diagno-
sis and long-term survival. Arthritis Rheum 2011;63:3522–3530.
329. Hao YJ, Jiang X, Zhou W, Wang Y, Gao L, Wang Y, Li GT, Hong T, Huo Y, Jing ZC,
Zhang ZL. Connective tissue disease-associated pulmonary arterial hypertension
in Chinese patients. Eur Respir J 2014;44:963–972.
330. Hachulla E, Carpentier P, Gressin V, Diot E, Allanore Y, Sibilia J, Launay D,
Mouthon L, Jego P, Cabane J, de Groote P, Chabrol A, Lazareth I, Guillevin L,
Clerson P, Humbert M, ItinerAIR-Sclerodermie Study Investigators. Risk factors
for death and the 3-year survival of patients with systemic sclerosis: the French
ItinerAIR-Sclerodermie study. Rheumatology 2009;48:304–308.
331. Avouac J, Airo P, Meune C, Beretta C, Dieude P, Caramaschi P, Cappelli S, Diot E,
Vacca A, Cracowski JL, Sibilia J, Kahan A, Matucci-Cerinic M, Allanore Y. Preva-
lence of pulmonary hypertension in systemic sclerosis in European Caucasians
and metaanalysis of 5 studies. J Rheumatol 2010;37:2290–2298.
332. Gunther S, Jaı¨s X, Maitre S, Berezne A, Dorfmuller P, Seferian A, Savale L,
Mercier O, Fadel E, Sitbon O, Mouthon L, Simonneau G, Humbert M,
Montani D. Computed tomography findings of pulmonary venoocclusive disease
in scleroderma patients presenting with precapillary pulmonary hypertension.
Arthritis Rheum 2012;64:2995–3005.
333. Coghlan G. Does left heart disease cause most systemic sclerosis associated pul-
monary hypertension? Eur Respir J 2013;42:888–890.
334. Humbert M, Sitbon O, Yaı¨ci A, Montani D, O’Callaghan DS, Jaı¨s X, Parent F,
Savale L, Natali D, Gu¨nther S, Chaouat A, Chabot F, Cordier JF, Habib G,
Gressin V, Jing ZC, Souza R, Simonneau G. Survival in incident and prevalent co-
horts of patients with pulmonary arterial hypertension. Eur Respir J 2010;36:
549–555.
335. Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L,
Krishnan JA, Wigley F, Hassoun PM. Clinical differences between idiopathic and
scleroderma-related pulmonary hypertension. Arthritis Rheum 2006;54:
3043–3050.
336. Launay D, Sitbon O, Hachulla E, Mouthon L, Gressin V, Rottat L, Clerson P,
Cordier JF, Simonneau G, Humbert M. Survival in systemic sclerosis-associated
pulmonary arterial hypertension in the modern management era. Ann Rheum
Dis 2013;72:1940–1946.
337. O’Callaghan DS, Dorfmuller P, Jaı¨s X, Mouthon L, Sitbon O, Simonneau G,
Humbert M, Montani D. Pulmonary veno-occlusive disease: the bete noire of pul-
monary hypertension in connective tissue diseases? Presse Med 2011;40:
e65–e78.
338. Demling RH, Smith M, Gunther R, Flynn JT, Gee MH. Pulmonary injury and pros-
taglandin production during endotoxemia in conscious sheep. Am J Physiol 1981;
240:H348–H353.
339. Jaı¨s X, Launay D, Yaici A, Le PJ, Tcherakian C, Sitbon O, Simonneau G,
Humbert M. Immunosuppressive therapy in lupus- and mixed connective tissue
disease-associated pulmonary arterial hypertension: a retrospective analysis of
twenty-three cases. Arthritis Rheum 2008;58:521–531.
ESC/ERS Guidelines 119b
Downloaded from https://academic.oup.com/eurheartj/article-abstract/37/1/67/2887599
by Olivier Borsus user
on 26 January 2018
340. Avouac J, Wipff J, Kahan A, Allanore Y. Effects of oral treatments on exercise cap-
acity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis
of randomised controlled trials. Ann Rheum Dis 2008;67:808–814.
341. Launay D, Savale L, Berezne A, Le PJ, Hachulla E, Mouthon L, Sitbon O, Lambert B,
Gaudric M, Jaı¨s X, Stephan F, Hatron PY, Lamblin N, Vignaux O, Cottin V, Farge D,
Wallaert B, Guillevin L, Simonneau G, Mercier O, Fadel E, Dartevelle P,
Humbert M, Mussot S. Lung and heart-lung transplantation for systemic sclerosis
patients. A monocentric experience of 13 patients, review of the literature and
position paper of a multidisciplinary working group. Presse Med 2014;43:
e345–e363.
342. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepa-
topulmonary syndrome. Lancet 2004;363:1461–1468.
343. Zopey R, Susanto I, Barjaktarevic I, Wang T. Transition from hepatopulmonary
syndrome to portopulmonary hypertension: a case series of 3 patients. Case
Rep Pulmonol 2013;2013:561870.
344. Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH. Portopulmonary
hypertension: results from a 10-year screening algorithm. Hepatology 2006;44:
1502–1510.
345. Kawut SM, Krowka MJ, Trotter JF, Roberts KE, Benza RL, Badesch DB,
Taichman DB, Horn EM, Zacks S, Kaplowitz N, Brown RS Jr, Fallon MB. Clinical
risk factors for portopulmonary hypertension. Hepatology 2008;48:196–203.
346. Roberts KE, Fallon MB, Krowka MJ, Brown RS, Trotter JF, Peter I, Tighiouart H,
Knowles JA, Rabinowitz D, Benza RL, Badesch DB, Taichman DB, Horn EM,
Zacks S, Kaplowitz N, Kawut SM. Genetic risk factors for portopulmonary hyper-
tension in patients with advanced liver disease. Am J Respir Crit Care Med 2009;179:
835–842.
347. Krowka MJ, Miller DP, Barst RJ, Taichman D, Dweik RA, Badesch DB,
McGoon MD. Portopulmonary hypertension: a report from the US-based
REVEAL Registry. Chest 2012;141:906–915.
348. Le Pavec J, Souza R, Herve P, Lebrec D, Savale L, Tcherakian C, Jaı¨s X, Yaici A,
Humbert M, Simonneau G, Sitbon O. Portopulmonary hypertension: survival
and prognostic factors. Am J Respir Crit Care Med 2008;178:637–643.
349. Provencher S, Herve P, Jaı¨s X, Lebrec D, Humbert M, Simonneau G, Sitbon O.
Deleterious effects of beta-blockers on exercise capacity and hemodynamics in
patients with portopulmonary hypertension. Gastroenterology 2006;130:120–126.
350. Hoeper MM, Seyfarth HJ, Hoeffken G, Wirtz H, Spiekerkoetter E, Pletz MW,
Welte T, Halank M. Experience with inhaled iloprost and bosentan in portopul-
monary hypertension. Eur Respir J 2007;30:1096–1102.
351. Halank M, Knudsen L, Seyfarth HJ, Ewert R, Wiedemann B, Kolditz M, Hoffken G,
Hoeper MM. Ambrisentan improves exercise capacity and symptoms in patients
with portopulmonary hypertension. Z Gastroenterol 2011;49:1258–1262.
352. Reichenberger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H,
Grimminger F, Seeger W, Ghofrani HA. Sildenafil treatment for portopulmonary
hypertension. Eur Respir J 2006;28:563–567.
353. Kuo PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ. Continuous
intravenous infusion of epoprostenol for the treatment of portopulmonary
hypertension. Transplantation 1997;63:604–606.
354. Swanson KL, Wiesner RH, Nyberg SL, Rosen CB, Krowka MJ. Survival in porto-
pulmonary hypertension: Mayo Clinic experience categorized by treatment sub-
groups. Am J Transplant 2008;8:2445–2453.
355. Sakai T, Planinsic RM, Mathier MA, de Vera ME, Venkataramanan R. Initial experi-
ence using continuous intravenous treprostinil to manage pulmonary arterial
hypertension in patients with end-stage liver disease. Transpl Int 2009;22:
554–561.
356. Savale L, Magnier R, Le Pavec J, Jaı¨s X, Montani D, O’Callaghan DS, Humbert M,
Dingemanse J, Simonneau G, Sitbon O. Efficacy, safety and pharmacokinetics of
bosentan in portopulmonary hypertension. Eur Respir J 2013;41:96–103.
357. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of
European post-marketing surveillance of bosentan in pulmonary hypertension.
Eur Respir J 2007;30:338–344.
358. Kia L, Shah SJ, Wang E, Sharma D, Selvaraj S, Medina C, Cahan J, Mahon H,
Levitsky J. Role of pretransplant echocardiographic evaluation in predicting out-
comes following liver transplantation. Am J Transplant 2013;13:2395–2401.
359. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary
hemodynamics and perioperative cardiopulmonary-related mortality in patients
with portopulmonary hypertension undergoing liver transplantation. Liver Trans-
plant 2000;6:443–450.
360. Ashfaq M, Chinnakotla S, Rogers L, Ausloos K, Saadeh S, Klintmalm GB, Ramsay M,
Davis GL. The impact of treatment of portopulmonary hypertension on survival
following liver transplantation. Am J Transplant 2007;7:1258–1264.
361. Raevens S, De Pauw M, Reyntjens K, Geerts A, Verhelst X, Berrevoet F, Rogiers X,
Troisi RI, Van Vlierberghe H, Colle I. Oral vasodilator therapy in patients with
moderate to severe portopulmonary hypertension as a bridge to liver transplant-
ation. Eur J Gastroenterol Hepatol 2013;25:495–502.
362. Plotkin JS, Kuo PC, Rubin LJ, Gaine S, Howell CD, Laurin J, Njoku MJ, Lim JW,
Johnson LB. Successful use of chronic epoprostenol as a bridge to liver transplant-
ation in severe portopulmonary hypertension. Transplantation 1998;65:457–459.
363. Austin MJ, McDougall NI, Wendon JA, Sizer E, Knisely AS, Rela M, Wilson C,
Callender ME, O’Grady JG, Heneghan MA. Safety and efficacy of combined use
of sildenafil, bosentan, and iloprost before and after liver transplantation in severe
portopulmonary hypertension. Liver Transplant 2008;14:287–291.
364. Grannas G, Neipp M, Hoeper MM, Gottlieb J, Luck R, Becker T, Simon A,
Strassburg CP, Manns MP, Welte T, Haverich A, Klempnauer J, Nashan B,
Strueber M. Indications for and outcomes after combined lung and liver trans-
plantation: a single-center experience on 13 consecutive cases. Transplantation
2008;85:524–531.
365. Robalino BD, Moodie DS. Association between primary pulmonary hypertension
and portal hypertension: analysis of its pathophysiology and clinical, laboratory
and hemodynamic manifestations. J Am Coll Cardiol 1991;17:492–498.
366. Barbaro G, Lucchini A, Pellicelli AM, Grisorio B, Giancaspro G, Barbarini G. Highly
active antiretroviral therapy compared with HAART and bosentan in combination
in patients with HIV-associated pulmonary hypertension. Heart 2006;92:
1164–1166.
367. Degano B. HIV-associated pulmonary arterial hypertension: survival and prognos-
tic factors in the modern therapeutic era. AIDS 2010;24:67–75.
368. Opravil M, Peche`re M, Speich R, Joller Jemelka HI, Jenni R, Russi EW, Hirschel B,
Lu¨thy R. HIV-associated primary pulmonary hypertension. A case control study.
Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997;155:990–995.
369. Sitbon O, Lascoux-Combe C, Delfraissy JF, Yeni PG, Raffi F, De Zuttere D,
Gressin V, Clerson P, Sereni D, Simonneau G. Prevalence of HIV-related pulmon-
ary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit
Care Med 2008;177:108–113.
370. Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, Fourme T,
Humbert M, Delfraissy JF, Simonneau G. Bosentan for the treatment of human im-
munodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit
Care Med 2004;170:1212–1217.
371. Montani D, Achouh L, Dorfmuller P, Le Pavec J, Sztrymf B, Tcherakian C,
Rabiller A, Haque R, Sitbon O, Jaı¨s X, Dartevelle P, Maitre S, Capron F,
Musset D, Simonneau G, Humbert M. Pulmonary veno-occlusive disease: clinical,
functional, radiologic, and hemodynamic characteristics and outcome of 24 cases
confirmed by histology. Medicine (Baltimore) 2008;87:220–233.
372. Lantuejoul S, Sheppard MN, Corrin B, Burke MM, Nicholson AG. Pulmonary
veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopatho-
logic study of 35 cases. Am J Surg Pathol 2006;30:850–857.
373. Humbert M, Maıˆtre S, Capron F, Rain B, Musset D, Simonneau G. Pulmonary ede-
ma complicating continuous intravenous prostacyclin in pulmonary capillary he-
mangiomatosis. Am J Respir Crit Care Med 1998;157:1681–1685.
374. Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit
Care Med 2000;162:1964–1973.
375. Langleben D, Heneghan JM, Batten AP, Wang NS, Fitch N, Schlesinger RD,
Guerraty A, Rouleau JL. Familial pulmonary capillary hemangiomatosis resulting
in primary pulmonary hypertension. Ann Intern Med 1988;109:106–109 [pub-
lished erratum appears in Ann Intern Med 1988;109:439].
376. Best DH, Sumner KL, Austin ED, Chung WK, Brown LM, Borczuk AC,
Rosenzweig EB, Bayrak-Toydemir P, Mao R, Cahill BC, Tazelaar HD, Leslie KO,
Hemnes AR, Robbins IM, Elliott CG. EIF2AK4 mutations in pulmonary capillary
hemangiomatosis. Chest 2014;145:231–236.
377. Seferian A, Helal B, Jaı¨s X, Girerd B, Price LC, Gunther S, Savale L, Dorfmuller P,
Parent F, Sitbon O, Humbert M, Simonneau G, Montani D. Ventilation/perfusion
lung scan in pulmonary veno-occlusive disease. Eur Respir J 2012;40:75–83.
378. Rabiller A, Jaı¨s X, Hamid A, Resten A, Parent F, Haque R, Capron F, Sitbon O,
Simonneau G, Humbert M. Occult alveolar haemorrhage in pulmonary
veno-occlusive disease. Eur Respir J 2006;27:108–113.
379. Montani D, Jaı¨s X, Price LC, Achouh L, Degano B, Mercier O, Mussot S, Fadel E,
Dartevelle P, Sitbon O, Simonneau G, Humbert M. Cautious epoprostenol ther-
apy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease.
Eur Respir J 2009;34:1348–1356.
380. Fang JC, DeMarco T, Givertz MM, Borlaug BA, Lewis GD, Rame JE,
Gomberg-Maitland M, Murali S, Frantz RP, McGlothlin D, Horn EM, Benza RL.
World Health Organization Pulmonary Hypertension Group 2: pulmonary
hypertension due to left heart disease in the adult—a summary statement from
the Pulmonary Hypertension Council of the International Society for Heart and
Lung Transplantation. J Heart Lung Transplant 2012;31:913–933.
381. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E,
Recusani F, Tavazzi L. Independent and additive prognostic value of right ventricu-
lar systolic function and pulmonary artery pressure in patients with chronic heart
failure. J Am Coll Cardiol 2001;37:183–188.
ESC/ERS Guidelines119c
Downloaded from https://academic.oup.com/eurheartj/article-abstract/37/1/67/2887599
by Olivier Borsus user
on 26 January 2018
382. Thenappan T, Shah SJ, Gomberg-Maitland M, Collander B, Vallakati A, Shroff P,
Rich S. Clinical characteristics of pulmonary hypertension in patients with heart
failure and preserved ejection fraction. Circ Heart Fail 2011;4:257–265.
383. Robbins IM, Newman JH, Johnson RF, Hemnes AR, Fremont RD, Piana RN,
Zhao DX, Byrne DW. Association of the metabolic syndrome with pulmonary
venous hypertension. Chest 2009;136:31–36.
384. Bursi F, McNallan SM, Redfield MM, Nkomo VT, Lam CS, Weston SA, Jiang R,
Roger VL. Pulmonary pressures and death in heart failure: a community study.
J Am Coll Cardiol 2012;59:222–231.
385. Gerges C, Gerges M, Lang MB, Zhang Y, Jakowitsch J, Probst P, Maurer G, Lang IM.
Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in
“out-of-proportion” pulmonary hypertension. Chest 2013;143:758–766.
386. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in
chronic heart failure: the role of the endothelium in pathophysiology and manage-
ment. Circulation 2000;102:1718–1723.
387. Rapp AH, Lange RA, Cigarroa JE, Keeley EC, Hillis LD. Relation of pulmonary ar-
terial diastolic and mean pulmonary arterial wedge pressures in patients with and
without pulmonary hypertension. Am J Cardiol 2001;88:823–824.
388. Miller WL, Grill DE, Borlaug BA. Clinical features, hemodynamics, and outcomes
of pulmonary hypertension due to chronic heart failure with reduced ejection
fraction: pulmonary hypertension and heart failure. JACC Heart Fail 2013;1:
290–299.
389. Tampakakis E, Leary PJ, Selby VN, De Marco T, Cappola TP, Felker GM,
Russell SD, Kasper EK, Tedford RJ. The diastolic pulmonary gradient does not
predict survival in patients with pulmonary hypertension due to left heart disease.
JACC Heart Fail 2015;3:9–16.
390. Pellegrini P, Rossi A, Pasotti M, Raineri C, Cicoira M, Bonapace S, Dini FL,
Temporelli PL, Vassanelli C, Vanderpool R, Naeije R, Ghio S. Prognostic relevance
of pulmonary arterial compliance in patients with chronic heart failure. Chest
2014;145:1064–1070.
391. Chatterjee NA, Lewis GD. Characterization of pulmonary hypertension in heart
failure using the diastolic pressure gradient: limitations of a solitary measurement.
JACC Heart Fail 2015;3:17–21.
392. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K,
Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L,
Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK,
Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA,
Zannad F, Zeiher A. ESC Guidelines for the diagnosis and treatment of acute
and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment
of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology.
Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur
Heart J 2012;33:1787–1847.
393. Khush KK, Tasissa G, Butler J, McGlothlin D, De MT. Effect of pulmonary hyper-
tension on clinical outcomes in advanced heart failure: analysis of the Evaluation
Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effect-
iveness (ESCAPE) database. Am Heart J 2009;157:1026–1034.
394. Patel ND, Weiss ES, Schaffer J, Ullrich SL, Rivard DC, Shah AS, Russell SD,
Conte JV. Right heart dysfunction after left ventricular assist device implantation:
a comparison of the pulsatile HeartMate I and axial-flow HeartMate II devices. Ann
Thorac Surg 2008;86:832–840.
395. Torre-Amione G, Southard RE, Loebe MM, Youker KA, Bruckner B, Estep JD,
Tierney M, Noon GP. Reversal of secondary pulmonary hypertension by axial
and pulsatile mechanical circulatory support. J Heart Lung Transplant 2010;29:
195–200.
396. Barnett CF, DeMarco T. Pulmonary hypertension associated with left-sided heart
disease. Heart Fail Clin 2012;8:447–459.
397. Bonderman D, Ghio S, Felix SB, Ghofrani HA, Michelakis E, Mitrovic V, Oudiz RJ,
Boateng F, Scalise AV, Roessig L, Semigran MJ. Riociguat for patients with pulmon-
ary hypertension caused by systolic left ventricular dysfunction: a phase IIb
double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.
Circulation 2013;128:502–511.
398. Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A,
Charpentier C, Kessler R. Prognostic factors in COPD patients receiving long-
term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995;107:
1193–1198.
399. Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, Ducolone A, Ehrhart M,
Oswald-Mammosser M. “Natural history” of pulmonary hypertension in a series
of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med
2001;164:219–224.
400. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes
of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis.
Chest 2006;129:746–752.
401. Thabut G, Dauriat G, Stern JB, Logeart D, Levy A, Marrash-Chahla R, Mal H. Pul-
monary hemodynamics in advanced COPD candidates for lung volume reduction
surgery or lung transplantation. Chest 2005;127:1531–1536.
402. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, Ehrhart M,
Kessler R, Weitzenblum E. Severe pulmonary hypertension and chronic obstruct-
ive pulmonary disease. Am J Respir Crit Care Med 2005;172:189–194.
403. Arcasoy SM, Christie JD, Ferrari VA, St John SM, Zisman DA, Blumenthal NP,
Pochettino A, Kotloff RM. Echocardiographic assessment of pulmonary hyperten-
sion in patients with advance lung disease. Am J Respir Crit Care Med 2003;167:
735–740.
404. Fisher MR, Forfia PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE,
Corretti MC, Hassoun PM. Accuracy of Doppler echocardiography in the hemo-
dynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009;
179:615–621.
405. Nathan SD, Shlobin OA, Barnett SD, Saggar R, Belperio JA, Ross DJ, Ahmad S,
Saggar R, Libre E, Lynch JP III, Zisman DA. Right ventricular systolic pressure by
echocardiography as a predictor of pulmonary hypertension in idiopathic pul-
monary fibrosis. Respir Med 2008;102:1305–1310.
406. Agusti AG, Barbera JA, Roca J, Wagner PD, Guitart R, Rodriguez-Roisin R. Hyp-
oxic pulmonary vasoconstriction and gas exchange during exercise in chronic ob-
structive pulmonary disease. Chest 1990;97:268–275.
407. Barbera JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez-Roisin R.
Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic ob-
structive pulmonary disease. Lancet 1996;347:436–440.
408. Simonneau G, Escourrou P, Duroux P, Lockhart A. Inhibition of hypoxic pulmon-
ary vasoconstriction by nifedipine. N Engl J Med 1981;304:1582–1585.
409. Morrell NW, Higham MA, Phillips PG, Shakur BH, Robinson PJ, Beddoes RJ. Pilot
study of losartan for pulmonary hypertension in chronic obstructive pulmonary
disease. Respir Res 2005;6:88–95.
410. Saadjian A, Philip-Joet F, Paganelli F, Arnaud A, Levy S. Long-term effects of cicle-
tanine on secondary pulmonary hypertension. J Cardiovasc Pharmacol 1998;31:
364–371.
411. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M, Tamm M. A ran-
domised, controlled trial of bosentan in severe COPD. Eur Respir J 2008;32:
619–628.
412. Blanco I, Gimeno E, Munoz PA, Pizarro S, Gistau C, Rodriguez-Roisin R, Roca J,
Barbera JA. Hemodynamic and gas exchange effects of sildenafil in patients with
chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir
Crit Care Med 2010;181:270–278.
413. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW.
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J
Med 2010;363:620–628.
414. Blanco I, Santos S, Gea J, Guell R, Torres F, Gimeno-Santos E, Rodriguez DA,
Vilaro J, Gomez B, Roca J, Barbera JA. Sildenafil to improve respiratory rehabilita-
tion outcomes in COPD: a controlled trial. Eur Respir J 2013;42:982–992.
415. Lederer DJ, Bartels MN, Schluger NW, Brogan F, Jellen P, Thomashow BM,
Kawut SM. Sildenafil for chronic obstructive pulmonary disease: a randomized
crossover trial. COPD 2012;9:268–275.
416. Goudie AR, Lipworth BJ, Hopkinson PJ, Wei L, Struthers AD. Tadalafil in patients
with chronic obstructive pulmonary disease: a randomised, double-blind,
parallel-group, placebo-controlled trial. Lancet Respir Med 2014;2:293–300.
417. Lang IM, Pesavento R, Bonderman D, Yuan JX. Risk factors and basic mechanisms
of chronic thromboembolic pulmonary hypertension: a current understanding.
Eur Respir J 2013;41:462–468.
418. Guerin L, Couturaud F, Parent F, Revel MP, Gillaizeau F, Planquette B, Pontal D,
Guegan M, Simonneau G, Meyer G, Sanchez O. Prevalence of chronic thrombo-
embolic pulmonary hypertension after acute pulmonary embolism. Prevalence of
CTEPH after pulmonary embolism. Thromb Haemost 2014;112:598–605.
419. Pepke-Zaba J, Jansa P, Kim NH, Naeije R, Simonneau G. Chronic thromboembolic
pulmonary hypertension: role of medical therapy. Eur Respir J 2013;41:985–990.
420. Madani MM, Wittine LM, Auger WR, Fedullo PF, Kerr KM, Kim NH, Test VJ,
Kriett JM, Jamieson SW. Chronic thromboembolic pulmonary hypertension in
pediatric patients. J Thorac Cardiovasc Surg 2011;141:624–630.
421. Pepke-Zaba J, Hoeper MM, Humbert M. Chronic thromboembolic pulmonary
hypertension: advances from bench to patient management. Eur Respir J 2013;
41:8–9.
422. Lang IM, Simonneau G, Pepke-Zaba JW, Mayer E, Ambroz D, Blanco I, Torbicki A,
Mellemkjaer S, Yaici A, Delcroix M. Factors associated with diagnosis and oper-
ability of chronic thromboembolic pulmonary hypertension. A case-control study.
Thromb Haemost 2013;110:83–91.
423. Lang IM, Plank C, Sadushi-Kolici R, Jakowitsch J, Klepetko W, Maurer G. Imaging in
pulmonary hypertension. JACC Cardiovasc Imaging 2010;3:1287–1295.
424. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmon-
ary hypertension. Circulation 2006;113:2011–2020.
425. Sherrick AD, Swensen SJ, Hartman TE. Mosaic pattern of lung attenuation on CT
scans: frequency among patients with pulmonary artery hypertension of different
causes. Am J Roentgenol 1997;169:79–82.
ESC/ERS Guidelines 119d
Downloaded from https://academic.oup.com/eurheartj/article-abstract/37/1/67/2887599
by Olivier Borsus user
on 26 January 2018
426. Ley S, Ley-Zaporozhan J, Pitton MB, Schneider J, Wirth GM, Mayer E, Duber C,
Kreitner KF. Diagnostic performance of state-of-the-art imaging techniques for
morphological assessment of vascular abnormalities in patients with chronic
thromboembolic pulmonary hypertension (CTEPH). Eur Radiol 2012;22:
607–616.
427. Sugiyama M, Fukuda T, Sanda Y, Morita Y, Higashi M, Ogo T, Tsuji A, Demachi J,
Nakanishi N, Naito H. Organized thrombus in pulmonary arteries in patients with
chronic thromboembolic pulmonary hypertension; imaging with cone beam com-
puted tomography. Jpn J Radiol 2014;32:375–382.
428. Shure D, Gregoratos G, Moser KM. Fiberoptic angioscopy: role in the diagnosis of
chronic pulmonary arterial obstruction. Ann Intern Med 1985;103:844–850.
429. Skoro-Sajer N, Marta G, Gerges C, Hlavin G, Nierlich P, Taghavi S,
Sadushi-Kolici R, Klepetko W, Lang IM. Surgical specimens, haemodynamics
and long-term outcomes after pulmonary endarterectomy. Thorax 2014;69:
116–122.
430. Mayer E, Jenkins D, Lindner J, D’Armini A, Kloek J, Meyns B, Ilkjaer LB,
Klepetko W, Delcroix M, Lang I, Pepke-Zaba J, Simonneau G, Dartevelle P. Sur-
gical management and outcome of patients with chronic thromboembolic pul-
monary hypertension: results from an international prospective registry.
J Thorac Cardiovasc Surg 2011;141:702–710.
431. Madani MM, Auger WR, Pretorius V, Sakakibara N, Kerr KM, Kim NH, Fedullo PF,
Jamieson SW. Pulmonary endarterectomy: recent changes in a single institution’s
experience of more than 2,700 patients. Ann Thorac Surg 2012;94:97–103.
432. Jenkins D, Mayer E, Screaton N, Madani M. State-of-the-art chronic thrombo-
embolic pulmonary hypertension diagnosis and management. Eur Respir Rev
2012;21:32–39.
433. Vuylsteke A, Sharples L, Charman G, Kneeshaw J, Tsui S, Dunning J, Wheaton E,
Klein A, Arrowsmith J, Hall R, Jenkins D. Circulatory arrest versus cerebral perfu-
sion during pulmonary endarterectomy surgery (PEACOG): a randomised con-
trolled trial. Lancet 2011;378:1379–1387.
434. Thistlethwaite PA, Madani MM, Kemp AD, Hartley M, Auger WR, Jamieson SW.
Venovenous extracorporeal life support after pulmonary endarterectomy: indica-
tions, techniques, and outcomes. Ann Thorac Surg 2006;82:2139–2145.
435. Berman M, Tsui S, Vuylsteke A, Snell A, Colah S, Latimer R, Hall R, Arrowsmith JE,
Kneeshaw J, Klein AA, Jenkins DP. Successful extracorporeal membrane oxygen-
ation support after pulmonary thromboendarterectomy. Ann Thorac Surg 2008;86:
1261–1267.
436. Mydin M, Berman M, Klein A, Tsui S, Dunning J, Valchanov K, Vuylsteke A,
Jenkins DP. Extracorporeal membrane oxygenation as a bridge to pulmonary end-
arterectomy. Ann Thorac Surg 2011;92:e101–e103.
437. Hughes RJ, Jaı¨s X, Bonderman D, Suntharalingam J, Humbert M, Lang I,
Simonneau G, Pepke-Zaba J. The efficacy of bosentan in inoperable chronic
thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J
2006;28:138–143.
438. Skoro-Sajer N, Bonderman D, Wiesbauer F, Harja E, Jakowitsch J, Klepetko W,
Kneussl MP, Lang IM. Treprostinil for severe inoperable chronic thromboembolic
pulmonary hypertension. Thromb Haemost 2007;5:483–489.
439. Reichenberger F, Voswinckel R, Enke B, Rutsch M, Fechtali EE, Schmehl T,
Olschewski H, Schermuly R, Weissmann N, Ghofrani HA, Grimminger F,
Mayer E, Seeger W. Long-term treatment with sildenafil in chronic thrombo-
embolic pulmonary hypertension. Eur Respir J 2007;30:922–927.
440. Jaı¨s X, D’Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM,
Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ.
Bosentan for treatment of inoperable chronic thromboembolic pulmonary hyper-
tension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc
Thromboembolic pulmonary hypertension), a randomized, placebo-controlled
trial. J Am Coll Cardiol 2008;52:2127–2134.
441. Ghofrani HA, D’Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH,
Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G,
Wang C. Riociguat for the treatment of chronic thromboembolic pulmonary
hypertension. N Engl J Med 2013;369:319–329.
442. Reesink HJ, Surie S, Kloek JJ, Tan HL, Tepaske R, Fedullo PF, Bresser P. Bosentan as
a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary
hypertension. J Thorac Cardiovasc Surg 2010;139:85–91.
443. Feinstein JA, Goldhaber SZ, Lock JE, Ferndandes SM, Landzberg MJ. Balloon pul-
monary angioplasty for treatment of chronic thromboembolic pulmonary hyper-
tension. Circulation 2001;103:10–13.
444. Kataoka M, Inami T, Hayashida K, Shimura N, Ishiguro H, Abe T, Tamura Y,
Ando M, Fukuda K, Yoshino H, Satoh T. Percutaneous transluminal pulmonary
angioplasty for the treatment of chronic thromboembolic pulmonary hyperten-
sion. Circ Cardiovasc Interv 2012;5:756–762.
445. Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara H. Refined
balloon pulmonary angioplasty for inoperable patients with chronic thrombo-
embolic pulmonary hypertension. Circ Cardiovasc Interv 2012;5:748–755.
446. Sugimura K, Fukumoto Y, Satoh K, Nochioka K, Miura Y, Aoki T, Tatebe S,
Miyamichi-Yamamoto S, Shimokawa H. Percutaneous transluminal pulmonary
angioplasty markedly improves pulmonary hemodynamics and long-term progno-
sis in patients with chronic thromboembolic pulmonary hypertension. Circ J 2012;
76:485–488.
447. Inami T, Kataoka M, Shimura N, Ishiguro H, Yanagisawa R, Taguchi H, Fukuda K,
Yoshino H, Satoh T. Pulmonary edema predictive scoring index (PEPSI), a new in-
dex to predict risk of reperfusion pulmonary edema and improvement of hemo-
dynamics in percutaneous transluminal pulmonary angioplasty. JACC Cardiovasc
Interv 2013;6:725–736.
448. Andreassen AK, Ragnarsson A, Gude E, Geiran O, Andersen R. Balloon pulmon-
ary angioplasty in patients with inoperable chronic thromboembolic pulmonary
hypertension. Heart 2013;99:1415–1420.
449. Rubin LJ, Hoeper MM, Klepetko W, Galie` N, Lang IM, Simonneau G. Current and
future management of chronic thromboembolic pulmonary hypertension: from
diagnosis to treatment responses. Proc Am Thorac Soc 2006;3:601–607.
450. Peacock A. Pulmonary hypertension due to chronic hypoxia. BMJ 1990;300:763.
451. Recommendations on the management of pulmonary hypertension in clinical
practice. Heart 2001;86(Suppl 1):I1–I13.
452. Consensus statement on the management of pulmonary hypertension in clinical
practice in the UK and Ireland. Thorax 2008;63(Suppl 2):ii1– ii41.
453. Barbera JA, Escribano P, Morales P, Gomez MA, Oribe M, Martinez A, Roman A,
Segovia J, Santos F, Subirana MT. [Standards of care in pulmonary hypertension.
Consensus statement of the Spanish Society of Pulmonology and Thoracic Sur-
gery (SEPAR) and the Spanish Society of Cardiology (SEC)]. Rev Esp Cardiol
2008;61:170–184.
454. Armstrong I, Rochnia N, Harries C, Bundock S, Yorke J. The trajectory to diagno-
sis with pulmonary arterial hypertension: a qualitative study. BMJ Open 2012;2:
e000806.
455. Ghofrani HA, Distler O, Gerhardt F, Gorenflo M, Grunig E, Haefeli WE, Held M,
Hoeper MM, Kahler CM, Kaemmerer H, Klose H, Kollner V, Kopp B, Mebus S,
Meyer A, Miera O, Pittrow D, Riemekasten G, Rosenkranz S, Schranz D,
Voswinckel R, Olschewski H. Treatment of pulmonary arterial hypertension
(PAH): updated Recommendations of the Cologne Consensus Conference
2011. Int J Cardiol 2011;154(Suppl 1):S20–S33.
456. Vachiery JL, Gaine S. Challenges in the diagnosis and treatment of pulmonary ar-
terial hypertension. Eur Respir Rev 2012;21:313–320.
ESC/ERS Guidelines119e
Downloaded from https://academic.oup.com/eurheartj/article-abstract/37/1/67/2887599
by Olivier Borsus user
on 26 January 2018
